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ABSTRACT 
 The microbiome forms an integral part of the gut microenvironment. Once ignored, 
the topic has gained momentum in research during the past decade, where studies have 
strongly suggested the association of microbiota with health and a misbalance thereof, to 
many disease conditions ranging from inflammation and colitis to diabetes, obesity and 
colon cancer. The Human Microbiome Project (HMP, NIH common fund - 2008) has used 
a variety of high throughput analyses in order to study gut microbiota in health. The 
consortium has so far been able to isolate and characterize more than 1,300 reference 
bacterial strains from the human body. The large amount of data generated has led to a 
baseline need to address the implications of different microbial members, or groups 
thereof, in health and disease. The microorganisms residing in the gut comprise of bacteria, 
archaea, fungi and viruses that are distributed throughout the length of the gastrointestinal 
tract. While there will be limitations to studying all types of microorganisms owing to their 
overwhelming numbers and types, our study is focused only on bacterial populations of the 
gut, and for the purpose of convenience, terms of gut microbiota/microbiome will be used 
for describing gut bacteria pertaining to the mice used in our study. The overall purpose 
of this study is to determine the effects of alterations in the gut microbiome on tumor 
development and inflammation, and if it leads to recolonization of the gut by altered 
bacterial communities. The working hypothesis was that an alteration of bacterial 
microbiome occurs during tumorigenesis and manipulation of the gut microbiome 
externally exacerbates the clinical symptoms associated with intestinal cancer, leading 
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to higher gut and systemic inflammation. Specific aim 1 studied the composition of gut 
microbiota during the stages of tumor initiation and progression. It aimed at studying the 
gut microbial profiles pertaining to bacteria that reside inside the gut of the ApcMin/+ mice 
during normal conditions and comparing it to control mice. Among the different bacterial 
phyla residing in the murine gut, the Bacteroidetes and Firmicutes comprised of dominant 
bacterial populations. Specific aim 2 studied the effects of external manipulation of the gut 
microbiome on gut health and tumorigenesis. The manipulation of the gut microbial 
community was used to help elucidate how alterations in the gut microbiome effect the 
intestinal tumor and mucus production outcomes along with their effects on the gut health 
in measurable terms. Specific aim 3 studied the altered inflammatory response of the mouse 
gut with respect to relative abundances of the Bacteroidetes and Firmicutes bacterial phyla 
populations. 
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CHAPTER 1 
INTRODUCTION 
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The topic of gut microbiome has recently gained attention due to research 
suggesting its significant role in not only maintenance of gut health but also in disease 
conditions such as obesity, diabetes, arthritis, colitis and cancers of the digestive system  
(Cho, Carter, Harari, & Pei, 2014; Dziarski, Park, Kashyap, Dowd, & Gupta, 2016; 
Kabeerdoss, Sandhya, & Danda, 2015; Knip and Siljander (2016)). The gut microbiome 
comprises of around 500-1000 species and a genetic diversity which has 100-fold more 
genes than humans (Dugas, Fuller, Gilbert, & Layden, 2016). 
Another field that aims at answering the questions on gut microbiome and its links 
to health and disease is the usage of probiotics including one or more important bacteria. 
The bacteria Lactobacillus acidophilus has been implicated in a significant suppression of 
colon tumor incidence and size and a reduction in pro-inflammatory cytokines such as 
TNF-α and IFN-γ (Perdigon, Valdez, & Rachid, 1998; Urbanska, Bhathena, Martoni, & 
Prakash, 2009). Some studies also state that the link between the microbiome and the actual 
development of polyps in the gut is solely linked through the erosion of the gut lumen 
microenvironment and the resulting inflammation (Dianda et al., 1997). 
An altered microbiome has been previously linked to inflammatory bowel disease 
and colorectal cancer. However, we still lack the knowledge of a characterizing the gut 
microbiome that relates to health or disease condition. An early event of inflammatory 
insult to the gut can very well result in tumorigenesis when combined with processes of 
bacterial DNA damage and chromatin alterations (Zhu, Michelle Luo, Jobin, & Young, 
2011). Studies on mouse models such as the IL-10-/- have demonstrated a protective role 
of the presence of gut microbiome on inflammation, where the WT mice were rendered 
protected against inflammation in the gut while the germ-free (no microbiome) animals 
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developed colitis (S. Wu et al., 2009). It should be noted here that germ-free animals may 
not represent the human gut as an individual can never be completely without microbiome 
in the gut. From the perspective of any given disease state that can be linked to microbiome, 
the basis of its linkage can only be an altered microbiome. It should also be noted that the 
process of inflammation is the one that alters the microbiome (Uronis & Jobin, 2009), 
although inflammation alone is not sufficient to promote colorectal cancer and altered 
microbiota works hand in hand with inflammatory insults that eventually lead to cancer 
(Arthur & Jobin, 2013). The gut microbiome has been shown to complement AOM and 
DSS mouse models in causing tumorigenesis, but is yet to be elucidated if it is the increase 
or loss of certain bacterial populations that lead to development of polyps (Zackular et al., 
2013).  It is, however, not known what effect the microbial dysbiosis has at different stages 
of progression of tumorigenesis in the mouse, or if it leads to different consequences in 
normal versus tumorigenic conditions. 
 
What is unknown? 
Studies are needed to characterize the interplay between the gut microbiome, inflammation 
and cancer. Another aspect which may be helpful in correctly defining the microbiome and 
inflammation-to-cancer axis is the progression of alterations in the microbiome with 
worsening disease pathology. Of all the diseases that are affected by a change or loss of 
gut microbiome, cancer of the small and large intestine is clearly the one which can be 
physically and physiologically related to the presence of alterations in gut microbiome 
community. 
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AIM 1: Examine the gut microbiome composition during tumor initiation and 
development in ApcMin/+ mice. 
 
Rationale: An altered gut microbiome can cause inflammation ranging from acute bouts 
to chronically inflamed gut. An altered microbiome, which shifts from symbiotic to a more 
inflammation-inducing phenotype, leads to a vicious cycle of erosion of the gut epithelial 
lining that, in turn, leads to more and more inflammatory processes taking place inside the 
gut microenvironment (Saxena et al., 2012; Wang & Zhang, 2015). Our previous study on 
chronic inflammation-induced colon cancer in the APNKO (Adiponectin-knockout) mice 
demonstrated microbiota profiles that were clearly altered during tumorigenesis (data not 
published). The alterations mainly pertained to the altered percentages of the Firmicutes 
and Bacteroidetes bacterial phyla during inflammation-induced tumorigenesis in the mice 
(Figure 1). As opposed to externally administered chemically-induced tumorigenesis in 
mice, the microbiota has not been studied with respect to a spontaneously induced 
tumorigenesis such as that in the ApcMin/+ mouse. It was recently concluded that an 
alteration of gut microbiome precedes polyposis in the ApcMin/+ mouse (Son et al., 2015). 
Also, it has been seen that specific pathogen-free (SPF) ApcMin/+ exhibit a higher tumor 
load and anemia with a higher infiltration of inflammatory cells specifically at advanced 
stages as compared to germ-free animals, indicating that a mere modulation of gut 
microbiome profiles can abrogate the disease condition in the gut (Y. Li et al., 2012). 
However, there are no studies that study the gut microbiome with respect to gut 
inflammation and tumorigenesis in an age/time- dependent manner. Therefore, the first aim 
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of the present study was directed towards characterization of alterations of microbiome 
profiles from early to later stages of tumorigenesis in an ApcMin/+ mouse model. 
 
Hypothesis: The gut microbiota in ApcMin/+ mice exhibits a higher percentage of 
Firmicutes bacterial phylum and a lower percentage of Bacteroidetes, along with the 
reduction in overall bacterial diversity during onset of tumorigenesis when compared to 
the WT mice. Furthermore, the percentage of Firmicutes increases, while overall diversity 
decreases during the progression of tumorigenesis. 
 
AIM 1.1: Study of the gut microbiome profiles during intestinal tumor initiation. 
Hypothesis 1.1: The microbiome profile of ApcMin/+ mice exhibits a higher percentage of 
Firmicutes bacteria and a lower percentage of Bacteroidetes as compared to WT mice at 
initiation of tumor development. The overall microbial diversity decreases lower in 
ApcMin/+ mice as compared to their WT counterparts. 
 
AIM 1.2: To study the profile of the gut microbiome during the progression of intestinal 
tumor development. 
Hypothesis 1.2: The microbiome profile of ApcMin/+ mice exhibit a higher percentage of 
Firmicutes bacteria and a lower percentage of Bacteroidetes as compared to their WT 
counterparts during tumor progression. Firmicutes population is higher during later stages 
of tumorigenesis as compared to initial stages of tumorigenesis. Also, the microbial 
diversity values are lower in ApcMin/+ mice during tumor progression as compared to WT 
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mice, and within ApcMin/+ mice at later stages of tumor development as compared to their 
initial stages of tumorigenesis. 
 
AIM 2: Determine if gut microbiome manipulation can regulate the ApcMin/+ mouse 
health and tumorigenesis. 
 
Rationale: The mucus layer tends to thickness with increased diversity of the microbiota 
(Jakobsson et al., 2015). Our preliminary data from a study on chronic inflammation-
induced colon cancer using APNKO mice suggested that the gut microbiota changes in a 
way that favors an increased percentage of bacteria of certain phyla (here, Firmicutes) as 
compared to others (such as Bacteroidetes). It has not been studied yet as to whether there 
is a relation between the altered percentages of especially the Firmicutes and Bacteroidetes 
phyla populations, and tumor number, tumor size and goblet cell numbers. It is known that 
the mucus layer provides a source of nutritional carbon and therefore energy to some of 
the intestinal flora that are able to lyse the glycans present in the mucus, making the inter-
relationship between the gut bacteria and the mucus layer really important (Kaur et al., 
2015). Also, the metabolites produced by these microbes also influence the differentiation 
and function of the epithelial and immune cells in the intestinal mucosa (Kato, Kawamoto, 
Maruya, & Fagarasan, 2014; Shan et al., 2013). The regulation of the mucin gene 
expression as well as mucus production have been shown to be two levels at which the gut 
microbial community may modulate mucins (Comelli et al., 2008). Our recent study (Kaur, 
et al., 2015) also suggested that a reduction in the secretory mucin profile is associated with 
an inflammatory phenotype of the gut (Figure 4). Therefore, the present aim was directed 
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at knowing the mucus-producing phenotypes of the cells lining the gut of the experimental 
animals in relation to the changing profiles of the gut microbiota. 
 
Hypothesis: Manipulation of the gut microbiota leads to a decrease in gut health and an 
increase in tumor number and size in the ApcMin/+ mouse. Furthermore, manipulation of the 
gut microbiota decreases goblet cell number in the intestine and colon. 
 
AIM 2.1: To determine if manipulation of gut microbiome through antibiotic 
administration affects disease prognosis in the ApcMin/+ mouse. 
Hypothesis 2.1: The manipulation of gut microbiome by externally administered 
antibiotics leads to a worsening of disease prognosis in the experimental mice. 
 
AIM 2.2: To determine if manipulation of gut microbiome through antibiotic 
administration affects tumor number and size in the ApcMin/+ mouse. 
Hypothesis 2.2: The manipulation of the gut microbiome by externally administered 
antibiotics leads to an increase in tumor number and size in the ApcMin/+ mice. 
 
AIM 2.3: To determine if gut microbiome manipulation effects goblet cell numbers in 
small intestine and colon of ApcMin/+ mice as compared to WT mice. 
Hypothesis 2.3: The manipulation of the gut microbiome by externally administered 
antibiotics leads to a reduction in goblet cell numbers in the intestine and colon of ApcMin/+ 
mice. 
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AIM 3: Determine if the relative abundance of Bacteroidetes and Fimicutes bacterial 
populations is associated with intestinal and systemic inflammation in the ApcMin/+ 
mouse. 
 
Rationale: The induction of cancer in the gut by chronic inflammation has always 
indicated towards the importance of underlying altered inflammatory processes (Wang & 
Zhang, 2015). Different agents that have been documented to be effective against tumors 
and cancers are the agents that function by downregulating important inflammatory 
pathways and pro-inflammatory cytokines such as IL1-β, IL-6 and TNF-α, and reduction 
of macrophage infiltration (Y. Li, et al., 2012; Murphy, Davis, McClellan, & Carmichael, 
2011; Murphy, Davis, McClellan, Gordon, & Carmichael, 2011; Ritland et al., 1999). It 
has also been shown that the intestinal commensal bacteria plays a role in the development 
of gut microenvironmental immune system comprising both the humoral and cellular 
components and maintains the protective steady state immune function throughout life 
(Cebra, 1999; Talham, Jiang, Bos, & Cebra, 1999). It may be more appropriate to say that 
any alteration in comparative numbers of certain bacteria often lead to upregulation or 
downregulation of certain inflammatory pathways. The systemic release of microbial 
products as a result of the manipulation of the gut epithelium invokes an IL-23 response 
and a further IL-17 response in order to neutralize further invasion by the microbes, and 
the process is brought about by the Firmicutes bacteria Clostridia sp. (Shih et al., 2014). 
The bacteria especially promotes IL-17 cytokine in the small intestine which is the primary 
site of its attachment and survival (Omenetti & Pizarro, 2015). These Th17 cells may 
become autoreactive in case of intestinal epithelium insult. The bacteria Bacteroides 
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fragilis from the Bacteroidetes phylum leads to an increase in the production of IL-10 
cytokine (Omenetti & Pizarro, 2015), whereas its strains have been implicated in the 
production of the pro-inflammatory cytokine IL-17-dependent inflammation-related colon 
cancer (W. Wu et al., 2015). Inflammation, which is an integral part of tumorigenesis 
should therefore, may strongly be correlated with a reduced bacterial diversity or numbers. 
 
Hypothesis: An increase in the population of Firmicutes bacteria and/or a reduction in the 
population of Bacteroidetes leads to a higher inflammatory response in both the intestinal 
tissue and systemic circulation. 
 
AIM 3.1: To examine if the relative abundance of Bacteroidetes and Firmicutes 
populations regulate intestinal tissue inflammation in ApcMin/+ mice. 
Hypothesis 3.1: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial 
populations increases the inflammatory cellular infiltration into the mucosa of the intestinal 
tissue of the experimental mice. 
 
AIM 3.2: To examine if the relative abundance of Bacteroidetes and Firmicutes 
populations regulate intestine-secreted IL-1β, IL-17 and TNF-α in ApcMin/+ mice. 
Hypothesis 3.2: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial 
populations increases the intestine-secreted IL-1β, IL-17 and TNF-α levels in the 
experimental mice. 
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AIM 3.3: To examine if the relative abundance of Bacteroidetes and Firmicutes 
populations regulate systemic levels of cytokines IL-1β, IL-17 and TNF-α in ApcMin/+ mice. 
Hypothesis 3.3: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial 
populations increases systemic levels of IL-1β, IL-17 and TNF-α cytokines in the 
experimental mice. 
 
Working Model 
         
 
Figure 1.1. Working Model: Figure illustrating the working model for the study where 
the three different aims have been depicted with their respective factors measured during 
the study.
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The central idea of the present study is to study the role of gut microbiota (bacterial) in 
tumorigenesis, mucus producing phenotype and inflammation. In order to study this, we 
used the ApcMin/+ model of intestinal cancer. The ApcMin/+ mouse model is raised from the 
C57BL/6 background where a point mutation on codon 850 of the Apc (Adenomatous 
Polyposis Coli) gene leads to spontaneous development of polyps (adenomas) in the 
intestinal mucosa (Zhang et al., 2015). The mutation is responsible for the production of a 
truncated APC protein (2843 amino acids) that lacks its C-terminal domains. The protein 
functions to downregulate the Wnt signaling pathway by binding to and promoting the 
destruction of the β-catenin protein. It has been shown that altered interactions between the 
gut microbiota and colonic mucosa precede polyposis in the ApcMin/+ mouse (Son, et al., 
2015). Using the basis of an altered gut microbiota preceding polyposis, we are trying to 
delve further into the processes that are hampered by alterations in the gut microbiota, 
which can be used to elucidate the ways in which the gut microbiota affects tumorigenesis. 
The first aim of the study was directed towards examining the composition of gut 
microbiome during tumor initiation and development in the ApcMin/+ mouse. This aim acted 
as preliminary to aims 2 and 3 by characterizing and thereby defining the alterations 
occurring in the microbiome of ApcMin/+ mouse during initiation and progression of 
tumorigenesis. Previous studies have demonstrated an alteration in gut microbiota to be 
linked to a variety of conditions including diabetes, arthritis, colitis and cancer and even 
immune system. Conditions such as Crohn’s disease and obesity have implicated gut 
bacterial dysbiosis in pathogenesis (Chan, Kumar, & Mendall, 2015; Mai, Colbert, Perkins, 
Schatzkin, & Hursting, 2007). The characterization of the gut microbiome in the 
experimental ApcMin/+ mice helped define the abundance of different bacterial species in 
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the gut and their relative diversity values during the initiation and progression of 
tumorigenesis. 
The second aim of the study was directed towards elucidating the role of an altered 
microbiome on pathology of the experimental animals. Antibiotics were administered to 
experimental mice in order to perturb the gut microbiota during the initial and progressive 
stages of tumorigenesis. The use of antibiotics not only help get rid of pathogenic bacteria 
but also deplete related micro-organisms, which fail to return to normal levels even long 
after the antibiotic usage subsides (Cresci & Bawden, 2015). This aim was directed towards 
helping in elucidating the effect of alterations in microbiome in terms of their abundance 
and diversity on the disease condition of the animals. This aim was also being directed 
towards knowing if the tumor numbers and size are related to the microbiome and its 
alterations. The third part of this aim helped elucidate the effects of altered gut microbiome 
on expression of goblet cells in the intestine and colon of mice. Our previous study (Saxena 
et al., 2013) has demonstrated that a reduction in goblet cell numbers leads to worsened 
disease pathology and reduced protection against chronic inflammation-induced colon 
cancer. A reduction in the number of mucus-producing goblet cells may also be altered in 
the ApcMin/+ model and further worsen the disease state once they are administered 
antibiotics. 
The third aim of the present study was aimed at demonstrating the effects of an 
altered microbiome on the inflammatory status of the experimental animals. Inflammation 
is an important route through which alterations in gut microbiota affect the overall milieu 
of inflammatory processes closely associated with the gut. The inflammatory response, 
along with being systemic, has also been demonstrated to occur at a more localized level 
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such as the alterations in gut microbiota leading to increased levels of pro-inflammatory 
cytokines such as IL-1β and TNF-α (Singh, Yeoh, Carvalho, Gewirtz, & Vijay-Kumar, 
2015). In the first part of aim 3 was to study the effects of a changed microbiome on tissue-
localized inflammation and infiltration occurring at the level of intestinal mucosa. The 
second part of the aim helped study the effects of microbiome manipulation on intestine-
secreted pro-inflammatory cytokines. Whether the inflammatory effect is systemic or not, 
was elucidated through the third part of this aim where systemic levels of pro-inflammatory 
cytokines were measured. 
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CHAPTER 2 
LITERATURE REVIEW 
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2.1 The ApcMin/+ mouse model 
The ApcMin/+ mouse model is widely used by researchers to study gut inflammation and 
cancer. The ApcMin/+ mouse model is raised from the C57BL/6 background where a point 
mutation on codon 850 of the Apc (Adenomatous Polyposis Coli) gene leads to 
spontaneous development of polyps (adenomas) in the intestinal mucosa (Zhang, et al., 
2015). The mutation is responsible for the production of a truncated APC protein (2843 
amino acids) that lacks its C-terminal domains. The protein functions to downregulate the 
Wnt signaling pathway by binding to and promoting the destruction of the β-catenin 
protein. An altered APC protein thus leads to, apart from the development of intestinal 
polyps, dysregulation of processes like cell adhesion, cell migration, chromosome 
segregation and stability (McCart, Vickaryous, & Silver, 2008). 
 
 The ApcMin/+ mouse model represents the human cancer syndrome called the 
Familial Adenomatous Polyposis (FAP) where the human intestine may contain several 
thousand adenomas by the age of 20-30 years, which corresponds to ~4-6 weeks in mouse. 
The ApcMin/+ mouse exhibits more than 50 tumors along the entire length of the intestine 
and rarely live past the age of 21-22 weeks (Shoemaker, Gould, Luongo, Moser, & Dove, 
1997), which corresponds to ~60 years of age in humans. Since all intestinal tumors in B6 
Min/+ mice are benign adenomas, the premature death of these animals is associated with 
secondary effects of tumor growth, including severe, chronic anemia and intestinal 
blockage (Shoemaker, Moser, & Dove, 1995).  
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2.2 The Gut Microbiome 
The gut microbiome is an integral and an important symbiotic system present in the gut, 
which comprises of bacteria, archaea, fungi and viruses residing in the gastrointestinal tract 
throughout its length. The gut bacteria itself comprises a major percentage of the total gut 
microbiome, where its numbers are in trillions. While the stomach and duodenum contain 
about 101 to 102 Colony Forming Units (CFU) per mL of bacterial forms, the jejunum and 
ileum comprise 104 to 108, and the colon has 1010 to 1012 CFU/mL of bacteria (Cresci & 
Bawden, 2015). The microbiome acts advantageous for the gut such that it regulates gut 
epithelial and endocrine cellular structure (Uribe, Alam, Johansson, Midtvedt, & 
Theodorsson, 1994). The commensal bacterium B. thetaiotaomicron VPI-5482, for 
example, which is a member of the gut flora, has been linked to the functional processes 
of the gut such as nutrition absorption, mucosal barrier function, metabolism, angiogenesis 
and postnatal intestinal maturation (Hooper & Gordon, 2001; Hooper et al., 2001). 
Previously, many studies have demonstrated an alteration in gut microbiota to be 
linked to a variety of conditions including diabetes, arthritis, colitis and cancer and even 
immune system. Conditions such as Crohn’s disease and obesity have implicated gut 
bacterial dysbiosis in pathogenesis (Chan, et al., 2015; Mai, et al., 2007). The highest 
bacterial load is found in the distal small intestinal tract and colon - areas commonly found 
to be associated with disease conditions (Hooper, Midtvedt, & Gordon, 2002; Kanauchi, 
Mitsuyama, Araki, & Andoh, 2003). It was not clear if the bacterial dysbiosis is a cause or 
consequence of the disease until recently when it was shown that alterations in gut 
microbiome precede polyposis in the ApcMin/+ mouse (Son, et al., 2015). An altered gut 
microbiome can cause inflammation ranging from acute bouts to chronically inflamed gut. 
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An altered microbiome, which shifts from symbiotic to a more inflammation-inducing 
`phenotype, leads to a vicious cycle of erosion of the gut epithelial lining that, in turn, leads 
to more and more inflammatory processes taking place inside the gut microenvironment 
(Saxena, et al., 2012; Zhang, et al., 2015). A need to address and characterize host-microbe 
relations has been emphasized in recent years in order to elucidate the processes and factors 
involved in the relationship between the gut microbiome and inflammation and related 
tumorigenesis. 
The intestinal epithelial lining has a strong relationship to the gut bacteria. The 
bacterial flora of the intestine helps in digesting the food (especially carbohydrates) that 
cannot be digested by the mammalian gut, and in turn, the intestinal epithelial cells 
metabolize the short-chain fatty acids that result from the bacterial fermentation of the 
undigested carbohydrates and use them as an energy source (Abreu, 2010). 
 
2.3 Antibiotic usage, gut microbiome and inflammation 
Antibiotic treatments that are usually used against digestive tract infections not only target 
the pathogenic microbes but also the host-interactive useful microbes. It is already known 
that the use of antibiotics, especially broad spectrum, not only help get rid of pathogenic 
bacteria but also deplete related micro-organisms, which fail to return to normal levels even 
long after the antibiotic usage subsides (Cresci & Bawden, 2015). Microbial diversity also 
is seen to be reduced in the gut following antibiotic treatment which exerts detrimental 
effects (Lofmark, Jernberg, Jansson, & Edlund, 2006). 
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 Antibiotic usage can severely and permanently affect 30% of the microbial 
population (Dethlefsen & Relman, 2011). Once the antibiotic treatment is stopped, and 
some resilient bacteria repopulate the gut, the final state is never a complete replacement 
of the initial state (Francino, 2015). Any early antibiotic treatment in humans reduces the 
overall diversity of the microbiota populations inside the gut which leads a dysbalance of 
the inflammatory molecules in the body. The dysbalance between the Th1 and Th2 
paradigm was at first thought to be the main culprit in bringing out the inflammatory effects 
of the microbiota dysbalance. An increased Th1 activation was linked to harmful 
inflammatory changes (Akdis & Akdis, 2009; Oboki, Ohno, Saito, & Nakae, 2008). 
However recently, alterations in the gut microbiota have been linked to a dysregulation of 
the regulatory T cell paradigm and their associated cytokines (Shen, Hu, Kang, Tang, & 
Hong, 2014), where the regulation of this immunological pathway depends on the 
relationship between the gut microbiota and the immune system. Different cocktails of 
antibiotics administered to mice have led to an upregulation of either the Th2 or a Th17 
response (Atarashi & Honda, 2011; Dimmitt et al., 2010), indicating that an alteration in 
the gut microbiota may favor one pathway and downregulate another inflammatory 
pathway. How the microbiota changes in the first place and then a subsequent change 
occurs in the inflammatory pathways during spontaneous tumorigenesis is a question that 
the present study aimed at answering via studying different stages of tumorigenesis. 
 Inflammation is an important route through which alterations in gut microbiota 
affect the overall milieu of inflammatory processes closely associated with the gut. Gut 
microbiota manipulation through antibiotic treatment has been shown to cause a decrease 
in the expression of the Muc2 protein, a major component of the intestinal mucus layer 
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(Dimmitt, et al., 2010). A thinning of the protective mucus layer leads to a direct contact 
between the gut lining and the gut bacteria residing in the lumen, thereby triggering innate 
immune responses and inflammation (Francino, 2015). The inflammatory response, along 
with being systemic, also occurs at a more localized level such as the alterations in gut 
microbiota leading to increased levels of pro-inflammatory cytokines such as IL-1β and 
TNF-α (Vijay-Kumar, Carvalho, Aitken, Fifadara, & Gewirtz, 2010). 
 For the completion of aims 2 and 3, antibiotics were administered to the treatment 
group of mice in three sets: 1). One cycle of antibiotic administration starting at 6 weeks 
of age for 10 days and sacrifice at 8 weeks; 2). Two cycles of antibiotic administration 
starting at 6 weeks and 10 weeks and sacrifice at 12 weeks; and 3). Three cycles of 
antibiotic administration starting at 6, 10 and 14 weeks of age and sacrifice at 16 weeks. 
Antibiotic administration at 6 weeks of age signified the manipulation of gut microbiome 
at the onset of tumorigenesis. This stage of tumorigenesis is marked by a gradual increase 
in the number of polyps in the small intestine (Puppa et al., 2011). Antibiotic administration 
at 6 and 10 weeks of age helped define effects of microbiome altered at the beginning of 
tumorigenesis (6 weeks) and then at the middle of the life span of experimental mice which 
is marked by progression of tumor development resulting in more pronounced symptoms 
of anemia and intestinal blockage. While the polyp number reaches a plateau, they only 
increase in size during this stage and the animals continue to lose body weight (Puppa, et 
al., 2011). Antibiotic treatment at 6, 10 and 14 weeks represented the alterations in 
microbiome throughout the processes initiation of tumorigenesis. This stage is usually 
marked by severe inflammation, continuation of tumor size and maximum weight loss 
(Puppa, et al., 2011). 
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2.4 Impact of antibiotics 
Although antibiotics are used against pathogenic microbes, their usage affects other 
microbial members of the community as well. The effects that are established as a result of 
an altered microbiome can be long-lasting even after the antibiotic treatment has subsided 
(Jakobsson, et al., 2015; Jernberg, Lofmark, Edlund, & Jansson, 2007). While the more 
resilient bacteria are successful at returning to their pre-treatment levels, others are lost 
indefinitely (Willing, Russell, & Finlay, 2011). Moreover, the occurrence of co-
dependence between members of the community based on differential metabolite 
production and utilization pathways leads to perturbation of members that are not 
necessarily directly targeted by the antibiotic. 
The direct and indirect effects of the antibiotics are brought about at different levels 
and ways. The indirect effects are brought about by the changed gut microbiota. A change 
in the bacterial population is known to cause a change in the downstream signaling by the 
Pattern Recognition Receptors (PPRs) which help maintain epithelial integrity and repair 
process, while change in some bacterial populations that bind to Toll-like receptors, such 
as TLR4, are linked to an altered innate immune defenses (Willing, et al., 2011). A reduced 
production of short-chain fatty acids (SCFAs) is also a common feature of human 
metabolic profiles after antibiotic treatment (Romick-Rosendale et al., 2009; Yap et al., 
2008). Changes in bacterial populations also affects differentiation of certain immune 
system molecules such as IL-17 and often lead to a dysregulation of the immune system 
(Ivanov et al., 2009). More direct effects include undesirable inflammation of the gut such 
as gastroenteritis (Barthel et al., 2003) and even dermatitis (J. Watanabe, Fujiwara, 
Sasajima, Ito, & Sonoyama, 2010). 
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The antibiotics used for the present study are neomycin, vancomycin and 
ampicillin. The antibiotic neomycin is used against both Gram-positive and Gram-negative 
bacteria. Being nephrotoxic, it is almost always prescribed to be consumed through the oral 
route. Its primary method of action is binding the duplex of RNA of bacteria (Kaul & Pilch, 
2002). The antibiotic is water-soluble and has a low toxicity for animals (Waksman & 
Lechevalier, 1949). Vancomycin is an antibiotic which is used against Gram-positive 
bacteria (Gonzalez, Rubio, Romero-Vivas, Gonzalez, & Picazo, 1999; Small & Chambers, 
1990). It is not absorbed by the intestinal mucosa (Van Bambeke, 2006) and its acts by 
inhibiting the cell wall formation of the Gram-positive bacteria by binding to the terminal 
D-alanyl-D-alanine moieties of the N-acetyl glucosamine/N-acetyl muramic acid peptide 
(Chakraborty et al., 2010). The antibiotic ampicillin is active against both Gram-positive 
and Gram-negative bacteria and is usually no-toxic. It mechanism of action includes its 
penetration into the bacterial cell wall and acting as an irreversible inhibitor of the enzyme 
transpeptidase involved in the construction of the bacterial cell walls ultimately leading to 
bacterial cell lysis. 
 
2.5 Intestinal mucus layer 
The gut lining is folded into tubular invaginations called the villi in the intestine and crypts 
(of Leiberkuhn) in the colon. The gut lining is protected from the lumen microenvironment 
by a single-cell layer comprising of absorptive enterocytes (which make most of the 
epithelial cells), mucus-producing goblet cells, hormone-producing enteroendocrine cells 
and Paneth cells that produce anti-microbial products in the gut (Abreu, 2010). The four 
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types of the cells line the single-celled layer of the gut that faces the lumen. All the four 
types of cell arise from the pluripotent stem cells that lie at the base of the crypts. The 
differentiated cells that arise from the stem cells of the crypts slowly and continuously rise 
towards the crypt apex from where the single-celled layer is regularly shed and renewed to 
maintain a healthy gut, also providing the crypt with a feature of polarity. 
The mucus in the small and large intestine is secreted by the goblet cells. It forms 
the first line of defense between the gut lumen microenvironment and the underlying 
epithelial layer and the submucosa. The mucin proteins in the gut mainly comprise of the 
MUC2 and MUC5AC proteins. They have properties of forming gel like coating onto the 
gut lumen once getting hydrated and form highly glycosylated proteins that are resistant to 
the digestive environment of the gut (Koboziev, Reinoso Webb, Furr, & Grisham, 2014). 
Changes in goblet cell function, secretion of mucins into the lumen and composition of this 
mucus layer are shown to be altered by an altered microbiome (Deplancke & Gaskins, 
2001). The mucus layer provides a balanced ecosystem for the resident and as well as 
pathogenic bacteria in the intestinal lumen by acting as a source of nutrition, thus indicating 
a homeostatic balance between the host gut microenvironment and the microbiome 
associated with it (Aristoteli & Willcox, 2003). An alteration in one of them may render 
the other dysfunctional. It is also said that the resident bacteria may inhibit the adherence 
of pathogenic bacteria to the intestinal epithelial cells by increasing the production of 
intestinal mucus (Mack, Ahrne, Hyde, Wei, & Hollingsworth, 2003; Mack, Michail, Wei, 
McDougall, & Hollingsworth, 1999; Smirnova, Guo, Birchall, & Pearson, 2003). 
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2.6 Mucus and gut microbiome 
It has been shown that the mucus layer tends to thickness with increased diversity of the 
microbiota (Jakobsson, et al., 2015). The mucus layer provides a source of nutritional 
carbon and therefore energy to some of the intestinal flora that are able to lyse the glycans 
present in the mucus, making the inter-relationship between the gut bacteria and the mucus 
layer really important (Kaur, et al., 2015). Also, the metabolites produced by these 
microbes also influence the differentiation and function of the epithelial and immune cells 
in the intestinal mucosa (Kato, et al., 2014; Shan, et al., 2013). Our recent study (Kaur, et 
al., 2015) also suggested that a reduction in the secretory mucin profile is associated with 
an inflammatory phenotype of the gut. Inflammation, which is an integral part of 
tumorigenesis should therefore, may strongly be correlated with a reduced bacterial 
diversity or numbers. Moreover, both Gram-positive and Gram-negative bacteria are 
known to enhance the intestinal mucin expression (Dohrman et al., 1998). The regulation 
of the mucin gene expression as well as mucus production have been shown to be two 
levels at which the gut microbial community may modulate mucins (Comelli, et al., 2008). 
Gut microbiota manipulation through antibiotic treatment has been shown to cause a 
decrease in the expression of the Muc2 protein, a major component of the intestinal mucus 
layer (Wlodarska et al., 2011). A thinning of the protective mucus layer leads to a direct 
contact between the gut lining and the gut bacteria residing in the lumen, thereby triggering 
innate immune responses and inflammation (Francino, 2015). 
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2.7 Gut microbiome and ApcMin/+ 
Studies that work at elucidating the role of gut microbes in disease models, are limited, 
especially due to the fact that most of the important gut bacteria are difficult to grow in a 
laboratory setting making them unavailable for studying unless mammalian models are 
used. However, there is evidence that the manipulation of the gut microbiome through diet 
modulations, can alter the disease conditions such as those in Crohn’s disease and 
Inflammatory Bowel Disease (Mai, et al., 2007). Studies that use the ApcMin/+ mouse model 
for studying gut diseases and their association with microbiota often report significant 
changes in microbiome profiles of the large intestine, but also report that differences in the 
polyps is only significant in the small intestine (Mai, et al., 2007) The detrimental effects 
are also brought about via loss of certain colonizing bacterial species that are dependent on 
other colonizers for processes such as nutritional interactions and removal of secondary 
metabolites and toxic waste products (Belenguer et al., 2006), or through loss of useful co-
evolved processes brought about by the host-microbial co-dependence (Atarashi & Honda, 
2011; Ferreira, Willing, & Finlay, 2011). There are no studies that study the gut 
microbiome with respect to gut inflammation and tumorigenesis in an age/time- dependent 
manner. It has been seen that specific pathogen-free (SPF) ApcMin/+ exhibit a higher tumor 
load and anemia with a higher infiltration of inflammatory cells specifically at advanced 
stages as compared to germ-free animals, indicating that a mere modulation of gut 
microbiome profiles can abrogate the disease condition in the gut (Y. Li, et al., 2012). 
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2.8 Gut microbiome, inflammatory cytokines and tumorigenesis 
It is a fact that till date, one of the most effective class of chemopreventive agents is the 
non-steroidal anti-inflammatory drugs (NSAIDs). The induction of cancer in the gut by 
chronic inflammation has always indicated towards the importance of underlying altered 
inflammatory processes (Zhang, et al., 2015). Different agents that have been documented 
to be effective against tumors and cancers are the agents that function by downregulating 
important inflammatory pathways and pro-inflammatory cytokines. Apart from the usual 
NSAIDs that function by downregulating the metabolism of the arachidonic acid through 
the Cyclooxygenase (COX) pathways agents such as curcumin and quercetin exert their 
chemopreventive effects through the downregulation of mRNA expression levels of pro-
inflammatory cytokines such as IL1-β, IL-6 and TNF-α, and reduction of macrophage 
infiltration (Y. Li, et al., 2012; Murphy, Davis, McClellan, & Carmichael, 2011; Murphy, 
Davis, McClellan, Gordon, et al., 2011; Ritland, et al., 1999).  
 It has also been shown that the intestinal commensal bacteria play a role in the 
development of gut microenvironmental immune system comprising both the humoral and 
cellular components and maintains the protective steady state immune function throughout 
life (Cebra, 1999; Talham, et al., 1999). It may be more appropriate to say that any 
alteration in the composition of the gut microbiome leads to a dysfunctional immune 
system. 
 Certain bacterial species such as B. thetaiotaomicron bacterium have been 
associated with the attenuation of pro-inflammatory responses by reducing the levels of the 
pro-inflammatory cytokine IL-8 (Zhao et al., 2001). 
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 Comparative numbers of certain bacteria often lead to upregulation or 
downregulation of certain inflammatory pathways. The systemic release of microbial 
products as a result of the manipulation of the gut epithelium invokes an IL-23 response 
and a further IL-17 response in order to neutralize further invasion by the microbes, and 
the process is brought about by the Firmicutes bacteria Clostridia sp. (Shih, et al., 2014). 
The bacteria especially promotes IL-17 cytokine in the small intestine which is the primary 
site of its attachment and survival (Omenetti & Pizarro, 2015). These Th17 cells may 
become autoreactive in case of intestinal epithelium insult. The bacteria Bacteroides 
fragilis from the Bacteroidetes phylum leads to an increase in the production of IL-10 
cytokine (Omenetti & Pizarro, 2015), whereas its strains have been implicated in the 
production of the pro-inflammatory cytokine IL-17-dependent inflammation-related colon 
cancer (W. Wu, et al., 2015). 
 It is widely accepted that inflammation contributes to the development of cancer 
and inflammatory cells have been noted in and around tumors (Hanahan & Weinberg, 
2011). A relationship between inflammation and intestinal neoplasia is supported by the 
facts that inflammatory bowel disease predisposes patients to intestinal carcinomas and 
that the anti-inflammatory drugs aspirin (Baron et al., 2003), celecoxib (Bertagnolli et al., 
2006), and rofecoxib (Bertagnolli, et al., 2006), all have proven efficacy in preventing 
human colorectal adenoma development. 
Adenoma formation has been shown to increase following adoptive transfer of pro-
inflammatory lymphocytes (Rao et al., 2006) and decreased after the adoptive transfer of 
anti-inflammatory regulatory T-cells (Treg cells) (Erdman et al., 2005). Apart from direct 
effects of inflammatory cells, adenomas are also known to be impaired by the absence of 
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the molecule MyD88 which mediates the downstream inflammatory signaling as a 
response to bacterial and viral products (Rakoff-Nahoum & Medzhitov, 2007). Pro-
inflammatory pathways such as those involved with IL-17 secretion are associated with 
many chronic inflammatory conditions such as asthma (Schnyder-Candrian et al., 2006) 
and inflammatory bowel disease (Yen et al., 2006), along with colon carcinogenesis 
(Langowski et al., 2006). IL-17, especially, has been denoted as a marker and mediator of 
tumor angiogenesis (Langowski, et al., 2006). Over-expression of pro-inflammatory 
factors such as IL-6, MCP-1, NF-ᴋB and IL-8 can aggravate tumors (Wang & Zhang, 
2015). 
Mechanisms of how the microbiome dysbiosis can lead to inflammation and 
tumorigenesis is not clear, however, recent studies have shown that microbiota species such 
as the Bacteroides fragilis and Escherichia coli can cause colorectal cancer by producing 
virulence factors such as toxins and gene products (Arthur et al., 2012; S. Wu, et al., 2009). 
It has been suggested that the interplay of inflammation and tumorigenesis is modulates 
strongly by the gut microbiota but the mechanisms leading to the process have not 
elucidated. Recently, some light has been shed on thei phenomena by a study which could 
demonstrate the process of tumorigenesis to occur in germ-free mice when transplanted 
with isolated gut microbiota from intestinal tumor-bearing mice (Zackular, et al., 2013) 
In the context of the ApcMin/+ mouse model, the mutual interaction of macrophages 
with cancer cells enhances production of inflammatory cytokines such as IL-1, IL-6 and 
TNF-α that transform the tumor microenvironment so that it favors the survival, growth 
and motility of cancer cells. Reduction in pro-inflammatory molecules such as MCP-1 
leads to a decrease in the total polyp number and size in the ApcMin/+ mouse along with 
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downregulating inflammatory processes in tumor tissues and surrounding tumor 
microenvironment (McClellan, Davis, Steiner, Day, et al., 2012). An elevation in the 
intestinal inflammatory cytokine (MCP-1, IL-1β, IL-6 and TNF-α) response occurs at 12 
weeks of age as a result of the rapid increase in polyp number, which are further elevated 
with increase in polyp size. A similar study by McClellan et al (2012) (McClellan, Davis, 
Steiner, Enos, et al., 2012) shows an increased mRNA expression of MCP-1, IL-1β, IL-6 
and TNF-α that is evident at 12 weeks of age and is consistent with the increase in polyp 
number that occurs at this time. After the age of 12 weeks which is associated with the 
largest number of small polyps, the inflammatory response continues to increase while the 
number of polyps remain constant which indicates that the inflammatory response after 12 
weeks could largely be driven by polyp size. However, it is still unclear whether the 
changes in polyp number and size that occurs in this model is a result of the elevated 
inflammatory response or vice versa (McClellan, Davis, Steiner, Enos, et al., 2012). 
 
2.9 The Bacteroidetes and Firmicutes 
The gut microflora plays a very important role in the immunology, nutrition and pathology 
of an organism. A limitation in the methodical techniques and inherent biases involved in 
the carrying out culture-based techniques to study gut microbiome had previously limited 
our knowledge in better understanding the gut microbiome from the point of view of not 
only characterizing it as whole but also elucidating the mechanisms it can affect that may 
lead to various disease outcomes in living systems. New methodologies have now been 
developed to study the diversity of the gut microbial community, which was formerly 
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thought to contain merely 400-500 species. The total of 1250 Operational Taxonomic Units 
representing the gut bacterial species have been identified by the use of the recently 
developed mapping techniques (Mariat et al., 2009). In the context of humans, 80% of the 
mapped fecal bacteria contains three major phyla: Bacteroidetes, Firmicutes and 
Actinobacteria (Lay et al., 2005). The gut microbiome is a complex ecosystem containing 
a dominant population (>109 CFU/g) of anaerobic bacterial species represented by genera 
of Bacteroides, Eubacterium, Bifidobacterium, Peptostreptococcus, Ruminococcus, 
Clostridium and Propionibacterium, and sub-dominant (< 109 CFU/g) population of 
aerobic bacteria pertaining to the Enterobacteriaceae family, especially E. coli, and the 
genera Streptococcus, Enterococcus, Lactobacillus, Fusobacterium, 
Desulfovibrio and Methanobrevibacter (Harmsen, Raangs, He, Degener, & Welling, 
2002).  
 
 The establishment and diversification of the gut microbiome is a gradual process 
that is required for proper development and overall health. Once the gut microbiome 
manifests itself completely, its stays constant during the life of a healthy individual (Franks 
et al., 1998) which explains the fact that an alteration in one or more of the resident 
microbial populations lead to pathological conditions. 
 The Bacteroidetes phylum is comprised of Gram-negative anaerobic and aerobic 
bacterial species. Some studies link the absence or reduction of, or delayed colonization of 
the gut by the phylum Bacteroidetes to be associated with a weakened immune system in 
humans. For example, a delayed postnatal colonization of Bacteroidetes population has 
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been associated with development of allergies in children born by Caesarian section (S. 
Watanabe et al., 2003). 
The Firmicutes represent the phylum mostly containing Gram-positive bacterial 
species. The phylum contains both aerobic and anaerobic bacterial species. 
Many Firmicutes are capable of producing endospores which help them survive 
desiccation and extreme conditions. Their capability to survive extreme conditions may be 
one reason that these bacteria are found in high numbers in the gut under pathological and 
inflammatory conditions. Comparisons of gut microbiota of lean and obese mice and lean 
and obese human individuals revealed that the Bacteroidetes significantly decrease while 
the Firmicutes significantly increase with obesity (Guo et al., 2008).  
 
2.10 16S rRNA gene profiling and sequencing 
The gut microflora plays a very important role in the immunology, nutrition and pathology 
of an organism. A limitation in the methodical techniques and inherent biases involved in 
the carrying out culture-based techniques to study gut microbiome had previously limited 
our knowledge in better understanding the gut microbiome from the point of view of not 
only characterizing it as whole but also elucidating the mechanisms it can affect that may 
lead to various disease outcomes in living systems. New methodologies have now been 
developed to study the diversity of the gut microbial community, which was formerly 
thought to contain merely 400-500 species. The total of 1250 Operational Taxonomic Units 
representing the gut bacterial species have been identified by the use of the recently 
developed mapping techniques (Mariat, et al., 2009). In the context of humans, 80% of the 
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mapped fecal bacteria contains three major phyla: Bacteroidetes, Firmicutes and 
Actinobacteria (Lay, et al., 2005). One of the most widely used of these methods is the 16S 
rRNA method. The 16S rRNA gene method is one of the earliest and most widely used 
methods used for phylogenetic, taxonomic and bioinformatics analyses. It targets the 16S 
rRNA bacterial genes to know diversity or similarities in biological samples. The 16S 
rRNA gene provides many advantages in microbiome analyses including its universal 
distribution in bacterial species, relative stability in evolution and ideal size (1500 bp). 
Consisting of both constant and variable regions, the 16S gene is easy to amplify used 
broad-range primers used against regions flanking its variable regions (Sankar, Lagier, 
Pontarotti, Raoult, & Fournier, 2015). 
 
2.11 Statistical Power of the study 
The microbiome analysis in our study was done using the fecal samples from experimental 
mice. A 16S rRNA gene sequencing technique was used to study the gut microbial 
populations in the animals. The sample size for the study is 4. Some of the previous studies 
that have been directed towards similar microbial analyses have used similar samples sizes. 
Russell et al (2012) (Russell et al., 2012) used n = 3-5 to study changes in the gut microbial 
communities in C57BL/6 mice following antibiotic treatment at neonatal and adult stages 
of life. The results showed significant reductions in the overall bacterial diversity and phyla 
abundance in antibiotic-treated mice as compared to control mice (p value<0.05). Oh et al 
(2016) (Oh et al., 2016) used a sample size of 5 mice per group in order to show significant 
differences in bacterial load and diminished rDNA in antibiotic-treated mouse fecal 
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samples as compared to their control counterparts. Similar studies have used n = 4-6 mice 
per group in order to show Significant (p value<0.01) changes in gut microbial constituents 
as a result of administration of the antibiotic enrofloxacin with an increase in type-2 
cytokines has been shown in a study that used 4 to 6 (n) mice per group (Strzepa et al., 
2016). 
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CHAPTER 3 
 
GUT MICROBIOME PROFILE DURING INITIATION AND PROGRESSION OF 
TUMORIGENESIS IN APCMIN/+ MOUSE1 
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Anindya Chanda and James Carson. To be submitted. 
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3.1 Abstract 
 
An altered gut microbiome can cause inflammation ranging from acute bouts to 
chronically inflamed gut. An altered microbiome, which shifts from symbiotic to a more 
inflammation-inducing phenotype, leads to a vicious cycle of erosion of the gut epithelial 
lining that, in turn, leads to more and more inflammatory processes taking place inside the 
gut microenvironment. However, there are no studies that study the gut microbiome with 
respect to gut inflammation and tumorigenesis in an age/time- dependent manner. Four 
weeks old male ApcMin/+ and C57BL/6 (WT) mice were obtained from the Jackson 
Laboratories and bred and housed at the Animal Resource Facility at University of South 
Carolina. Food (Purina chow) and drinking water was available to the mice ad libidum 
under a 12:12 hour light-dark cycle and a low-stress environment (22oC, 50% humidity 
and low noise). All animal care followed institutional guidelines under a protocol approved 
by the Institutional Animal Care and Use Committee at the University of South Carolina. 
Mice were monitored throughout the course of study for weight loss, diarrhea and blood in 
stools as a basis for calculating clinical scores (Saxena, et al., 2012). Mice were sacrificed 
at 8, 12 and 16 weeks. Bacterial 16S rRNA gene amplification and sequencing were 
performed using Polymerase Chain Reaction (PCR) amplification of the V4 region of the 
bacterial 16 S rRNA gene. The clinical scores increased with tumor progression in the 
ApcMin/+ mice and were significant as compared to the WT mice for which the score 
remained 0 for the course of the study. The Bacteroidetes and Firmicutes were found to be 
the two dominant phyla in the WT and ApcMin/+ gut which remained so at all three 
experimental time points of the study. However, their overall percentages change with 
antibiotic treatment where Firmicutes phyla dominated with the treatment. It could be 
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concluded from the study that the Firmicutes phyla of bacteria may play a role during the 
initiation of tumorigenesis. 
Keywords: Microbiome, Inflammation, Bacteroidetes, Firmicutes 
 
3.2 Introduction 
 
 The gut microbiome is an integral and an important symbiotic system present in the 
gut, which comprises of bacteria, archaea, fungi and viruses residing in the gastrointestinal 
tract throughout its length. The gut bacteria itself comprises a major percentage of the total 
gut microbiome, where its numbers are in trillions. While the stomach and duodenum 
contain about 101 to 102 Colony Forming Units (CFU) per mL of bacterial forms, the 
jejunum and ileum comprise 104 to 108, and the colon has 1010 to 1012 CFU/mL of bacteria 
(Cresci & Bawden, 2015). The microbiome acts advantageous for the gut such that it 
regulates gut epithelial and endocrine cellular structure (Uribe, et al., 1994). Previously, 
many studies have demonstrated an alteration in gut microbiota to be linked to a variety of 
conditions including diabetes, arthritis, colitis and cancer and even immune system. 
Conditions such as Crohn’s disease and obesity have implicated gut bacterial dysbiosis in 
pathogenesis (Chan, et al., 2015; Mai, et al., 2007). It was not clear if the bacterial dysbiosis 
is a cause or consequence of the disease until recently when it was shown that alterations 
in gut microbiome precede polyposis in the ApcMin/+ mouse (Son, et al., 2015). An altered 
gut microbiome can cause inflammation ranging from acute bouts to chronically inflamed 
gut. An altered microbiome, which shifts from symbiotic to a more inflammation-inducing 
phenotype, leads to a vicious cycle of erosion of the gut epithelial lining that, in turn, leads 
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to more and more inflammatory processes taking place inside the gut microenvironment 
(Saxena, et al., 2012; Zhang, et al., 2015). A need to address and characterize host-microbe 
relations has been emphasized in recent years in order to elucidate the processes and factors 
involved in the relationship between the gut microbiome and inflammation and related 
tumorigenesis. The intestinal epithelial lining has a strong relationship to the gut bacteria. 
The bacterial flora of the intestine helps in digesting the food (especially carbohydrates) 
that cannot be digested by the mammalian gut, and in turn, the intestinal epithelial cells 
metabolize the short-chain fatty acids that result from the bacterial fermentation of the 
undigested carbohydrates and use them as an energy source (Abreu, 2010). There are no 
studies that study the gut microbiome with respect to gut inflammation and tumorigenesis 
in an age/time- dependent manner. How the microbiota changes in the first place and then 
a subsequent change occurs in the inflammatory pathways during spontaneous 
tumorigenesis is a question that the present study aimed at answering via studying different 
stages of tumorigenesis. 
 
3.3 Methods 
 
Experimental animals and groups 
Four weeks old male ApcMin/+ and C57BL/6 (WT) mice were obtained from the Jackson 
Laboratories and bred and housed at the Animal Resource Facility at University of South 
Carolina. Food (Purina chow) and assigned to each of the following six groups with four 
mice each (n=4): WT- 8, 12 and 16 weeks; and ApcMin/+- 8, 12 and 16 weeks. Food (Purina 
chow) and drinking water was available to the mice ad libidum under a 12:12 hour light-
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dark cycle and a low-stress environment (22oC, 50% humidity and low noise). All animal 
care followed institutional guidelines under a protocol approved by the Institutional Animal 
Care and Use Committee at the University of South Carolina. 
 
Clinical score 
Mice were monitored throughout the course of study for weight loss, diarrhea and blood in 
stools. Clinical score was measured for each mouse twice during each week of the study 
based on our earlier published criteria (Saxena et al., 2012). Mice were sacrificed after the 
last clinical score measurement. Cumulative clinical scores for each mouse equaled a 
maximum score of 12, which was based on weight loss measurement, diarrhea and fecal 
hemoccult (kit, BECKMAN COULTER) with a maximum score of 4 within each of the 
three quantitative parameters. Score for the weight loss was based on the following 
published scale where 0 = 0–5% weight loss; 1 = 6–10% weight loss; 2 = 11–15% weight 
loss; 3 = 16–20% weight loss; and 4 = >20% weight loss. Scoring of diarrhea was as 
follows: 0 = well-formed pellets, 2 = pasty and semi-formed stools that do not adhere to 
the anus, 4 = liquid stools that adhere to the anus. Detection of blood in the stools was 
determined by using hemoccult kit (BECKMAN COULTER), which is a hydrogen 
peroxide-based kit that forms a visible blue colored complex with blood. The followings 
were the score rates for the fecal hemoccult: 0 = no blood, 2 = positive hemoccult, 4 = 
gross bleeding. The total clinical score was the summation of the individual score of weight 
loss, diarrhea and fecal hemoccult. The maximum score a mouse could get was 12. 
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Collection of tissues 
Mice (n=4 for each age group and genotype) were sacrificed at 8, 12 and 16 weeks by 
cervical dislocation. Blood was collected before sacrifice through retro-orbital puncture, 
centrifuged at 10,000 rpm for 15 minutes and serum was isolated and stored at -20°C. Small 
intestine and colon were excised and flushed clean with PBS. 2 mm2 colon tissue sections 
were fixed in 10% formalin and were replaced with 70% ethanol after 24 hours, followed 
by paraffin embedding and sectioning to obtain 5 µm thin sections on glass slides. 2 mm2 
intestine and colon tissue sections were incubated in RPMI medium at 37°C for 24 hours 
followed by centrifugation at 2500 rpm for 15 minutes. Supernatant was obtained and 
stored at -20°C for tissue-secreted cytokine expression analyses. The rest of the tissues 
were stored at -80oC for further usage. Fecal samples were snap frozen at the time of 
sacrifice for microbiome analysis. 
 
Microbiome analysis 
At sacrifice, fecal samples were obtained from the experimental mice to perform bacterial 
(luminal) microbiome analysis (n=3). Bacterial n16S rRNA gene amplification and 
sequencing were performed at the Alkek Center for Metagenomics and Microbiome 
Research, Department of Molecular Virology and Microbiology, Baylor College of 
Medicine (Houston, TX). Polymerase Chain Reaction (PCR) amplification of the V4 
region of the bacterial 16 S rRNA gene was performed using the Illumnia Miseq sequencer. 
The consensus sequences obtained from the analysis were mapped into Operational 
Taxonomic Units (OTUs). Alpha- and beta-diversity values were obtained based on the 
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OTUs’ relative abundance table. Chao1 (estimator of richness) and Shannon Diversity 
Index (richness and evenness) were used to obtain the alpha diversity values. Weighted 
Unifrac (dissimilarity based on phylogenetic differences and taxonomic abundance) and 
Unweighted Unifrac (dissimilarity based on phylogenetic differences but not abundance) 
were performed to obtain the beta-diversity values for the experimental samples (He et al., 
2016). Kruskal Wallis and Mann Whitney statistical analyses were performed to calculate 
significance in diversity and relative abundance respectively, by comparing different 
treatments and disease stages. A p value of less than 0.05 was considered significant. 
Statistical analysis 
Two-way analysis of variance (ANOVA), Two-way repeated measure ANOVA and One-
way ANOVA were used to analyze the data with Tukey post hoc-analyses to estimate the 
significance of differences obtained between different experimental treatment conditions 
and between the experimental mouse strains used in the study. A p<0.05 were considered 
statistically significant. All the statistical analyses were done using SigmaStat 3.5 (SPSS, 
Chicago, IL). The sample size (n) was kept as 4 for the study. 
 
3.4 Results 
 
Clinical score increases with tumor progression in ApcMin/+ mice 
Clinical score which is a culmination of diarrhea, weight loss and fecal hemoccult was 
plotted against the age of mice (n=4) at 8, 12 and 16 weeks (figure 3.1). Clinical score was 
found to increase with age of ApcMin/+ mice. ApcMin/+ mice at 6, 8, 10, 12, 14, and 16 showed 
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a significantly higher clinical score when compared to ApcMin/+ mice at 5 weeks (#p<0.03, 
dotted line) (figure 3.1 A, B and C).  ApcMin/+ mice of 8, 10, 12, 14 and 16 weeks of age 
showed a significantly higher clinical score when compared to ApcMin/+ mice at 6 weeks of 
age (*p<0.05).  ApcMin/+ mice of 10, 12, 14 and 16 weeks of age showed a significantly 
higher clinical score when compared to ApcMin/+ mice at 8 weeks of age (**p<0.01). No 
significant difference was found between the clinical score of ApcMin/+ mice at age 10, 12, 
14 and 16 weeks (figure 3.1 A, B and C). 
 
Microbiome profile during tumor initiation 
The bacterial microbiome profiles of the experimental animals were studied without 
antibiotic treatment to establish the control profiles of the gut microbial community. The 
Bacteroidetes and Firmicutes were the two main phyla among others that were profiled 
through the 16S rRNA sequencing. The bacterial population including proteobacteria, 
firmicutes and bacteroidetes was found to fluctuate with age and genotype. The percentage 
of Proteobacteria was found be significantly higher in ApcMin/+ mice at 8 weeks (16.9%) 
when compared to WT mice (3.7%) and ApcMin/+ mice at 12 (3.8%) and 16 weeks (5.1%). 
No significant difference was observed in the proteobacterial population between the 
ApcMin/+ mice and WT mice at 12 and 16 weeks (figure 3.2 A). Percentage of firmicutes 
bacteria in the feces of the ApcMin/+ mice at 8 weeks (48.8%) was significantly higher than 
at 12 weeks (33.2%) and 16 weeks (21.2%). Percentage of firmicutes bacteria was found 
to be significantly higher at 8, 12 and 16 weeks when compared to their WT counterparts 
(12.0%). Percentage of firmicutes population in ApcMin/+ mice at 16 weeks (21.2%) was 
found be significantly lower than the ApcMin/+ mice at 12 weeks (33.2%) (figure 3.2 B). 
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Bacteroidetes showed an opposite trend in bacterial population when compared with 
firmicutes and proteobacteria. Percentage of bacteroidetes in ApcMin/+ mice at 8 weeks 
(30.6%) was found be significantly lower than both WT (83.6%) and ApcMin/+ mice at 12 
(61.8%) and 16 weeks (71.8%) of age. ApcMin/+ mice at 12 weeks of age showed a 
significantly lower bacteroidetes population when compared to WT mice. No significant 
difference was observed in the bacteroidetes population of ApcMin/+ mice at 16 weeks and 
WT mice (figure 3.2 C).  
 
3.5 Discussion  
 
An alteration in gut microbiome has been previously demonstrated to be linked to a variety 
of conditions including diabetes, arthritis, colitis and cancer and even immune system. 
Conditions such as Crohn’s disease and obesity have implicated gut bacterial dysbiosis in 
pathogenesis (Chan, et al., 2015; Mai, et al., 2007). It was not clear if the bacterial dysbiosis 
is a cause or consequence of the disease until recently when it was shown that alterations 
in gut microbiome precede polyposis in the ApcMin/+ mouse (Son, et al., 2015). Our present 
study aimed at characterizing the bacterial populations that can be regarded as significant 
in the process of tumorigenesis. The Proteobacteria and the Firmicutes phylum were 
significantly higher in ApcMin/+ mouse during initial stages of tumorigenesis as compared 
to WT mice indicating that the phyla can be a precursor to and important during the initial 
stages of tumorigenesis. The study by Son et al (Son, et al., 2015) demonstrated a higher 
Bacteroidetes population in this regard. A reason that can be cited for this discrepancy in 
observations is that the mice used were at initial stages of tumorigenesis and it can well be 
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possible that some of the ApcMin/+ may not have even developed polyps at the age of 
euthanization (8 weeks). The observations however, support the higher percentages of the 
Bacteroidetes phylum that was observed in the WT mice at the age of 8 weeks in our study. 
Moreover, the observation that the ApcMin/+ mice showing a clinical score at 5 weeks which 
continued to increase till 8 weeks, while the WT mice exhibited no clinical signs of disease, 
makes Firmicutes the likely bacterial phylum that can set the stage for tumorigenesis rather 
than the Bacteroidetes that are abundant in the WT mice at this age but do not lead to any 
clinical score. 
The percentage of Proteobacteria and the Firmicutes phylum decreased 
significantly at 12 and 16 weeks. Percentage of Proteobacteria phylum in ApcMin/+ mouse 
becomes almost similar to the WT mice. However, the percentage of Firmicutes showed a 
similar pattern but remains significantly higher than WT mice. Both of these phylum 
showed a decrease with increase in tumorigenesis. The restoration of these phylum levels 
to almost those of the WT mice may be seen as a defense mechanism of the digestive tract 
under the absence of any external manipulation of the gut microbiome. Concomitantly, we 
also observed an increase in the percentage of Bacteroidetes with age further strengthening 
the idea that higher percentage of Proteobacteria and Firmicutes and lower percentage of 
Bacteroidetes could set a stage for tumorigenesis and then body defense mechanism tries 
to restore the gut microbiome (figure 3.2). However, clinical scores for the tumor-bearing 
mice continued to increase until 16 weeks (figure 3.1), an indication that levels of 
Proteobacteria, Firmicutes and Bacteroidetes may not correlate with disease prognosis 
once the process of tumorigenesis starts. This finding is also corroborated by the 
observation of the species richness values that were not significantly different between 
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experimental time points within the two animal groups. However, the overall diversity 
between the ApcMin/+ and WT mice was significant whether species abundance is taken into 
account or not.  
3.6 Conclusion 
In conclusion, it can be stated that reduced abundance of the phylum Firmicutes 
can be cited as one of the factors that set the conditions for initiation of tumorigenesis in 
the mouse gut although the two phyla Firmicutes and Bacteroidetes do not bear any 
significant correlation to the clinical scores for the tumor-bearing mice during the 
progression of tumorigenesis. With an absence of any external manipulation of the gut 
microbiome, the species present in the normal mice may not be similar to that present in 
tumor-bearing mice at 8, 12 and 16 weeks of age. However, phylogenetically, the species 
members residing in a tumor-bearing gut may significantly be different and diverse from 
those residing in a normal gut. A bigger samples size may help elucidate interesting links 
between the major gut microbial members and tumorigenesis with respect to phylogenetic 
and diversity analyses. 
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3.7 Figure Legends 
 
Figure 3.1. Clinical score (A–C) Clinical scores for ApcMin/+plotted for different time 
points during the study (n=4). The scores were calculated out of twelve points; four points 
for each parameter: weight loss, diarrhea and hemoccult. Two-way repeated measure of 
analysis of variance (ANOVA) was used to calculate the significant difference between the 
clinical score for ApcMin/+ mice between different time points throughout the length of the 
experiment. #p<0.03 ApcMin/+ vs ApcMin/+ 5 weeks, *p<0.05 vs ApcMin/+ at 6 weeks and 
**p<0.01 vs ApcMin/+ at 8 weeks . 
 
Figure 3.2. Intestinal microbiome phylum profiles. Relative percentages of the major 
phyla obtained from fecal 16S rRNA (V4 region) sequencing analysis from experimental 
mice (n=4): (A) Proteobacteria, (B) Firmicutes and (C) Bacteroidetes (C). (Percentage 
values represent fractions of depicted bacteria out of the total microbial pool). Two-way 
analysis of variance (ANOVA) was used to calculate the significant difference between the 
percentage of bacteria in ApcMin/+ control and WT control mice at age 8, 12 and 16 weeks. 
*p<0.05 vs Apc-min 8 weeks, **p<0.05 Apc-min (12 weeks vs 16 weeks) and #p<0.01 
Apc-min vs WT.  
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Figure 3.1. Clinical score (A–C) Clinical scores for ApcMin/+ plotted for different time 
points during the study (n=4). The scores were calculated out of twelve points; four points 
for each parameter: weight loss, diarrhea and hemoccult. Two-way repeated measure of 
analysis of variance (ANOVA) was used to calculate the significant difference between the 
clinical score for ApcMin/+ mice between different time points throughout the length of the 
experiment. #p<0.03 ApcMin/+ vs ApcMin/+ 5 weeks, *p<0.05 vs ApcMin/+ at 6 weeks and 
**p<0.01 vs ApcMin/+ at 8 weeks. 
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Figure 3.2. Intestinal microbiome phylum profiles. Relative percentages of the major 
phyla obtained from fecal 16S rRNA (V4 region) sequencing analysis from experimental 
mice (n=4): (A) Proteobacteria, (B) Firmicutes and (C) Bacteroidetes (C). (Percentage 
values represent fractions of depicted bacteria out of the total microbial pool). Two-way 
analysis of variance (ANOVA) was used to calculate the significant difference between the 
percentage of bacteria in ApcMin/+ control and WT control mice at age 8, 12 and 16 weeks. 
*p<0.05 vs Apc-min 8 weeks, **p<0.05 Apc-min (12 weeks vs 16 weeks) and #p<0.01 
Apc-min vs WT.   
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CHAPTER 4 
 
EFFECT OF GUT MICROBIOME MANIPULATION ON GUT HEALTH AND 
TUMORIGENESIS IN APCMIN/+ MOUSE2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
Kamaljeet Kaur, Arpit Saxena, Sarah Depeape, Alexander Chumanevich, Raja Fayad, 
Anindya Chanda and James Carson. To be submitted. 
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4.1 Abstract 
 
The mucus layer acts as a site of residence for the gut microbiota. The metabolites 
produced by the microbes influence the differentiation and function of the epithelial and 
immune cells in the intestinal mucosa. The gut microbiota can regulate mucin gene 
expression and mucus production. Our recent study suggested a reduction in the secretory 
mucin profile to be associated with an inflammatory phenotype of the gut. 4 weeks old 
ApcMin/+ and C57BL/6 (WT) mice were housed at the Animal Resource Facility, University 
of South Carolina with access to food and water ad libidum. The ApcMin/+ and C56BL/6 
mice were assigned to the following groups:  WT-Control (no antibiotic)-8 weeks, WT-
Antibiotic (ABT)-8 weeks, WT-Control-12 weeks, WT-ABT-12 weeks, WT-Control-16 
weeks, WT-ABT-16 weeks, ApcMin/+-Control-8 weeks, ApcMin/+-ABT-8 weeks, ApcMin/+-
Control-12 weeks, ApcMin/+-ABT-12 weeks, ApcMin/+-Control-16 weeks and ApcMin/+-ABT-
16 weeks. An antibiotic mixture containing Vancomycin, Neomycin and Ampicillin (each 
1 mg/mL) was administered to experimental mice through drinking water starting at the 
5th, 10th and 14th weeks of age for 10 days followed by normal drinking water. Mice were 
monitored twice during each week of the study for weight loss, diarrhea and blood in stools 
to serve as basis for calculating clinical scores. Small intestine and colon from the animals 
was excised, flushed with PBS and tumor number and area were counted using 1% Methyl 
Blue stain. Small intestinal samples were stained with Alcian Blue dye solution for 
quantifying mucus-containing goblet cells. The clinical scores for the animals increased 
with antibiotic treatment except for WT-C mice for which the scores were 0 throughout the 
study. The highest clinical scores were exhibited with tumorigenesis as well as microbiome 
manipulation. Polyp counts for the ApcMin/+ mice increased with antibiotic treatment. A 
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significantly higher percentage of the Firmicutes phylum was observed with microbiome 
manipulation. The goblet to epithelial cell ratio was significantly reduced in both ApcMin/+ 
and WT mice with antibiotic treatment during all three experimental time points. Our 
results suggest that Firmicutes within the gut microbiome plays a regulatory role in colonic 
epithelial to goblet cell differentiation and tumorigenesis. 
 
Keywords: Microbiome, polyps, tumor, Firmicutes, ApcMin/+ 
 
 
4.2 Introduction 
 
An altered gut microbiome can cause inflammation ranging from acute bouts to 
chronically inflamed gut. An altered microbiome, which shifts from symbiotic to a more 
inflammation-inducing phenotype, leads to a vicious cycle of erosion of the gut epithelial 
lining that, in turn, leads to more and more inflammatory processes taking place inside the 
gut microenvironment (Saxena, et al., 2012; Zhang, et al., 2015). A need to address and 
characterize host-microbe relations has been emphasized in recent years in order to 
elucidate the processes and factors involved in the relationship between the gut microbiome 
and inflammation and related tumorigenesis. Inflammation is an important route through 
which alterations in gut microbiota affect the overall milieu of inflammatory processes 
closely associated with the gut. Gut microbiota manipulation through antibiotic treatment 
has been shown to cause a decrease in the expression of the Muc2 protein, a major 
component of the intestinal mucus layer (Dimmitt, et al., 2010). A thinning of the 
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protective mucus layer leads to a direct contact between the gut lining and the gut bacteria 
residing in the lumen, thereby triggering innate immune responses and inflammation 
(Francino, 2015). The inflammatory response, along with being systemic, also occurs at a 
more localized level such as the alterations in gut microbiota leading to increased levels of 
pro-inflammatory cytokines such as IL-1β and TNF-α (Vijay-Kumar, et al., 2010). It has 
been shown that the mucus layer tends to thickness with increased diversity of the 
microbiota (Jakobsson, et al., 2015). The mucus layer provides a source of nutritional 
carbon and therefore energy to some of the intestinal flora that are able to lyse the glycans 
present in the mucus, making the inter-relationship between the gut bacteria and the mucus 
layer really important (Kaur, et al., 2015). Also, the metabolites produced by these 
microbes also influence the differentiation and function of the epithelial and immune cells 
in the intestinal mucosa (Kato, et al., 2014; Shan, et al., 2013). Our recent study (Kaur, et 
al., 2015) also suggested that a reduction in the secretory mucin profile is associated with 
an inflammatory phenotype of the gut. Both Gram-positive and Gram-negative bacteria are 
known to enhance the intestinal mucin expression (Dohrman, et al., 1998). The regulation 
of the mucin gene expression as well as mucus production have been shown to be two 
levels at which the gut microbial community may modulate mucins (Comelli, et al., 2008). 
Gut microbiota manipulation through antibiotic treatment has been shown to cause a 
decrease in the expression of the Muc2 protein, a major component of the intestinal mucus 
layer (Wlodarska, et al., 2011). A thinning of the protective mucus layer leads to a direct 
contact between the gut lining and the gut bacteria residing in the lumen, thereby triggering 
innate immune responses and inflammation (Francino, 2015). 
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 Studies that work at elucidating the role of gut microbes in disease models, have 
been limited, especially due to the fact that most of the important gut bacteria are difficult 
to grow in a laboratory setting making them unavailable for studying unless mammalian 
models are used. However, there are evidences that the manipulation of the gut microbiome 
through diet modulations, can alter the disease conditions such as those in Crohn’s disease 
and Inflammatory Bowel Disease (Mai, et al., 2007). Studies that use the ApcMin/+ mouse 
model for studying gut diseases and their association with microbiota often report 
significant changes in microbiome profiles of the large intestine, but also report that 
differences in the polyps is only significant in the small intestine (Mai, et al., 2007) The 
detrimental effects are also brought about via loss of certain colonizing bacterial species 
that are dependent on other colonizers for processes such as nutritional interactions and 
removal of secondary metabolites and toxic waste products (Belenguer, et al., 2006), or 
through loss of useful co-evolved processes brought about by the host-microbial co-
dependence (Atarashi & Honda, 2011; Ferreira, et al., 2011). There are no studies that 
study the gut microbiome with respect to gut inflammation and tumorigenesis in an 
age/time- dependent manner. 
 
 
4.3 Materials and methods 
 
 
 
Experimental animals and groups, Collection of tissues 
4 weeks old ApcMin/+ and C57BL/6 (WT) mice were obtained from Jackson Laboratories 
and bred in-house at the Animal Resource Facility, University of South Carolina. Food 
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(Purina chow) and drinking water was available to the mice ad libidum under a 12:12 hour 
light-dark cycle and a low-stress environment (22oC, 50% humidity and low noise). The 
ApcMin/+ and C56BL/6 mice were assigned to the following twelve groups with 4 mice in 
each group (n=4):  WT-Control (no antibiotic)-8 weeks, WT-Antibiotic (ABT)-8 weeks, 
WT-Control-12 weeks, WT-ABT-12 weeks, WT-Control-16 weeks, WT-ABT-16 weeks, 
ApcMin/+-Control-8 weeks, ApcMin/+-ABT-8 weeks, ApcMin/+-Control-12 weeks, ApcMin/+-
ABT-12 weeks, ApcMin/+-Control-16 weeks and ApcMin/+-ABT-16 weeks. Experimental 
animals from aim 1 were used for aim 2 as control animals. All animal care followed 
institutional guidelines under a protocol approved by the Institutional Animal Care and Use 
Committee at the University of South Carolina. 
 
Collection of tissues 
Mice (n=4 separate for each age group, genotype and treatment group) were sacrificed at 
8, 12 and 16 weeks by cervical dislocation. The control mice for the present experiment 
were the same as used under aim1. Blood was collected before sacrifice through retro-
orbital puncture, centrifuged at 10,000 rpm for 15 minutes and serum was isolated and 
stored at -20°C. Small intestine and colon were excised and flushed clean with PBS. 2 mm2 
colon tissue sections were fixed in 10% formalin and were replaced with 70% ethanol after 
24 hours, followed by paraffin embedding and sectioning to obtain 5 µm thin sections on 
glass slides. 2 mm2 intestine and colon tissue sections were incubated in RPMI medium at 
37°C for 24 hours followed by centrifugation at 2500 rpm for 15 minutes. Supernatant was 
obtained and stored at -20°C for tissue-secreted cytokine expression analyses. The rest of 
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the tissues were stored at -80oC for further usage. Fecal samples were snap frozen at the 
time of sacrifice for microbiome analysis. 
 
Microbiome analysis 
At sacrifice, fecal samples were obtained from the experimental mice to perform bacterial 
(luminal) microbiome analysis (n=3). Bacterial 16S rRNA gene amplification and 
sequencing were performed at the Alkek Center for Metagenomics and Microbiome 
Research, Department of Molecular Virology and Microbiology, Baylor College of 
Medicine (Houston, TX). Polymerase Chain Reaction (PCR) amplification of the V4 
region of the bacterial 16S rRNA gene was performed using the Illumnia Miseq sequencer. 
The consensus sequences obtained from the analysis were mapped into Operational 
Taxonomic Units (OTUs). Alpha- and beta-diversity values were obtained based on the 
OTUs’ relative abundance table. Chao1 (estimator of richness) and Shannon Diversity 
Index (richness and evenness) were used to obtain the alpha diversity values. Weighted 
Unifrac (dissimilarity based on phylogenetic differences and taxonomic abundance) and 
Unweighted Unifrac (dissimilarity based on phylogenetic differences but not abundance) 
were performed to obtain the beta-diversity values for the experimental samples (He, et al., 
2016). Kruskal Wallis and Mann Whitney statistical analyses were performed to calculate 
significance in diversity and relative abundance respectively, by comparing different 
treatments and disease stages. A p value of less than 0.05 was considered significant. 
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Antibiotic treatment 
An antibiotic mixture containing Vancomycin, Neomycin and Streptomycin (each 1 
mg/mL) was administered to experimental mice belonging to the antibiotic treatment 
groups. While neomycin and streptomycin act against Gram-negative bacteria, 
vancomycin is used against Gram-positive bacteria. The antibiotics mixture was 
administered to the mice through drinking water starting at the 5th, 10th and 14th weeks of 
age for 10 days followed by normal drinking water. 
 
Clinical score 
Mice were monitored throughout the course of study for weight loss, diarrhea and blood in 
stools. Clinical score was measured for each mouse twice during each week of the study. 
Mice were sacrificed after the last clinical score measurement. Cumulative clinical scores 
for each mouse equaled a maximum score of 12, which was based on weight loss 
measurement, diarrhea and fecal hemoccult (kit, BECKMAN COULTER) with a 
maximum score of 4 within each of the three quantitative parameters. Score for the weight 
loss was based on the following published scale where 0 = 0–5% weight loss; 1 = 6–10% 
weight loss; 2 = 11–15% weight loss; 3 = 16–20% weight loss; and 4 = >20% weight loss. 
Scoring of diarrhea was as follows: 0 = well-formed pellets, 2 = pasty and semi-formed 
stools that do not adhere to the anus, 4 = liquid stools that adhere to the anus. Detection of 
blood in the stools was determined by using hemoccult kit (BECKMAN COULTER), 
which is a hydrogen peroxide-based kit that forms a visible blue colored complex with 
blood. The followings were the score rates for the fecal hemoccult: 0 = no blood, 2 = 
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positive hemoccult, 4 = gross bleeding. The total clinical score was the summation of the 
individual score of weight loss, diarrhea and fecal hemoccult. The maximum score a mouse 
could get was 12. 
Polyp count 
Small intestine and colon from the experimental animals were excised and flushed with 
PBS. Tumor number and area was counted using 1% Methyl Blue stain under the light 
microscope for all mice in different groups and significant difference was calculated. 
Tumor number and/or area were also correlated with the manipulation of the microbiome. 
Goblet to epithelial cell ratio 
Small intestinal samples (0.5 cm) were embedded in paraffin wax and sectioned using a 
microtome into 10 µm sections obtained on glass slides. Standard deparaffinization 
procedure was followed using xylene and gradations of ethanol for the small intestinal 
sections. Alcian Blue dye solution for staining mucus-containing goblet cells was prepared 
by dissolving the dye powder (8GX) at 1% concentration in 3% acetic acid solution and 
setting the pH at 2.5. Nuclear Fast Red solution for staining the epithelial cells of the 
mucosa were prepared at a final concentration of 0.1% dissolved in 5% aluminum sulfate 
solution. Tissues were firstly stained with Alcian Blue and then counterstained with 
Nuclear Fast Red solution. Goblet to epithelial cell ratio was calculated per crypt with ten 
crypts per section and five sections per group. 
Statistical analysis 
Two-way analysis of variance (ANOVA), Two-way repeated measure ANOVA and One-
way ANOVA were used to analyze the data with Tukey post hoc-analyses to estimate the 
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significance of differences obtained between different experimental treatment conditions 
and between the experimental mouse strains used in the study. A p<0.05 were considered 
statistically significant. All the statistical analyses were done using SigmaStat 3.5 (SPSS, 
Chicago, IL). The sample size was kept as 4 for the study. 
 
4.4 Results 
Clinical scores 
Clinical scores were recorded twice per week during the course of study for all 
experimental animals to know the disease prognosis and health. Mice sacrificed at 8 weeks 
of age (figure 4.1 A): ApcMin/+ mice ABT group showed significantly higher clinical score 
than both ApcMin/+ control and WT-ABT group at 6 weeks. ApcMin/+ mice at 8 weeks 
showed significantly higher clinical score than 6 weeks and WT-ABT group. Lastly, 
ApcMin/+ mice ABT group showed significantly higher clinical score than WT-ABT mice 
at 8 weeks.  
 Mice sacrificed at 12 weeks of age (figure 4.1 B): ApcMin/+ mice at 6 and 8 weeks 
of age showed a significantly lower clinical score than WT-ABT group. ApcMin/+ mice at 
8, 10 and 12 weeks of age showed a significantly higher clinical when compared to ApcMin/+ 
mice at 6 weeks of age. ApcMin/+ mice at 10 and 12 weeks of age showed a significantly 
higher clinical score than ApcMin/+ mice at 8 weeks of age. ApcMin/+ mice ABT group at 6 
and 8 weeks of age showed a significantly higher clinical score than ApcMin/+ mice at the 
same age respectively. ApcMin/+ mice ABT group at 12 weeks of age showed a significantly 
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higher clinical score than WT-ABT group. No significant difference was observed between 
other treatment groups.  
 Mice sacrificed at 16 weeks of age (figure 4.1 C): ApcMin/+ mice at 6 weeks of age 
showed a significantly lower clinical score than WT-ABT group. ApcMin/+ mice at 8, 10, 
12, 14 and 16 weeks of age showed a significantly higher clinical score than ApcMin/+ mice 
at 6 weeks of age. ApcMin/+ mice at 16 weeks of age showed a significantly higher clinical 
score than ApcMin/+ ABT mice at 8 weeks of age. ApcMin/+ ABT group at 6, 8, 12 and 16 
weeks of age showed a significantly higher clinical score than ApcMin/+ mice at the same 
age respectively. ApcMin/+ mice ABT group at 16 weeks of age showed a significantly 
higher clinical score than ApcMin/+ ABT group at 6, 8, 12 and 14 weeks of age. 
 
Polyp count 
The total polyp count in ApcMin/+ ABT and ApcMin/+ control mice group at 12 and 16 weeks 
of age was significantly higher when compared to the mice within the same group at 8 
weeks.  ApcMin/+ ABT and ApcMin/+ control at 16 weeks of age showed a significant increase 
in the polyp count when compared to the mice belonging to the same group at 12 weeks of 
age.  Only ApcMin/+ ABT mice at 16 weeks of age showing a significantly higher polyp 
count when compared to the ApcMin/+ control at the same age (figure 4.2A). No significant 
difference was observed in the polyp count of ApcMin/+ ABT and ApcMin/+ control at 8 and 
12 weeks of age.   
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Polyp count (<1 mm2) 
No significant difference was observed between the ABT-treated and control ApcMin/+ mice 
for the number of intestinal polyps less than 1 mm2 area, at 8, 12 and 16 weeks. Also no 
significance was observed within the ApcMin/+ ABT and ApcMin/+ control group at 8, 12 and 
16 weeks of age (figure 4.2B).  
 
Polyp count (>1 mm2) 
Intestinal polyps measuring more than 1 mm2 in area were significantly increased in 
ApcMin/+ ABT and ApcMin/+ control mice group at 12 and 16 weeks of age was significantly 
higher when compared to the mice within the same group at 8 weeks.  ApcMin/+ ABT and 
ApcMin/+ control at 16 weeks of age showed a significant increase in the polyp count (>1 
mm2) when compared to the mice belonging to the same group at 12 weeks of age.  Only 
ApcMin/+ ABT mice at 16 weeks of age showed a significantly higher polyp count (>1 mm2) 
when compared to the ApcMin/+ control at the same age (figure 4.2B). No significant 
difference was observed in the polyp count of ApcMin/+ ABT and ApcMin/+ control at 8 and 
12 weeks of age. 
 
Goblet cells 
Goblet to epithelial cell ratio provide an indirect measure in order to quantify mucus 
production in the small intestine which is closely related to the gut resident bacterial 
community although the mechanisms for the same are not known. The goblet to epithelial 
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cell ratio decreased significantly at 12 and 16 weeks of age and increased significantly at 
12 and 16 weeks of age in WT control group and WT ABT group respectively when 
compared within the respective group at 8 weeks of age. Goblet to epithelial cell ratio was 
found to be significantly higher in WT control group at 8, 12 and 16 weeks when compared 
to WT ABT group at the same age (figure 4.3 A and B). No significant difference was 
observed in the goblet to epithelial cell ratio with other group or with age.  
The goblet to epithelial cell ratio decreased significantly at 12 and 16 weeks of age 
in ApcMin/+-Control and ApcMin/+-ABT group when compared within the respective group 
at 8 weeks of age. The ratio was also found to be significantly lower in ApcMin/+ control 
group at 16 weeks of age when compared with 12 weeks of age within the same group. 
Goblet to epithelial cell ratio was found to be significantly higher in ApcMin/+ control group 
at 8, 12 and 16 weeks when compared to ApcMin/+ ABT group at the same age (figure 4.3 
A and C). No significant difference was observed in the goblet to epithelial cell ratio with 
other group or within group with age.  
 
The bacterial population including proteobacteria, firmicutes and bacteroidetes was found 
to fluctuate with age, genotype and antibiotic treatment. The percentage of Proteobacteria 
was found be significantly higher in ApcMin/+ control mice at 8 weeks when compared to 
WT control mice and ApcMin/+ control mice at 12 and 16 weeks. No significant difference 
was observed in the proteobacterial population between the ApcMin/+ and WT control mice 
at 12 and 16 weeks. Percentage of proteobacteria in ApcMin/+ control mice at 8 weeks was 
found to be significantly higher when compared to ApcMin/+ ABT treated mice at the same 
age. However, at 16 weeks the percentage of proteobacteria in ApcMin/+ control mice were 
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found to be significantly lower than ApcMin/+ ABT treated mice at the same age. No 
significance in the proteobacterial population was observed between other groups with 
change in either treatment, age or genotype. The percentage of firmicutes bacteria in WT 
ABT treated mice, ApcMin/+ control mice and ApcMin/+ ABT treated mice at age 8, 12 and 
16 weeks was found to be significantly higher than the WT control mice. The percentage 
of firmicutes bacteria in WT ABT treated and ApcMin/+ ABT treated mice at age 8, 12 and 
16 weeks was significantly higher than the ApcMin/+ control mice at the respective age. 
Percentage of firmicutes bacteria in the feces of the ApcMin/+ mice at 8 weeks was 
significantly higher than at 12 weeks and 16 weeks. Percentage of firmicutes bacteria was 
found to be significantly higher at 8, 12 and 16 weeks when compared to their WT 
counterparts. Percentage of firmicutes population in ApcMin/+ mice at 16 weeks was found 
be significantly lower than the ApcMin/+ mice at 12 weeks. No significant difference was 
observed in the firmicutes population of WT ABT treated and ApcMin/+ ABT treated mice 
with age. The percentage of bacteroidetes bacteria in WT ABT treated mice, ApcMin/+ 
control mice and ApcMin/+ ABT treated mice at age 8, 12 and 16 weeks was found to be 
significantly lower than the WT control mice. Percentage of bacteroidetes in ApcMin/+ mice 
at 8 weeks was found be significantly lower than both WT and ApcMin/+ mice at 12 and 16 
weeks of age. No significant difference was observed in the bacteroidetes population at 16 
weeks between ApcMin/+ mice and WT mice. The percentage of bacteroidetes bacteria in 
WT ABT treated and ApcMin/+ ABT treated mice at age 8, 12 and 16 weeks was found to 
be significantly lower than the ApcMin/+ control mice. No significant difference was 
observed in the bacteroidetes population of WT ABT treated and ApcMin/+ ABT treated 
mice with age. 
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4.5 Discussion 
 
 
Our study aimed at following the processes of tumorigenesis and its resulting 
disease prognosis and intestinal mucus secretion phenotype upon microbial manipulation 
at three different time points representing different stages of tumorigenesis. The antibiotic 
treatment lead to an significant increase in the percentage of the Firmicutes population. In 
our previous study, the phylum was observed to be present abundantly during the initial 
stages of tumorigenesis while decreasing in abundance gradually from 12 weeks to 16 
weeks. The phylum showed a similar trend in the control groups while continuing to remain 
high even at 12 (tumor development) and 16 weeks (later stages of tumorigenesis) of age 
with antibiotic treatment. Our data may corroborate other studies that demonstrated that 
even when the antibiotic treatment is stopped, and some resilient bacteria repopulate the 
gut, the final state is never a complete replacement of the initial state (Francino, 2015). Our 
clinical score continued to remain high at 12 and 16 weeks for the ApcMin/+ with and without 
antibiotic treatment and for WT mice with antibiotic treatment. The observation that after 
8 weeks, the clinical scores of antibiotic treated ApcMin/+ were not significantly different 
from those of the control ApcMin/+ mice indicates towards the insult incurred by the process 
of tumorigenesis in the intestinal mucosa. Thus, the physical erosion of the mucosa and the 
inflammatory insult by the process of tumorigenesis are not additive during tumorigenic 
conditions. However, the antibiotic treatment can lead to an increase in the numbers of 
polyps. Moreover, the clinical scores did not correlate to the three time points of antibiotic 
administration to the mice, indicating that neither the timing of antibiotic administration 
nor the levels of the Firmicutes may have any effect on the disease prognosis. This is not 
however the case with the WT phenotype, where antibiotic treatment did produce a clinical 
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score even without tumorigenesis during 8, 12 and 16 weeks as compared to the WT mice 
without treatment. This indicates towards a more physical effect of microbiome 
manipulation on the gut that may lead to the same clinical symptoms that are present with 
processes of inflammation and tumorigenesis.  
While the external manipulation of the gut microbiome may have physical impacts, 
it surely effects the physiology of the intestine as well, as can be seen from the data on the 
polyp numbers of the ApcMin/+ mice. While the manipulation of gut microbiome 
significantly increased the small intestinal total polyp counts at 16 weeks, the numbers 
were not significantly increased between antibiotic and control groups of 8 and 12 weeks. 
The antibiotic treatment also significantly increased the polyp numbers at 16 weeks as 
compared to those at 12 weeks with antibiotic treatment. The effects of the gut microbiome 
manipulation followed a similar trend in case of polyps that measured more than 1 mm in 
diameter, while had no significant effect on polyps less than 1 mm diameter. The effects 
of gut microbiome manipulation were more pronounced at 16 weeks of age as, the polyp 
numbers at 12 weeks with or without antibiotics were significantly increased as compared 
to those at 8 weeks with or without antibiotics, there was no significant difference between 
the polyp numbers at 12 weeks with and without antibiotics. Interestingly, the manipulation 
of the gut microbiome could significantly increase the polyp numbers from 12 to 16 weeks 
in the ApcMin/+ mice, there was no significant difference between the polyp numbers at 12 
and 16 weeks without antibiotics - a usual characteristic of tumorigenesis in the ApcMin/+ 
without any treatment, where the polyps only increase in their size and not numbers from 
12 weeks to later stages of tumorigenesis (McClellan, Davis, Steiner, Enos, et al., 2012). 
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The manipulation of the gut microbiome through antibiotics also significantly 
decreased the mucus-producing goblet cell numbers (measured by goblet to epithelial cell 
ratio) at all three time points of the present study. While the effect was significant only 
between antibiotic treatment and control within the ApcMin/+ and WT mice at 8 weeks, the 
microbial manipulation could lower the goblet to epithelial cell ratio in the ApcMin/+ mice 
as compared to the WT mice. This may again reflect the additive effects of inflammation, 
genetic susceptibility to polyp generation and the physical intestinal insult by the antibiotic 
treatment – an effect that was not observed in case of the WT mice. 
  
 
4.6 Conclusion 
 
 
It can be concluded that alterations in the gut microbiome community through antibiotic 
treatment can render the gut susceptible to an altered re-establishment of microbial 
community. The effects of the microbiome manipulation protocol are more obvious on the 
total number of polyp numbers in the gut and the on the goblet to epithelial cell ratios in 
the intestinal. While under no external treatment, an ApcMin/+ may exhibit only an increase 
in polyp size during progression of tumorigenesis towards its later stages, the effect of an 
externally manipulated ApcMin/+ microbiome may result in an increase is both polyp 
numbers and size as the process of tumorigenesis progress. While the ratio of the intestinal 
goblet to epithelia cells is significantly reduced as a result of gut microbial manipulation 
in both ApcMin/+ and WT mice, the effect is more obvious in the tumor-bearing mice as 
compared to the WT mice. 
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4.7 Figure Legends 
 
Figure 4.1. Clinical score with antibiotic treatment. (A–C) Clinical scores for ApcMin/+ 
mice at different time points (8, 12 and 16 weeks) (n=4 for each group) during the study. 
The scores were calculated out of twelve points; four points for each parameter: weight 
loss, diarrhea and hemoccult. Two-way repeated measure analysis of variance (ANOVA) 
was applied to calculate the significant difference between the clinical scores between 
different groups. #p<0.03 vs WT-ABT, *p<0.04 vs ApcMin/+ control group at 6 weeks, 
$p<0.05 vs ApcMin/+ within the same age group and φp<0.05 ApcMin/+ ABT at 16 weeks vs 
ApcMin/+ ABT at 14, 12, 10, 8 and 6 weeks of age. 
 
Figure 4.2. Tumor Quantification: (A) Graph representing the small intestine polyp 
count in ApcMin/+-Control and ApcMin/+-ABT at 8 weeks, 12 weeks and 16 weeks after 1, 2 
and 3 cycles of antibiotics respectively. (B) Graph showing polyp number (size < 1mm2) 
at 8 weeks, 12 weeks and 16 weeks. (C) Graph showing polyp number (size < 1mm2) at 8 
weeks, 12 weeks and 16 weeks. Two-way repeated measure analysis of variance (ANOVA) 
was applied to calculate the significant difference between the total polyp, small polyp and 
large polyp count between different groups at different ages.  *p<0.01 vs 8 weeks within 
the same group. **p<0.02 16 weeks vs 12 weeks within the same treatment group. #p<0.01  
ApcMin/+-Control vs ApcMin/+-ABT at 16 weeks of age. 
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Figure 4.3. Goblet and epithelial cell production: Figure illustrates (A) Alcian blue 
staining for small intestine tissue sections of WT and ApcMin/+ mice with and without 
antibiotic treatment. Blue and pink staining indicates goblet and epithelial cells 
respectively. (B) and (C): Graphs showing goblet to epithelial cell ratio per view per group 
for WT (B) and ApcMin/+ (C) mice. Two-way and two-way ANOVA was used to determine 
the significant difference in goblet to epithelial cell ratio between and within groups. *p 
value<0.05 vs 8 weeks within treatment group, **p<0.01 ApcMin/+ control mice 16 vs 12 
weeks. #p<0.01 control vs ABT group. 
 
Figure 4.4. Intestinal microbiome phylum profiles. Relative percentages of the major 
phyla obtained from fecal 16S rRNA (V4 region) sequencing analysis from experimental 
mice at (A) Proteobacteria, (B) Firmicutes and (C) Bacteroidetes (C). (Percentage values 
represent fractions of depicted bacteria out of the total microbial pool). Two-way analysis 
of variance (ANOVA) was used to calculate the significant difference between the 
percentage of bacteria in ApcMin/+ control, ApcMin/+ ABT treated, WT ABT treated and WT 
control mice at age 8, 12 and 16 weeks. *p<0.05 vs ApcMin/+ 8 weeks, **p<0.05 ApcMin/ 
+_ (12 weeks vs 16 weeks) and #p<0.01 ApcMin/+ or ApcMin/+ ABT treated or WT ABT 
treated vs WT.$p<0.001 WT ABT treated and ApcMin/+ ABT treated vs ApcMin/+ control.  
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Figure 4.1. Clinical score with antibiotic treatment. (A–C) Clinical scores for ApcMin/+ 
mice at different time points (8, 12 and 16 weeks) (n=4 for each group) during the study. 
The scores were calculated out of twelve points; four points for each parameter: weight 
loss, diarrhea and hemoccult. Two-way repeated measure analysis of variance (ANOVA) 
was applied to calculate the significant difference between the clinical scores between 
different groups. #p<0.03 vs WT-ABT, *p<0.04 vs ApcMin/+-Control group at 6 weeks, 
**p<0.03 ApcMin/+-ABT 16 weeks vs 12 and 8 weeks, $p<0.05 vs ApcMin/+ within the same 
age group and φp<0.05 ApcMin/+-ABT at 16 weeks vs ApcMin/+-ABT at 14, 12, 10, 8 and 6 
weeks of age. 
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Figure 4.2. Tumor Quantification: (A) Graph representing the small intestine polyp 
count in ApcMin/+-Control and ApcMin/+-ABT at 8 weeks, 12 weeks and 16 weeks after 1, 2 
and 3 cycles of antibiotics respectively. (B) Graph showing polyp number (size < 1mm2) 
at 8 weeks, 12 weeks and 16 weeks. (C) Graph showing polyp number (size < 1mm2) at 8 
weeks, 12 weeks and 16 weeks. Two-way repeated measure analysis of variance (ANOVA) 
was applied to calculate the significant difference between the total polyp, small polyp and 
large polyp count between different groups at different ages.  *p<0.01 vs 8 weeks within 
the same group. **p<0.02 16 weeks vs 12 weeks within the same treatment group. #p<0.01  
ApcMin/+-Control vs ApcMin/+-ABT at 16 weeks of age. 
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Figure 4.3. Goblet and epithelial cell production: Figure illustrates (A) Alcian blue 
staining for small intestine tissue sections of WT and ApcMin/+ mice with and without 
antibiotic treatment. Blue and pink staining indicates goblet and epithelial cells 
respectively. (B) and (C): Graphs showing goblet to epithelial cell ratio per view per group 
for WT (B) and ApcMin/+ (C) mice. Two-way and two-way ANOVA was used to determine 
the significant difference in goblet to epithelial cell ratio between and within groups. *p 
value<0.05 vs 8 weeks within treatment group, **p<0.01 ApcMin/+ control mice 16 vs 12 
weeks. #p<0.01 control vs ABT group.  
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Figure 4.4. Intestinal microbiome phylum profiles. Relative percentages of the major 
phyla obtained from fecal 16S rRNA (V4 region) sequencing analysis from experimental 
mice at (A) Proteobacteria, (B) Firmicutes and (C) Bacteroidetes (C). (Percentage values 
represent fractions of depicted bacteria out of the total microbial pool). Dotted line 
represents WT-C group as a comparative baseline. Two-way analysis of variance 
(ANOVA) was used to calculate the significant difference between the percentage of 
bacteria in ApcMin/+ control, ApcMin/+ ABT treated, WT ABT treated and WT control mice 
at age 8, 12 and 16 weeks. *p<0.05 vs Apc-min 8 weeks, **p<0.05 Apc-min (12 weeks vs 
16 weeks) and #p<0.01 Apc-min or ApcMin/+ ABT treated or WT ABT treated vs 
WT.$p<0.001 WT ABT treated and ApcMin/+ ABT treated vs ApcMin/+ control.  
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CHAPTER 5 
 
ASSOCIATION OF BACTEROIDETES AND FIRMICUTES WITH INFLAMMATION IN 
APCMIN/+ MOUSE3 
 
 
 
 
                                                          
3 Kamaljeet Kaur, Arpit Saxena, Samantha Truman, Matthew Rorro, Bianca Larsen, Emma 
Fletcher, Alexander Chumanevich and Raja Fayad. To be submitted 
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5.1 Abstract 
 
The induction of cancer in the gut by chronic inflammation has always indicated 
towards the importance of underlying altered inflammatory processes. Apart from 
chemopreventive agents that act by modulating and alleviating harmful inflammation, the 
intestinal commensal bacteria also plays a role in the development of gut 
microenvironmental immune system and maintains a protective steady state immune 
function throughout life. The systemic release of microbial products as a result of insults 
to gut epithelium has been associated with inflammation-related colon cancer and the 
present study aimed at characterizing this association. 4 weeks old ApcMin/+ and C57BL/6 
(WT) mice were housed at the Animal Resource Facility, University of South Carolina 
with access to food and water ad libidum. The ApcMin/+ and C56BL/6 mice were assigned 
to the following groups:  WT-Control (no antibiotic)-8 weeks, WT-Antibiotic (ABT)-8 
weeks, WT-Control-12 weeks, WT-ABT-12 weeks, WT-Control-16 weeks, WT-ABT-16 
weeks, ApcMin/+-Control-8 weeks, ApcMin/+-ABT-8 weeks, ApcMin/+-Control-12 weeks, 
ApcMin/+-ABT-12 weeks, ApcMin/+-Control-16 weeks and ApcMin/+-ABT-16 weeks. An 
antibiotic mixture containing Vancomycin, Neomycin and Ampicillin (each 1 mg/mL) was 
administered to experimental mice through drinking water starting at the 5th, 10th and 14th 
weeks of age for 10 days followed by normal drinking water. Small intestinal paraffin-
embedded sections were used for performing hematoxylin and eosin staining to determine 
the histopathology of small intestine and colon epithelial layer and for calculating crypt 
depth to villus ratio (CVR). Spleen weight was also measured to quantify general 
inflammation. The antibiotic treatment caused a physical insult to the intestinal mucosa 
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and caused a reduction in spleen weight. The CVR increased significantly with antibiotic 
treatment in the WT mice as compared to controls at all three time points, while its increase 
was significant only at 12 weeks in case of ApcMin/+ mice. The overall of percentage of 
Firmicutes increased with antibiotic treatment. It could be concluded that the effects of an 
altered microbiome may have both physical and physiological effects during initiation and 
progression of tumorigenesis. These effects may manifest as an insult to the intestinal 
mucosa, reduced spleen size and increased CVR, and may also be enhanced by an increased 
percentage of the Firmicutes phylum. 
 
Keywords: Firmicutes, inflammation, polyp, gut microbiome, crypts 
 
5.2 Introduction 
A need to address and characterize host-microbe relations has been emphasized in 
recent years in order to elucidate the processes and factors involved in the relationship 
between the gut microbiome and inflammation and related tumorigenesis. Alterations in 
the gut microbiota have been linked to a dysregulation of the regulatory T cell paradigm 
and their associated cytokines (Shen, et al., 2014), where the regulation of this 
immunological pathway depends on the relationship between the gut microbiota and the 
immune system. There have been no studies that study the gut microbiome with respect to 
gut inflammation and tumorigenesis in an age/time- dependent manner. It has been seen 
that specific pathogen-free (SPF) ApcMin/+ exhibit a higher tumor load and anemia with a 
higher infiltration of inflammatory cells specifically at advanced stages as compared to 
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germ-free animals, indicating that a mere modulation of gut microbiome profiles can 
abrogate the disease condition in the gut (Y. Li, et al., 2012). 
The significance of inflammation as a process underlying and crucial to cancer is 
demonstrated by the fact that till date, one of the most effective class of chemopreventive 
agents is the non-steroidal anti-inflammatory drugs (NSAIDs). The induction of cancer in 
the gut by chronic inflammation has always indicated towards the importance of underlying 
altered inflammatory processes (Zhang, et al., 2015). Different agents that have been 
documented to be effective against tumors and cancers are the agents that function by 
downregulating important inflammatory pathways and pro-inflammatory cytokines. It has 
also been shown that the intestinal commensal bacteria play a role in the development of 
the immune system of the gut microenvironment comprising both the humoral and cellular 
components and maintains the protective steady state immune function throughout life 
(Cebra, 1999; Talham, et al., 1999). It may be more appropriate to say that any alteration 
in the composition of the gut microbiome leads to a dysfunctional immune system. Certain 
bacterial species such as B. thetaiotaomicron bacterium have been associated with the 
attenuation of pro-inflammatory responses by reducing the levels of the pro-inflammatory 
cytokine IL-8 (Zhao, et al., 2001). Comparative numbers of certain bacteria often lead to 
upregulation or downregulation of certain inflammatory pathways. The systemic release of 
microbial products as a result of the manipulation of the gut epithelium invokes an IL-23 
response and a further IL-17 response in order to neutralize further invasion by the 
microbes, and the process is brought about by the bacteria Clostridia sp. (Shih, et al., 2014). 
Other bacterial species may also be involved with anti-inflammatory effects such as the 
bacteria Bacteroides fragilis from the Bacteroidetes phylum leads to an increase in the 
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production of IL-10 cytokine (Omenetti & Pizarro, 2015). It has been suggested that the 
interplay of inflammation and tumorigenesis is modulates strongly by the gut microbiota 
but the mechanisms leading to the process have not elucidated. Recently, some light has 
been shed on the phenomena by a study which could demonstrate the process of 
tumorigenesis to occur in germ-free mice when transplanted with isolated gut microbiota 
from intestinal tumor-bearing mice (Zackular, et al., 2013). 
 The establishment and diversification of the gut microbiome is a gradual process 
that is required for proper development and overall health. Once the gut microbiome 
manifests itself completely, its stays constant during the life of a healthy individual (Franks, 
et al., 1998) which explains the fact that an alteration in one or more of the resident 
microbial populations lead to pathological conditions. 
 The Bacteroidetes phylum is comprised of Gram-negative anaerobic and aerobic 
bacterial species. Some studies link the absence or reduction of, or delayed colonization of 
the gut by the phylum Bacteroidetes to be associated with a weakened immune system in 
humans. For example, a delayed postnatal colonization of Bacteroidetes population has 
been associated with development of allergies in children born by Caesarian section (S. 
Watanabe, et al., 2003). 
The Firmicutes represent the phylum mostly containing Gram-positive bacterial species. 
The phylum contains both aerobic and anaerobic bacterial species. 
Many Firmicutes are capable of producing endospores which help them survive desiccation 
and extreme conditions. Their capability to survive extreme conditions may be one reason 
that these bacteria are found in high numbers in the gut under pathological and 
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inflammatory conditions. Comparisons of gut microbiota of lean and obese mice and lean 
and obese human individuals revealed that the Bacteroidetes significantly decrease while 
the Firmicutes significantly increase with obesity (Guo, et al., 2008).  
An altered ratio between the two main gut bacterial phyla Bacteroidetes and 
Firmicutes may help elucidate at least way through which the gut changes during initiation 
of progression of tumorigenesis. 
 
5.3 Material and Methods 
 
Experimental animals and groups 
4 weeks old ApcMin/+ and C57BL/6 (WT) mice were obtained from Jackson Laboratories 
and bred in-house at the Animal Resource Facility, University of South Carolina. Food 
(Purina chow) and drinking water was available to the mice ad libidum under a 12:12 hour 
light-dark cycle and a low-stress environment (22oC, 50% humidity and low noise). The 
ApcMin/+ and C56BL/6 mice were assigned to the following twelve groups with four mice 
in each group (n=4):  WT-Control (no antibiotic)-8 weeks, WT-Antibiotic (ABT)-8 weeks, 
WT-Control-12 weeks, WT-ABT-12 weeks, WT-Control-16 weeks, WT-ABT-16 weeks, 
ApcMin/+-Control-8 weeks, ApcMin/+-ABT-8 weeks, ApcMin/+-Control-12 weeks, ApcMin/+-
ABT-12 weeks, ApcMin/+-Control-16 weeks and ApcMin/+-ABT-16 weeks. Experimental 
animals from aim 1 were used for aim 2 as control animals. All animal care followed 
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institutional guidelines under a protocol approved by the Institutional Animal Care and Use 
Committee at the University of South Carolina. 
Histopathology 
Small intestinal paraffin-embedded sections from aim 2 were used for performing 
hematoxylin and eosin staining in order to determine the morphology of small intestine and 
colon epithelial layer. Histopathology were quantified visually in a double-blind condition 
using light microscopy by a pathologist. Localized inflammatory status were indicated by 
inflammatory cells present in the mucosal layers of intestine and colon. Aberrant villi and 
crypts were also used as indicators of intestinal and colonic insults due to inflammatory 
response. 
Hematoxylin and eosin staining was used to observe the morphology of the intestinal 
mucosa and the disease severity was quantified on the basis of inflammation, immune cell 
infiltration into the mucosa and degree of tumor. Histopathology was quantified based on the 
scoring system indicating the severity of disease and constituting inflammation and immune cell 
infiltration. This was on the scale of 8 where highest score of 4 was given for each parameter, where 
0 = no infiltration or no inflammation; 2 = moderate infltration or inflammation; and 4 = severe 
inflammation with distorted crypts or infiltration and formation of lymphatic follicles (Saxena et 
al., 2009).. All the images were taken in 20X magnification with Nikon e600 microscope. Two 
investigators in blinded fashion measured the scores independently and the average was plotted in 
a graph.” 
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Crypt depth to villus height ratio 
Paraffin-embedded 10 µm small intestinal sections were deparaffinized and stained with 
hematoxylin and eosin. Digitized images of the tissues were obtained using a digital camera 
connected to a light microscope. The images were analyzed in a double blinded manner 
using the digital image software ImageJ, and crypt depth and villus height were measured 
(mm/mm) to calculate the crypt depth to villus height ratio. 
Spleen weight 
Spleens were excised from the animals at the time of sacrifice and their weights were 
recorded to estimate levels of systemic inflammation. The spleen samples were then rinsed 
with PBS and snap frozen. 
 
Enzyme-linked Immunosorbent Assay 
Enzyme-linked Immunosorbent Assay (ELISA) was performed to calculate the levels of 
pro-inflammatory cytokines TNF-α, IL-1β and IL-17 using kits (BD Pharmingen). The 
ELISA were performed on serum to know the levels of systemic cytokines. At the time of 
sacrifice, 1 cm sections of ileum and distal colon were excised from the experimental mice 
and incubated in 1 mL of RPMI medium at 37oC for 24 hours. The medium incubated with 
the excised tissues was then collected into separate centrifuge tubes and centrifuged at 4000 
rpm at 25oC for 15 minutes. The supernatant collected from the centrifuged contents served 
as the sample containing small intestine or colon tissue-secreted cytokines. 
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Statistical analysis 
Two-way analysis of variance (ANOVA), Two-way repeated measure ANOVA and One-
way ANOVA were used to analyze the data with Tukey post hoc-analyses to estimate the 
significance of differences obtained between different experimental treatment conditions 
and between the experimental mouse strains used in the study. A p<0.05 were considered 
statistically significant. All the statistical analyses were done using SigmaStat 3.5 (SPSS, 
Chicago, IL). 
 
5.4. Results 
 
Histopathology  
Histopathology of the small intestine was revealed by hematoxylin and eosin staining. 
Signs of inflammation were observed during all stages of tumorigenesis in the intestinal 
tissue of ApcMin/+ mice. Hyperplasia was observed in all ApcMin/+ mice at 8 weeks with and 
without antibiotic treatment. Mucosal dysplasia, blunted villi and increased monocytic 
inflammation was observed at 12 weeks. High grade chronic-type inflammation as shown 
by the presence of plasma cells and macrophages but no neutrophils was observed at 16 
weeks in the ApcMin/+ mice without antibiotic treatment. High grade dysplasia and 
dysplastic lesions were observed with antibiotic treatment in the ApcMin/+ mice at 16 weeks 
as compared to low-grade dysplasia that was observed at 16 weeks without antibiotic 
treatment (figure 5.1 A).  
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Histopathology scoring was used to determine quantitative difference in the histopathology 
of the colon of the mice belonging to different groups and with age. Degree of inflammation 
and immune cell infiltration was found to be significantly higher in ApcMin/+ ABT group 
when compared to ApcMin/+ control and WT ABT group. All the groups showed 
significantly higher clinical score than WT control group. Colon of the mice belonging to 
the ApcMin/+ control, ApcMin/+ ABT and WT ABT group showed a significantly higher 
inflammation and immune cell infiltration when compared to mice within the same group 
at 8 weeks. No significant difference was found between other groups and within group 
with age (figure 5.1 B). 
 
Spleen Weight 
Spleen weight was assessed as a measure of systemic inflammation along with serum 
cytokines. Spleen weight of ApcMin/+ ABT group at 16 weeks and ApcMin/+ control group at 
12 and 16 weeks was found to be significantly higher than the mice within the same groups 
at 8 weeks of age. Spleen weight of  ApcMin/+ ABT and ApcMin/+ control group mice at 16 
weeks of age was found to be significantly higher than both WT control mice and within 
the same group at 12 weeks of age. ApcMin/+ control group mice was found to have a 
significantly higher spleen weight as compared to the WT control mice (figure 5.2A).  
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Crypt depth to villus height ratio (CVR) 
The crypt depth to villus ratio (CVR) was calculated as a measure of intestinal 
inflammation for all animals. The CVR ratio in both ApcMin/+ and WT group with ABT at 
12 and 16 weeks was found to be significantly higher than the mice within the same group 
at 8 weeks of age. The CVR ratio of WT and ApcMin/+ with ABT treatment was 12 weeks 
of age was found to be significantly higher than the control mice with the same genotype. 
Spleen weight of the WT mice with ABT treatment was significantly higher at 16 weeks 
of age when compared to WT control at the same age. ApcMin/+ control mice at 16 weeks 
of age was found to have significantly higher CVR ratio when compared to the control 
mice at 12 weeks of age with the same genotype. NO significance was found between other 
treatment groups and with age in the same treatment group with same or different genotype 
(figure 5.3 A and B).  
 
Cytokines 
The pro-inflammatory cytokines TNF-α, IL-1β and IL-17 did not show any significant 
difference between the experimental groups when measured for their levels in the serum 
(systemic) (figure 5.2 B,C and D) and as secreted by the small intestine and colon (tissue-
level) (figure 5.3 C, D, E and F)suggesting that an alteration in gut microbiome may not 
significantly affect the systemic and tissue-level inflammation. 
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5.5. Discussion 
 
The present study aimed at defining the inflammatory effects of an altered gut 
microbiome with relation to stages of tumorigenesis. We have found previously that the 
manipulation of the gut microbiome through usage of antibiotics significantly decreases 
the goblet to epithelial cell ratio in the small intestine of ApcMin/+ and WT experimental 
mice. A reduction in the number of goblet cells reduces the production of the protective 
intestinal mucus, which thins over time until eventually lost thus exposing the underlying 
mucosa to possible physical erosion by the presence of antibiotics in the intestinal lumen. 
In the present study, the physical harmful effects of gut microbiome manipulation were 
observed to lead to the recruitment of certain inflammatory cells to the eroded mucosal 
sights. While damaged crypts result in the WT mice, the ApcMin/+ mice exhibit effects 
ranging from low-grade dysplasia to high-grade dysplasia, neutrophil and monocyte 
infiltration and villus edema, corroborating our previous findings that the use of antibiotics 
has an additive effect on gut health along with factors such as inflammation, polyp numbers 
and mucus production. The spleen weighs were significantly reduced with antibiotic 
treatment only in the ApcMin/+ mice, which indicates that the antibiotic treatment does not 
have any effect under normal conditions (Prior, Gander, Irache, & Gamazo, 2005; Reikvam 
et al., 2011). The significant difference in the spleen size between antibiotic treatment and 
control within the ApcMin/+ mice may reflect an effect of reduced immune system function 
as a result of inflammation caused due to tumorigenesis. Interestingly, the spleen weights 
were significantly higher in the ApcMin/+ as compared to those of the WT mice at 16 weeks, 
which may support the idea that a longer period of microbiome manipulation may lead an 
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even lower spleen weight in the WT but is not able to decrease it to the same level under 
tumorigenic conditions. However, out results from cytokine analyses failed to reiterate our 
spleen results as the serum cytokine levels were not significantly altered following 
antibiotic administration in both WT and ApcMin/+ mice. A higher samples size may help 
better standardize the effects of the antibiotics and microbiome manipulation on spleen size 
during tumorigenesis. 
 The CVR was also not significantly different between antibiotic-treated and control 
groups at 8 weeks, indicating a relatively balanced inflammatory status of the experimental 
animals at the initiation of tumorigenesis. The CVR increases significantly in the treatment 
group as compared to the control groups of animals at 12 weeks indicating an 
inflammatory-inducing effect of antibiotics on both the strains of mice. An absence of any 
difference between the antibiotic-treatment and control in the ApcMin/+ mice at 16 weeks is 
probably due to similarities between the measurements for antibiotic treatment and control. 
This observation, when compared to the WT mice indicates a healthier intestinal CVR 
during the absence of antibiotics which is abrogated once the WT intestine is exposed to 
the antibiotics. However, an absence of secretion of pro-inflammatory cytokines by the 
small intestine and colon indicates towards a more physical effect of the antibiotic 
treatment than that on the physiology of the intestinal and colon tissues. A larger sample 
size may help to elucidate the physiological effects more coherently. 
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5.6. Conclusion 
In conclusion, the effects of gut microbiome manipulation through antibiotic 
treatment could not be established on the ApcMin/+ mouse clinical scores, spleen weights 
and CVR, and only some of the physical effects of erosion and insult to the intestinal 
mucosa could be established. A larger samples size will be required to support or negate 
the findings of the present study. 
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5.7. Figure Legends 
 
Figure 5.1. Histopathology: (A) Hemeatoxylin and eosin stained small intestinal tissues 
belonging to the WT and ApcMin/+ mice with and without antibiotic treatment at different 
ages of mice. (B) Histopathology  scoring determining the degree of inflammation and 
immune cell infiltration was plotted for different treatment group at different age. Two-
way analysis of variance (ANOVA) was used to calculate the significant difference 
between different treatment groups at different ages. *p<0.05- Apc-min-ABT vs Apc-min-
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C, *p<0.05- Apc-min-C vs WT-ABT, #p<0.01- Apc-min-ABT vs WT-ABT, ***p<0.05 
16 weeks vs 8 weeks.  
 
Figure 5.2. Systemic inflammation: Figure illustrating systemic inflammation in the form 
of (A) spleen weights (grams) for all four experimental groups and serum pro-
inflammatory cytokine (B) IL-17, (C) IL-1β and (D) TNF-α levels for the experimental 
groups. Two-way analysis of variance (ANOVA) was used to calculate the significant 
difference between different treatment groups at different ages. *p value<0.05 vs 8 weeks 
within the same treatment group. #p<0.05 vs WT control and **p<0.05 16 weeks vs 12 
weeks.  
 
Figure 5.3. Tissue-level inflammation: Figure illustrating tissue-level inflammation in 
the form of small intestinal crypt depth to villus height ratio (CVR) between different 
experimental groups for (A) WT and (B) ApcMin/+ mice; and small intestine-secreted levels 
of pro-inflammatory cytokines (C) IL-17, (D) Il-1β and (E) TNF-α; and colon-secreted 
levels of pro-inflammatory cytokines (F) IL-17, (G) IL-1β and (H) TNF-α. Two-way 
analysis of variance (ANOVA) was used to calculate the significant difference between 
different treatment groups at different ages. *p value<0.04 vs 8 weeks, #p<0.01 ABT vs 
control group and **p<0.05 16 vs 12 weeks within the same group.  
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Figure 5.1. Histopathology: (A) Hemeatoxylin and eosin stained small intestinal tissues 
belonging to the WT and ApcMin/+ mice with and without antibiotic treatment at different 
ages of mice. (B) Histopathology  scoring determining the degree of inflammation and 
immune cell infiltration was plotted for different treatment group at different age. Two-
way analysis of variance (ANOVA) was used to calculate the significant difference 
between different treatment groups at different ages. *p<0.05- Apc-min-ABT vs Apc-min-
C, **p<0.05- Apc-min-C vs WT-ABT, #p<0.01- Apc-min-ABT vs WT-ABT, ***p<0.05 
16 weeks vs 8 weeks.  
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Figure 5.2. Systemic inflammation: Figure illustrating systemic inflammation in the form 
of (A) spleen weights (grams) for all four experimental groups and serum pro-
inflammatory cytokine (B) IL-17, (C) IL-1β and (D) TNF-α levels for the experimental 
groups. Two-way analysis of variance (ANOVA) was used to calculate the significant 
difference between different treatment groups at different ages. *p value<0.05 vs 8 weeks 
within the same treatment group, #p<0.05 vs WT control and between ApcMin/+-C vs 
ApcMin/+- ABT, and **p<0.05 16 weeks vs 12 weeks. 
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Figure 5.3. Tissue-level inflammation: Figure illustrating tissue-level inflammation in 
the form of small intestinal crypt depth to villus height ratio (CVR) between different 
experimental groups for (A) WT and (B) ApcMin/+ mice; and small intestine-secreted levels 
of pro-inflammatory cytokines (C) IL-17, (D) Il-1β and (E) TNF-α; and colon-secreted 
levels of pro-inflammatory cytokines (F) IL-17, (G) IL-1β and (H) TNF-α. Two-way 
analysis of variance (ANOVA) was used to calculate the significant difference between 
different treatment groups at different ages. *p value<0.04 vs 8 weeks, #p<0.01 ABT vs 
control group and **p<0.05 16 vs 12 weeks within the same group.   
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CHAPTER 6 
OVERALL DISCUSSION 
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Our first experiment was aimed at studying alterations in the gut microbiome at the stages 
of tumor initiation and progression in an age-dependent manner using a spontaneously-
developing tumor mouse model. We hypothesized that an increase in the levels of 
Firmicutes and a reduction in the Bacteroidetes levels would be associated with 
tumorigenesis. We also hypothesized that the process of tumorigenesis will result in lower 
diversity values of gut microbiome. We found that the Firmicutes were significantly higher 
than the Bacteroidetes during tumorigenesis at all three ages – 8, 12 and 16 weeks, 
indicating that the Firmicutes may be precursors to tumorigenesis. While this was true, the 
diversity values (supplemental data) were not significantly different between tumor-
bearing and control mice, indicating that the overall diversity may not be indicative of 
tumorigenesis as can be the altered levels of certain phyla. The Firmicutes phylum was the 
only factor that was seen to be increased in the tumor-bearing mice as compared to the WT 
mice. The fact that the WT mice did not show any clinical score makes Firmicutes the 
likely bacterial phylum that can set the stage for tumorigenesis. The observation that the 
clinical scores for tumor-bearing mice continued to increase until 16 weeks may indicate 
that levels of Firmicutes may not correlate with disease prognosis once the process of 
tumorigenesis begins. 
The relationship between altered percentages of the Firmicutes and Bacteroidetes 
phyla populations, and tumor number, tumor size and mucus-producing goblet cell 
numbers has not been previously examined. The regulation of the mucin gene expression 
as well as mucus production have been shown to be two levels at which the gut microbial 
community may modulate mucins (Comelli, et al., 2008). Our second study was aimed at 
following the processes of tumorigenesis, resulting disease prognosis, and intestinal mucus 
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secretion phenotype after microbial manipulation at three different time points – 8, 12 and 
16 weeks. We hypothesized that the manipulation of the gut microbiota would lead to a 
loss in gut health and an increase in tumor number and size in the ApcMin/+ mouse. 
Furthermore, manipulation of the gut microbiota would decrease goblet cell number in the 
intestine and colon. While our first study showed a progressive decrease in the percentage 
of Firmicutes population in tumor-bearing mice under normal conditions, the phylum 
showed a similar trend in the control groups while continuing to remain high even at 12 
(tumor development) and 16 weeks (later stages of tumorigenesis) of age with antibiotic 
treatment. Our data may support other studies that demonstrated that even when the 
antibiotic treatment is stopped, and some resilient bacteria repopulate the gut, the final state 
is never a complete replacement of the initial state (Francino, 2015). Our clinical score 
continued to remain high at 12 and 16 weeks for the ApcMin/+ with and without antibiotic 
treatment and for WT mice with antibiotic treatment and correlated to the time points of 
antibiotic administration to the mice. The external manipulation of the gut microbiome 
induced effects on the physiology of the intestine as well, as can be seen from the data on 
the polyp numbers of the ApcMin/+ mice.  The manipulation of gut microbiome significantly 
increased the polyp numbers at 16 weeks as compared to those at 12 weeks with antibiotic 
treatment. This implicates a role for the antibiotic treatment in the later stages of 
tumorigenesis, which is not seen under tumorigenic conditions without antibiotic treatment 
where the polyps increase in their size and not numbers from 12 weeks to later stages of 
tumorigenesis (McClellan, Davis, Steiner, Enos, et al., 2012). The effects of antibiotic 
treatment or gut microbiome manipulation followed a similar trend in case of polyps that 
 99 
measured more than 1 mm in diameter, while had no significant effect on polyps less than 
1 mm diameter. 
 Our study also demonstrated a significant reduction in the ratio of intestinal goblet 
to epithelial cells at all three time points, indicating the potential for the gut microbiome to 
influence mucus-producing phenotype of the cells comprising the intestinal mucosa. 
Histopathological observations of intestinal mucosa in the third part of the present study 
revealed a significant increment in the levels of inflammation and cellular infiltration in 
antibiotic-treated ApcMin/+ mice as compared to the control ApcMin/+ and antibiotic-treated 
WT mice at 8, 12 and 16 weeks indicating an inflammatory effect of antibiotic treatment, 
which is more pronounced during tumorigenic conditions. The levels of inflammation and 
cellular infiltration were significantly higher at 16 weeks as compared to those at 8 weeks 
for ApcMin/+-ABT, ApcMin/+-C and WT-ABT mice, but not at 12 weeks, indicating that not 
only the inflammatory responses following antibiotic treatment may exacerbate during 
tumor-bearing conditions and but antibiotic treatment may bring about significant 
inflammatory responses even in control conditions. A loss in the protective mucus in the 
gut lumen may be a reason for such an effect, however, we did not investigate such an 
interrelationship directly. We hypothesized for aim 3, an increase in systemic and tissue-
level inflammation with gut microbial manipulation with antibiotic administration. We 
found that spleen weight which is an indicator of systemic inflammation, increased 
significantly at 12 and 16 weeks as compared to 8 weeks in the ApcMin/+ mice under control 
conditions and antibiotic-treatment conditions which indicates an increased inflammatory 
response of tumorigenesis and microbiome manipulation. However, within 12 and 16 
weeks, the spleen weights were significantly reduced with antibiotic administration, an 
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effect that negated our hypothesis of an increased systemic inflammation with antibiotic 
administration. Our data on serum cytokines was not conclusive on systemic inflammation. 
We also hypothesized an increase in tissue-level inflammation with antibiotic-mediated gut 
microbial manipulation. We measured CVR for an estimate of the same. The gut microbial 
manipulation significantly increased the CVR for both ApcMin/+ and WT mice at 12 and 16 
weeks as compared to 8 weeks indicating a shift towards a more pronounced tissue-
inflammatory response at 12 and 16 weeks. The antibiotic treatment increased the CVR 
significantly at 12 and 16 weeks for the WT mice but only at 12 weeks for the tumor-
bearing ApcMin/+ mice, suggesting that gut microbial manipulation may be important for 
tissue level inflammation during progression of tumorigenesis. However, our data on 
tissue-secreted cytokines could not corroborate our findings on CVR indicating towards an 
effects of antibiotics exposure on intestinal mucosal morphology rather than on its secreted 
cytokines.  
Summary 
By means of this dissertation, we demonstrated that while certain members of the gut 
microbiome and any alterations thereof may seem to affect the process of tumorigenesis, 
there numbers and relative numbers may not affect the disease prognosis. The way by 
which the gut microbiome is altered may also play an important role in the way we see 
processes that are linked to tumorigenesis in the gut most importantly the physical aspects 
of the gut lumen. An externally manipulated gut microbiome specifically through 
antibiotics can disrupt the mucosal lining producing, under normal conditions, symptoms 
same as those manifested under tumor-bearing conditions. The effects of the method of gut 
microbiome manipulation through antibiotics seems to be more due to the physical effects 
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of the antibiotic rather than an altered gut microbiome. The polyp number increased with 
antibiotic administration as compared to untreated tumor-bearing conditions. Other 
physiological alterations and possible routes through which intestinal insult can result is 
the reduction in the size of the villi lining the absorptive surface of the intestinal lumen and 
hampering the development of goblet cells that produce protective mucus on the luminal 
surface. While antibiotics used to manipulate the gut microbiome may be broad-ranged and 
less specific, certain phyla of bacteria may be more susceptible to the same combination of 
the antibiotics as compared to others. In our study, while the Bacteroidetes phylum of 
bacteria is severely susceptible to the antibiotic treatment leading to negligible levels in the 
experimental groups with microbiome manipulation, Firmicutes phylum seem to thrive 
more than in normal conditions with the use of antibiotics. However, larger samples sizes 
with specific pathogen-free experimental conditions could be helpful for better 
understanding the role of certain classes of gut microbial community in processes such as 
tumorigenesis and inflammation. 
 
Future directions 
Studies on topics of the present dissertation need to be highly controlled and specific. The 
usage of specific pathogen-free animals or antibiotics against specific microbial 
community/communities will be necessary to better understand the role of specific classes 
of gut microbiome in disease processes such and inflammation and tumorigenesis. Another 
highly controlled and specific method to elucidate the role(s) of gut microbiota on 
inflammation and tumorigenesis and other disease conditions is the use of germ-free 
animals.  
 102 
REFERENCES 
Abreu, M. T. 2010. The Ying and Yang of bacterial signaling in necrotizing enterocolitis. 
Gastroenterology 138 (1):39-43. 
Akdis, C. A., and M. Akdis. 2009. Mechanisms and treatment of allergic disease in the big 
picture of regulatory T cells. J Allergy Clin Immunol 123 (4):735-746; quiz 747-
738. 
Aristoteli, L. P., and M. D. Willcox. 2003. Mucin degradation mechanisms by distinct 
Pseudomonas aeruginosa isolates in vitro. Infect Immun 71 (10):5565-5575. 
Arthur, J. C., and C. Jobin. 2013. The complex interplay between inflammation, the 
microbiota and colorectal cancer. Gut Microbes 4 (3):253-258. 
Arthur, J. C., E. Perez-Chanona, M. Muhlbauer, S. Tomkovich, J. M. Uronis, T. J. Fan, B. 
J. Campbell, T. Abujamel, B. Dogan, A. B. Rogers, J. M. Rhodes, A. Stintzi, K. W. 
Simpson, J. J. Hansen, T. O. Keku, A. A. Fodor, and C. Jobin. 2012. Intestinal 
inflammation targets cancer-inducing activity of the microbiota. Science 338 
(6103):120-123. 
Atarashi, K., and K. Honda. 2011. Microbiota in autoimmunity and tolerance. Curr Opin 
Immunol 23 (6):761-768. 
Baron, J. A., B. F. Cole, R. S. Sandler, R. W. Haile, D. Ahnen, R. Bresalier, G. McKeown-
Eyssen, R. W. Summers, R. Rothstein, C. A. Burke, D. C. Snover, T. R. Church, J. 
I. Allen, M. Beach, G. J. Beck, J. H. Bond, T. Byers, E. R. Greenberg, J. S. Mandel, 
N. Marcon, L. A. Mott, L. Pearson, F. Saibil, and R. U. van Stolk. 2003. A 
 103 
randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348 
(10):891-899. 
Barthel, M., S. Hapfelmeier, L. Quintanilla-Martinez, M. Kremer, M. Rohde, M. Hogardt, 
K. Pfeffer, H. Russmann, and W. D. Hardt. 2003. Pretreatment of mice with 
streptomycin provides a Salmonella enterica serovar Typhimurium colitis model 
that allows analysis of both pathogen and host. Infect Immun 71 (5):2839-2858. 
Belenguer, A., S. H. Duncan, A. G. Calder, G. Holtrop, P. Louis, G. E. Lobley, and H. J. 
Flint. 2006. Two routes of metabolic cross-feeding between Bifidobacterium 
adolescentis and butyrate-producing anaerobes from the human gut. Appl Environ 
Microbiol 72 (5):3593-3599. 
Bertagnolli, M. M., C. J. Eagle, A. G. Zauber, M. Redston, S. D. Solomon, K. Kim, J. 
Tang, R. B. Rosenstein, J. Wittes, D. Corle, T. M. Hess, G. M. Woloj, F. Boisserie, 
W. F. Anderson, J. L. Viner, D. Bagheri, J. Burn, D. C. Chung, T. Dewar, T. R. 
Foley, N. Hoffman, F. Macrae, R. E. Pruitt, J. R. Saltzman, B. Salzberg, T. 
Sylwestrowicz, G. B. Gordon, E. T. Hawk, and A. P. C. S. Investigators. 2006. 
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 
(9):873-884. 
Breban, M. 2016. Gut microbiota and inflammatory joint diseases. Joint Bone Spine. 
Cebra, J. J. 1999. Influences of microbiota on intestinal immune system development. Am 
J Clin Nutr 69 (5):1046S-1051S. 
Chakraborty, S. P., S. K. Sahu, S. K. Mahapatra, S. Santra, M. Bal, S. Roy, and P. 
Pramanik. 2010. Nanoconjugated vancomycin: new opportunities for the 
development of anti-VRSA agents. Nanotechnology 21 (10):105103. 
 104 
Chan, D., D. Kumar, and M. Mendall. 2015. What is known about the mechanisms of 
dietary influences in Crohn's disease? Nutrition 31 (10):1195-1203. 
Cho, M., J. Carter, S. Harari, and Z. Pei. 2014. The interrelationships of the gut microbiome 
and inflammation in colorectal carcinogenesis. Clin Lab Med 34 (4):699-710. 
Comelli, E. M., R. Simmering, M. Faure, D. Donnicola, R. Mansourian, F. Rochat, I. 
Corthesy-Theulaz, and C. Cherbut. 2008. Multifaceted transcriptional regulation of 
the murine intestinal mucus layer by endogenous microbiota. Genomics 91 (1):70-
77. 
Cresci, G. A., and E. Bawden. 2015. Gut Microbiome: What We Do and Don't Know. Nutr 
Clin Pract 30 (6):734-746. 
Deplancke, B., and H. R. Gaskins. 2001. Microbial modulation of innate defense: goblet 
cells and the intestinal mucus layer. Am J Clin Nutr 73 (6):1131S-1141S. 
Dethlefsen, L., and D. A. Relman. 2011.  
Incomplete recovery and individualized responses of the human distal gut microbiota to 
repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108 Suppl 1:4554-4561. 
Dianda, L., A. M. Hanby, N. A. Wright, A. Sebesteny, A. C. Hayday, and M. J. Owen. 
1997. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence 
of a microbial environment. Am J Pathol 150 (1):91-97. 
Dimmitt, R. A., E. M. Staley, G. Chuang, S. M. Tanner, T. D. Soltau, and R. G. Lorenz. 
2010. Role of postnatal acquisition of the intestinal microbiome in the early 
development of immune function. J Pediatr Gastroenterol Nutr 51 (3):262-273. 
Dohrman, A., S. Miyata, M. Gallup, J. D. Li, C. Chapelin, A. Coste, E. Escudier, J. Nadel, 
and C. Basbaum. 1998. Mucin gene (MUC 2 and MUC 5AC) upregulation by 
 105 
Gram-positive and Gram-negative bacteria. Biochim Biophys Acta 1406 (3):251-
259. 
Dugas, L. R., M. Fuller, J. Gilbert, and B. T. Layden. 2016. The obese gut microbiome 
across the epidemiologic transition. Emerg Themes Epidemiol 13:2. 
Dziarski, R., S. Y. Park, D. R. Kashyap, S. E. Dowd, and D. Gupta. 2016. Pglyrp-Regulated 
Gut Microflora Prevotella falsenii, Parabacteroides distasonis and Bacteroides 
eggerthii Enhance and Alistipes finegoldii Attenuates Colitis in Mice. PLoS One 
11 (1):e0146162. 
Erdman, S. E., J. J. Sohn, V. P. Rao, P. R. Nambiar, Z. Ge, J. G. Fox, and D. B. Schauer. 
2005. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors 
in ApcMin/+ mice. Cancer Res 65 (10):3998-4004. 
Ferreira, R. B., B. P. Willing, and B. B. Finlay. 2011. Bringing Koch's postulates to the 
table in IBD. Cell Host Microbe 9 (5):353-354. 
Francino, M. P. 2015. Antibiotics and the Human Gut Microbiome: Dysbioses and 
Accumulation of Resistances. Front Microbiol 6:1543. 
Franks, A. H., H. J. Harmsen, G. C. Raangs, G. J. Jansen, F. Schut, and G. W. Welling. 
1998. Variations of bacterial populations in human feces measured by fluorescent 
in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide 
probes. Appl Environ Microbiol 64 (9):3336-3345. 
Gonzalez, C., M. Rubio, J. Romero-Vivas, M. Gonzalez, and J. J. Picazo. 1999. Bacteremic 
pneumonia due to Staphylococcus aureus: A comparison of disease caused by 
methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 29 
(5):1171-1177. 
 106 
Guo, X., X. Xia, R. Tang, J. Zhou, H. Zhao, and K. Wang. 2008. Development of a real-
time PCR method for Firmicutes and Bacteroidetes in faeces and its application to 
quantify intestinal population of obese and lean pigs. Lett Appl Microbiol 47 
(5):367-373. 
Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 
144 (5):646-674. 
Harmsen, H. J., G. C. Raangs, T. He, J. E. Degener, and G. W. Welling. 2002. Extensive 
set of 16S rRNA-based probes for detection of bacteria in human feces. Appl 
Environ Microbiol 68 (6):2982-2990. 
He, Q., X. Li, C. Liu, L. Su, Z. Xia, X. Li, Y. Li, L. Li, T. Yan, Q. Feng, and L. Xiao. 2016. 
Dysbiosis of the fecal microbiota in the TNBS-induced Crohn's disease mouse 
model. Appl Microbiol Biotechnol. 
Hooper, L. V., and J. I. Gordon. 2001. Glycans as legislators of host-microbial interactions: 
spanning the spectrum from symbiosis to pathogenicity. Glycobiology 11 (2):1R-
10R. 
Hooper, L. V., T. Midtvedt, and J. I. Gordon. 2002. How host-microbial interactions shape 
the nutrient environment of the mammalian intestine. Annu Rev Nutr 22:283-307. 
Hooper, L. V., M. H. Wong, A. Thelin, L. Hansson, P. G. Falk, and J. I. Gordon. 2001. 
Molecular analysis of commensal host-microbial relationships in the intestine. 
Science 291 (5505):881-884. 
Ivanov, II, K. Atarashi, N. Manel, E. L. Brodie, T. Shima, U. Karaoz, D. Wei, K. C. 
Goldfarb, C. A. Santee, S. V. Lynch, T. Tanoue, A. Imaoka, K. Itoh, K. Takeda, Y. 
 107 
Umesaki, K. Honda, and D. R. Littman. 2009. Induction of intestinal Th17 cells by 
segmented filamentous bacteria. Cell 139 (3):485-498. 
Jakobsson, H. E., A. M. Rodriguez-Pineiro, A. Schutte, A. Ermund, P. Boysen, M. Bemark, 
F. Sommer, F. Backhed, G. C. Hansson, and M. E. Johansson. 2015. The 
composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep 16 
(2):164-177. 
Jernberg, C., S. Lofmark, C. Edlund, and J. K. Jansson. 2007. Long-term ecological 
impacts of antibiotic administration on the human intestinal microbiota. ISME J 1 
(1):56-66. 
Kabeerdoss, J., P. Sandhya, and D. Danda. 2015. Gut inflammation and microbiome in 
spondyloarthritis. Rheumatol Int. 
Kanauchi, O., K. Mitsuyama, Y. Araki, and A. Andoh. 2003. Modification of intestinal 
flora in the treatment of inflammatory bowel disease. Curr Pharm Des 9 (4):333-
346. 
Kato, L. M., S. Kawamoto, M. Maruya, and S. Fagarasan. 2014. The role of the adaptive 
immune system in regulation of gut microbiota. Immunol Rev 260 (1):67-75. 
Kaul, M., and D. S. Pilch. 2002. Thermodynamics of aminoglycoside-rRNA recognition: 
the binding of neomycin-class aminoglycosides to the A site of 16S rRNA. 
Biochemistry 41 (24):7695-7706. 
Kaur, K., A. Saxena, B. Larsen, S. Truman, N. Biyani, E. Fletcher, M. S. Baliga, V. 
Ponemone, S. Hegde, A. Chanda, and R. Fayad. 2015. Mucus mediated protection 
against acute colitis in adiponectin deficient mice. J Inflamm (Lond) 12:35. 
 108 
Knip, M., and H. Siljander. 2016. The role of the intestinal microbiota in type 1 diabetes 
mellitus. Nat Rev Endocrinol. 
Koboziev, I., C. Reinoso Webb, K. L. Furr, and M. B. Grisham. 2014. Role of the enteric 
microbiota in intestinal homeostasis and inflammation. Free Radic Biol Med 
68:122-133. 
Langowski, J. L., X. Zhang, L. Wu, J. D. Mattson, T. Chen, K. Smith, B. Basham, T. 
McClanahan, R. A. Kastelein, and M. Oft. 2006. IL-23 promotes tumour incidence 
and growth. Nature 442 (7101):461-465. 
Lay, C., M. Sutren, V. Rochet, K. Saunier, J. Dore, and L. Rigottier-Gois. 2005. Design 
and validation of 16S rRNA probes to enumerate members of the Clostridium 
leptum subgroup in human faecal microbiota. Environ Microbiol 7 (7):933-946. 
Li, Y., P. Kundu, S. W. Seow, C. T. de Matos, L. Aronsson, K. C. Chin, K. Karre, S. 
Pettersson, and G. Greicius. 2012. Gut microbiota accelerate tumor growth via c-
jun and STAT3 phosphorylation in APCMin/+ mice. Carcinogenesis 33 (6):1231-
1238. 
Lofmark, S., C. Jernberg, J. K. Jansson, and C. Edlund. 2006. Clindamycin-induced 
enrichment and long-term persistence of resistant Bacteroides spp. and resistance 
genes. J Antimicrob Chemother 58 (6):1160-1167. 
Mack, D. R., S. Ahrne, L. Hyde, S. Wei, and M. A. Hollingsworth. 2003. Extracellular 
MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal 
epithelial cells in vitro. Gut 52 (6):827-833. 
 109 
Mack, D. R., S. Michail, S. Wei, L. McDougall, and M. A. Hollingsworth. 1999. Probiotics 
inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin 
gene expression. Am J Physiol 276 (4 Pt 1):G941-950. 
Mai, V., L. H. Colbert, S. N. Perkins, A. Schatzkin, and S. D. Hursting. 2007. Intestinal 
microbiota: a potential diet-responsive prevention target in ApcMin mice. Mol 
Carcinog 46 (1):42-48. 
Mariat, D., O. Firmesse, F. Levenez, V. Guimaraes, H. Sokol, J. Dore, G. Corthier, and J. 
P. Furet. 2009. The Firmicutes/Bacteroidetes ratio of the human microbiota 
changes with age. BMC Microbiol 9:123. 
McCart, A. E., N. K. Vickaryous, and A. Silver. 2008. Apc mice: models, modifiers and 
mutants. Pathol Res Pract 204 (7):479-490. 
McClellan, J. L., J. M. Davis, J. L. Steiner, S. D. Day, S. E. Steck, M. D. Carmichael, and 
E. A. Murphy. 2012a. Intestinal inflammatory cytokine response in relation to 
tumorigenesis in the Apc(Min/+) mouse. Cytokine 57 (1):113-119. 
McClellan, J. L., J. M. Davis, J. L. Steiner, R. T. Enos, S. H. Jung, J. A. Carson, M. M. 
Pena, K. A. Carnevale, F. G. Berger, and E. A. Murphy. 2012b. Linking tumor-
associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-
1. Am J Physiol Gastrointest Liver Physiol 303 (10):G1087-1095. 
Murphy, E. A., J. M. Davis, J. L. McClellan, and M. D. Carmichael. 2011a. Quercetin's 
effects on intestinal polyp multiplicity and macrophage number in the Apc(Min/+) 
mouse. Nutr Cancer 63 (3):421-426. 
 110 
Murphy, E. A., J. M. Davis, J. L. McClellan, B. T. Gordon, and M. D. Carmichael. 2011b. 
Curcumin's effect on intestinal inflammation and tumorigenesis in the ApcMin/+ 
mouse. J Interferon Cytokine Res 31 (2):219-226. 
Oboki, K., T. Ohno, H. Saito, and S. Nakae. 2008. Th17 and allergy. Allergol Int 57 
(2):121-134. 
Oh, J. E., B. C. Kim, D. H. Chang, M. Kwon, S. Y. Lee, D. Kang, J. Y. Kim, I. Hwang, J. 
W. Yu, S. Nakae, and H. K. Lee. 2016. Dysbiosis-induced IL-33 contributes to 
impaired antiviral immunity in the genital mucosa. Proc Natl Acad Sci U S A 113 
(6):E762-771. 
Omenetti, S., and T. T. Pizarro. 2015. The Treg/Th17 Axis: A Dynamic Balance Regulated 
by the Gut Microbiome. Front Immunol 6:639. 
Perdigon, G., J. C. Valdez, and M. Rachid. 1998. Antitumour activity of yogurt: study of 
possible immune mechanisms. J Dairy Res 65 (1):129-138. 
Prior, S., B. Gander, J. M. Irache, and C. Gamazo. 2005. Gentamicin-loaded microspheres 
for treatment of experimental Brucella abortus infection in mice. J Antimicrob 
Chemother 55 (6):1032-1036. 
Puppa, M. J., J. P. White, S. Sato, M. Cairns, J. W. Baynes, and J. A. Carson. 2011. Gut 
barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. 
Biochim Biophys Acta 1812 (12):1601-1606. 
Rakoff-Nahoum, S., and R. Medzhitov. 2007. Regulation of spontaneous intestinal 
tumorigenesis through the adaptor protein MyD88. Science 317 (5834):124-127. 
Rao, V. P., T. Poutahidis, Z. Ge, P. R. Nambiar, C. Boussahmain, Y. Y. Wang, B. H. 
Horwitz, J. G. Fox, and S. E. Erdman. 2006. Innate immune inflammatory response 
 111 
against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma 
in mice. Cancer Res 66 (15):7395-7400. 
Reikvam, D. H., A. Erofeev, A. Sandvik, V. Grcic, F. L. Jahnsen, P. Gaustad, K. D. McCoy, 
A. J. Macpherson, L. A. Meza-Zepeda, and F. E. Johansen. 2011. Depletion of 
murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. 
PLoS One 6 (3):e17996. 
Ritland, S. R., J. A. Leighton, R. E. Hirsch, J. D. Morrow, A. L. Weaver, and S. J. Gendler. 
1999. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: 
lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. Clin 
Cancer Res 5 (4):855-863. 
Romick-Rosendale, L. E., A. M. Goodpaster, P. J. Hanwright, N. B. Patel, E. T. Wheeler, 
D. L. Chona, and M. A. Kennedy. 2009. NMR-based metabonomics analysis of 
mouse urine and fecal extracts following oral treatment with the broad-spectrum 
antibiotic enrofloxacin (Baytril). Magn Reson Chem 47 Suppl 1:S36-46. 
Russell, S. L., M. J. Gold, M. Hartmann, B. P. Willing, L. Thorson, M. Wlodarska, N. Gill, 
M. R. Blanchet, W. W. Mohn, K. M. McNagny, and B. B. Finlay. 2012. Early life 
antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. 
EMBO Rep 13 (5):440-447. 
Sankar, S. A., J. C. Lagier, P. Pontarotti, D. Raoult, and P. E. Fournier. 2015. The human 
gut microbiome, a taxonomic conundrum. Syst Appl Microbiol 38 (4):276-286. 
Saxena, A., M. S. Baliga, V. Ponemone, K. Kaur, B. Larsen, E. Fletcher, J. Greene, and R. 
Fayad. 2013. Mucus and adiponectin deficiency: role in chronic inflammation-
induced colon cancer. Int J Colorectal Dis 28 (9):1267-1279. 
 112 
Saxena, A., A. Chumanevich, E. Fletcher, B. Larsen, K. Lattwein, K. Kaur, and R. Fayad. 
2012. Adiponectin deficiency: role in chronic inflammation induced colon cancer. 
Biochim Biophys Acta 1822 (4):527-536. 
Schnyder-Candrian, S., D. Togbe, I. Couillin, I. Mercier, F. Brombacher, V. Quesniaux, F. 
Fossiez, B. Ryffel, and B. Schnyder. 2006. Interleukin-17 is a negative regulator of 
established allergic asthma. J Exp Med 203 (12):2715-2725. 
Shan, M., M. Gentile, J. R. Yeiser, A. C. Walland, V. U. Bornstein, K. Chen, B. He, L. 
Cassis, A. Bigas, M. Cols, L. Comerma, B. Huang, J. M. Blander, H. Xiong, L. 
Mayer, C. Berin, L. H. Augenlicht, A. Velcich, and A. Cerutti. 2013. Mucus 
enhances gut homeostasis and oral tolerance by delivering immunoregulatory 
signals. Science 342 (6157):447-453. 
Shen, Y., G. H. Hu, H. Y. Kang, X. Y. Tang, and S. L. Hong. 2014. Allergen induced Treg 
response in the peripheral blood mononuclear cells (PBMCs) of patients with nasal 
polyposis. Asian Pac J Allergy Immunol 32 (4):300-307. 
Shih, V. F., J. Cox, N. M. Kljavin, H. S. Dengler, M. Reichelt, P. Kumar, L. Rangell, J. K. 
Kolls, L. Diehl, W. Ouyang, and N. Ghilardi. 2014. Homeostatic IL-23 receptor 
signaling limits Th17 response through IL-22-mediated containment of commensal 
microbiota. Proc Natl Acad Sci U S A 111 (38):13942-13947. 
Shoemaker, A. R., K. A. Gould, C. Luongo, A. R. Moser, and W. F. Dove. 1997. Studies 
of neoplasia in the Min mouse. Biochim Biophys Acta 1332 (2):F25-48. 
Shoemaker, A. R., A. R. Moser, and W. F. Dove. 1995. N-ethyl-N-nitrosourea treatment 
of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of 
 113 
intestinal adenomas, cystic crypts, and epidermoid cysts. Cancer Res 55 (19):4479-
4485. 
Singh, V., B. S. Yeoh, F. Carvalho, A. T. Gewirtz, and M. Vijay-Kumar. 2015. Proneness 
of TLR5 deficient mice to develop colitis is microbiota dependent. Gut Microbes 6 
(4):279-283. 
Small, P. M., and H. F. Chambers. 1990. Vancomycin for Staphylococcus aureus 
endocarditis in intravenous drug users. Antimicrob Agents Chemother 34 (6):1227-
1231. 
Smirnova, M. G., L. Guo, J. P. Birchall, and J. P. Pearson. 2003. LPS up-regulates mucin 
and cytokine mRNA expression and stimulates mucin and cytokine secretion in 
goblet cells. Cell Immunol 221 (1):42-49. 
Son, J. S., S. Khair, D. W. Pettet, 3rd, N. Ouyang, X. Tian, Y. Zhang, W. Zhu, G. G. 
Mackenzie, C. E. Robertson, D. Ir, D. N. Frank, B. Rigas, and E. Li. 2015. Altered 
Interactions between the Gut Microbiome and Colonic Mucosa Precede Polyposis 
in APCMin/+ Mice. PLoS One 10 (6):e0127985. 
Strzepa, A., M. Majewska-Szczepanik, P. Kowalczyk, D. Wozniak, S. Motyl, and M. 
Szczepanik. 2016. Oral treatment with enrofloxacin early in life promotes Th2-
mediated immune response in mice. Pharmacol Rep 68 (1):44-50. 
Talham, G. L., H. Q. Jiang, N. A. Bos, and J. J. Cebra. 1999. Segmented filamentous 
bacteria are potent stimuli of a physiologically normal state of the murine gut 
mucosal immune system. Infect Immun 67 (4):1992-2000. 
Urbanska, A. M., J. Bhathena, C. Martoni, and S. Prakash. 2009. Estimation of the potential 
antitumor activity of microencapsulated Lactobacillus acidophilus yogurt 
 114 
formulation in the attenuation of tumorigenesis in Apc(Min/+) mice. Dig Dis Sci 
54 (2):264-273. 
Uribe, A., M. Alam, O. Johansson, T. Midtvedt, and E. Theodorsson. 1994. Microflora 
modulates endocrine cells in the gastrointestinal mucosa of the rat. 
Gastroenterology 107 (5):1259-1269. 
Uronis, J. M., and C. Jobin. 2009. Microbes and colorectal cancer: is there a relationship? 
Curr Oncol 16 (4):22-24. 
Van Bambeke, F. 2006. Glycopeptides and glycodepsipeptides in clinical development: a 
comparative review of their antibacterial spectrum, pharmacokinetics and clinical 
efficacy. Curr Opin Investig Drugs 7 (8):740-749. 
Vijay-Kumar, M., F. A. Carvalho, J. D. Aitken, N. H. Fifadara, and A. T. Gewirtz. 2010. 
TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity 
by flagellin. Eur J Immunol 40 (12):3528-3534. 
Waksman, S. A., and H. A. Lechevalier. 1949. Neomycin, a New Antibiotic Active against 
Streptomycin-Resistant Bacteria, including Tuberculosis Organisms. Science 109 
(2830):305-307. 
Wang, L., and Q. Zhang. 2015. Application of the Apc(Min/+) mouse model for studying 
inflammation-associated intestinal tumor. Biomed Pharmacother 71:216-221. 
Watanabe, J., R. Fujiwara, N. Sasajima, S. Ito, and K. Sonoyama. 2010. Administration of 
antibiotics during infancy promoted the development of atopic dermatitis-like skin 
lesions in NC/Nga mice. Biosci Biotechnol Biochem 74 (2):358-363. 
 115 
Watanabe, S., Y. Narisawa, S. Arase, H. Okamatsu, T. Ikenaga, Y. Tajiri, and M. 
Kumemura. 2003. Differences in fecal microflora between patients with atopic 
dermatitis and healthy control subjects. J Allergy Clin Immunol 111 (3):587-591. 
Weir, T. L., D. K. Manter, A. M. Sheflin, B. A. Barnett, A. L. Heuberger, and E. P. Ryan. 
2013. Stool microbiome and metabolome differences between colorectal cancer 
patients and healthy adults. PLoS One 8 (8):e70803. 
Willing, B. P., S. L. Russell, and B. B. Finlay. 2011. Shifting the balance: antibiotic effects 
on host-microbiota mutualism. Nat Rev Microbiol 9 (4):233-243. 
Wlodarska, M., B. Willing, K. M. Keeney, A. Menendez, K. S. Bergstrom, N. Gill, S. L. 
Russell, B. A. Vallance, and B. B. Finlay. 2011. Antibiotic treatment alters the 
colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-
induced colitis. Infect Immun 79 (4):1536-1545. 
Wu, S., K. J. Rhee, E. Albesiano, S. Rabizadeh, X. Wu, H. R. Yen, D. L. Huso, F. L. 
Brancati, E. Wick, F. McAllister, F. Housseau, D. M. Pardoll, and C. L. Sears. 
2009. A human colonic commensal promotes colon tumorigenesis via activation of 
T helper type 17 T cell responses. Nat Med 15 (9):1016-1022. 
Wu, W., C. He, C. Liu, A. T. Cao, X. Xue, H. L. Evans-Marin, M. Sun, L. Fang, S. Yao, I. 
V. Pinchuk, D. W. Powell, Z. Liu, and Y. Cong. 2015. miR-10a inhibits dendritic 
cell activation and Th1/Th17 cell immune responses in IBD. Gut 64 (11):1755-
1764. 
Yap, I. K., J. V. Li, J. Saric, F. P. Martin, H. Davies, Y. Wang, I. D. Wilson, J. K. 
Nicholson, J. Utzinger, J. R. Marchesi, and E. Holmes. 2008. Metabonomic and 
 116 
microbiological analysis of the dynamic effect of vancomycin-induced gut 
microbiota modification in the mouse. J Proteome Res 7 (9):3718-3728. 
Yen, D., J. Cheung, H. Scheerens, F. Poulet, T. McClanahan, B. McKenzie, M. A. 
Kleinschek, A. Owyang, J. Mattson, W. Blumenschein, E. Murphy, M. Sathe, D. J. 
Cua, R. A. Kastelein, and D. Rennick. 2006. IL-23 is essential for T cell-mediated 
colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116 (5):1310-
1316. 
Zackular, J. P., N. T. Baxter, K. D. Iverson, W. D. Sadler, J. F. Petrosino, G. Y. Chen, and 
P. D. Schloss. 2013. The gut microbiome modulates colon tumorigenesis. MBio 4 
(6):e00692-00613. 
Zhang, Y. S., Y. Li, Y. Wang, S. Y. Sun, T. Jiang, C. Li, S. X. Cui, and X. J. Qu. 2015. 
Naringin, a natural dietary compound, prevents intestinal tumorigenesis in Apc 
mouse model. J Cancer Res Clin Oncol. 
Zhao, D., A. C. Keates, S. Kuhnt-Moore, M. P. Moyer, C. P. Kelly, and C. Pothoulakis. 
2001. Signal transduction pathways mediating neurotensin-stimulated interleukin-
8 expression in human colonocytes. J Biol Chem 276 (48):44464-44471. 
Zhu, Y., T. Michelle Luo, C. Jobin, and H. A. Young. 2011. Gut microbiota and probiotics  
in colon tumorigenesis. Cancer Lett 309 (2):119-127. 
 
 
 117 
APPENDIX A 
SUPPLEMENTAL DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 118 
S1 
 
Figure S1: Alpha diversity values ApcMin/+-C and WT-C: Figure illustrating box plots 
of alpha diversity values obtained between ApcMin/+ and WT mice under control conditions 
and significance values obtained by Kruskal-Wallis statistical analysis where p value>0.05 
was considered significant. (OTUs: Observed Taxonomic Units between the two groups; 
Chao1 index: Estimator of richness between the two groups; and Shannon index: Estimator 
of richness and evenness between the two groups). The three horizontal lines contained 
within each box plot represent the third quartile, median and first quartile (from top to 
bottom). The vertical lines on top and bottom of the box plot represent the maximum and 
minimum values plotted respectively. 
S2(A) 
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S2(B) 
 
S2(C) 
 
Figure S2: Alpha diversity values. Figure illustrating box plots of alpha diversity values 
obtained between (A) ApcMin/+-ABT and ApcMin/+-C; (B) WT-ABT and WT-C; and (C) 
WT-C/ABT and ApcMin/+-C/ABT. Significance values were obtained by Kruskal-Wallis 
statistical analysis where p value>0.05 was considered significant. (OTUs: Observed 
Taxonomic Units between the two groups; Chao1 index: Estimator of richness between the 
two groups; and Shannon index: Estimator of richness and evenness between the two 
groups). The three horizontal lines contained within each box plot represent the third 
quartile, median and first quartile (from top to bottom) respectively. The vertical lines on 
top and bottom of the box plot represent the maximum and minimum values plotted 
respectively. 
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Alcian Blue Staining Protocol 
 
Solutions and Reagents: 
  
3% Acetic Acid Solution: 
      Glacial acetic acid ----------------- 3 mL 
      Distilled water --------------------- 97 mL 
  
Alcian Blue Solution (pH 2.5): 
      Alcian blue, 8GX -------------------- 1 g 
      Acetic acid, 3% solution ----------- 100 mL 
      Mix well and adjust pH to 2.5 using acetic acid. 
  
0.1% Nuclear Fast Red Solution: 
      Nuclear fast red ------------------- 0.1 g 
      Aluminum sulfate------------------ 5 g 
      Distilled water ---------------------100 mL 
      Dissolve aluminum sulfate in water. Add nuclear fast red and slowly heat  
      to boil and cool. Filter and add a grain of thymol as a preservative. 
  
Procedure: 
  
1.       Deparaffinize slides and hydrate to distilled water. 
2.       Stain in Alcian Blue solution for 30 minutes. 
3.       Wash in running tap water for 2 minutes. 
4.       Rinse in distilled water. 
5.       Counterstain in nuclear fast red solution for 5 minutes. 
6.       Wash in running tap water for 1 minute. 
7.       Dehydrate and through 95% alcohol, 2 changes of absolute alcohol,  
          3 minutes each. 
8.       Clear in xylene or xylene substitute. 
9.       Mount with resinous mounting medium. 
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Hematoxylin and Eosin Staining Protocol 
1. Deparaffinize in Xylene I and II and III (3 minutes) 
2. Rehydrate 
a. EtOH 100% (3 minutes) 
b. EtOH 100% (3 minutes) 
c. EtOH 95% (3 minutes) 
d. EtOH 95% (3 minutes) 
e. EtOH 70% (3 minutes) 
3. Rinse in distilled water (5 minutes) 
4. Stain in hematoxylin (6 minutes) Filter before each use to remove  
oxidized particles 
5. Rinse in running tap water (15 minutes) 
6. Decolorize in acid alcohol (1 second) 
7. Rinse well in tap water (5 minutes) 
8. Immerse in ammonia water  (3 Seconds)  
9. Rinse in tap water (5 minutes) 
10. Counterstain in Eosin (15 seconds) 
11. Dehydrate 
a. EtOH 95 % (3 minutes) Discard after each use  
b. EtOH 95% (3 minutes) 
c. EtOH 100 % (3 minutes) 
d. EtOH 100 % (3 minutes) 
12. Clear in Xylene I and II (5 minutes) 
13. Mount with Cytoseal in fume hood. 
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APPENDIX C 
DOCTORAL DISSERTATION PROPOSAL 
 
Role of altered gut microbiome on tumor development, mucus production 
and inflammation in ApcMin/+ mouse 
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Summary 
Background and significance: The microbiome forms an integral part of the gut 
microenvironment. Once ignored, the topic has gained momentum in research during the 
past decade, where studies have strongly suggested the association of microbiota with 
health and a misbalance thereof, to many disease conditions ranging from inflammation 
and colitis to diabetes, obesity and colon cancer. The Human Microbiome Project (HMP, 
NIH common fund - 2008) has used a variety of high throughput analyses in order to study 
gut microbiota in health. The consortium has so far been able to isolate and characterize 
more than 1,300 reference bacterial strains from the human body. The large amount of data 
generated has led to a baseline need to address the implications of different microbial 
members, or groups thereof, in health and disease. The microorganisms residing in the gut 
comprise of bacteria, archaea, fungi and viruses that are distributed throughout the length 
of the gastrointestinal tract. While there will be limitations to studying all types of 
microorganisms owing to their overwhelming numbers and types, our study is focused only 
on bacterial populations of the gut, and for the purpose of convenience, terms of gut 
microbiota/microbiome will be used for describing gut bacteria pertaining to the mice used 
in our study. The overall purpose of this study is to determine the effects of alterations in 
the gut microbiome on tumor development and inflammation, and if it leads to 
recolonization of the gut by altered bacterial communities. The working hypothesis is that 
an alteration of bacterial microbiome will occur during tumorigenesis and manipulation of 
the gut microbiome externally will exacerbate the clinical symptoms associated with 
intestinal cancer, leading to higher gut and systemic inflammation. 
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To test this hypothesis, the following specific aims will be used: 
Specific Aim 1: To examine the composition of gut microbiome during tumor 
initiation and development in the ApcMin/+ mouse. 
Specific Aim 2: To determine if gut microbiome manipulation can regulate the 
ApcMin/+ mouse gut health and tumorigenesis. 
Specific Aim 3: To determine if the relative abundance of Bacteroidetes and Fimicutes 
bacterial populations is associated with intestinal and systemic inflammation in the 
ApcMin/+ mouse. 
 
The primary objectives of this study are to: 1) determine whether the gut microbiome 
profiles change during early and later stages of tumorigenesis, 2) determine the effect of 
external manipulation of gut microbiome on tumor load and size, and on mucus-producing 
goblet cell population in the gut, 3) study any alterations in the bacterial populations 
pertaining to the Bacteroidetes and Firmicutes phyla that recolonize after external 
manipulations of the gut microbiome, 4) determine if altered Bacteroidetes and Firmicutes 
populations increases tissue inflammation in the intestine, 5) determine if altered 
Bacteroidetes and Firmicutes populations lead to an increase in circulatory cytokines. The 
rationale behind our study are the research studies that have been published and our 
preliminary data. It has been shown that the gut microbiota accelerates tumor growth in the 
ApcMin/+ mice through the c-jun/JNK and STAT3 phosphorylation pathways and causes a 
vicious cycle of inflammation in the intestine (Y. Li, et al., 2012). Recently, it has also 
been demonstrated that alterations in the gut microbiota precede tumor development in the 
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ApcMin/+ mice (Son, et al., 2015) which is due to the resulting alterations in interactions of 
gut microbiota and gut mucosa. The novelty of the present study is in answering the 
question as to how the gut microbiome shifts from early to later stages of tumorigenesis. 
Studies do indicate that the gut microbiota can be a potential target in the amelioration of 
cancer progression but it is not known how the microbiome paradigm of the gut shifts with 
respect to progression in tumorigenesis. This study will also be directed towards 
understanding inflammatory changes and changes in mucus producing function of the gut 
and their relation to a change in quantifiable disease severity and microbiota alterations. 
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CHAPTER 1 
Introduction and Aims 
The topic of gut microbiome has recently gained attention due to research suggesting its 
significant role in not only maintenance of gut health but also in disease conditions such as 
obesity, diabetes, arthritis, colitis and cancers of the digestive system  (Cho, et al., 2014; 
Dziarski, et al., 2016; Kabeerdoss, et al., 2015; Knip & Siljander, 2016). The gut 
microbiome comprises of around 500-1000 species and a genetic diversity which has 100-
fold more genes than humans (Dugas, et al., 2016). 
 Another field that aims at answering the questions on gut microbiome and its links 
to health and disease is the usage of probiotics including one or more important bacteria. 
The bacteria Lactobacillus acidophilus has been implicated in a significant suppression of 
colon tumor incidence and size and a reduction in pro-inflammatory cytokines such as 
TNF-α and IFN-γ (Perdigon, et al., 1998; Urbanska, et al., 2009). Some studies also state 
that the link between the microbiome and the actual development of polyps in the gut is 
solely linked through the erosion of the gut lumen microenvironment and the resulting 
inflammation (Dianda, et al., 1997). 
An altered microbiome has been previously linked to inflammatory bowel disease 
and colorectal cancer. However, we still lack the knowledge of a characterizing the gut 
microbiome that relates to health or disease condition. An early event of inflammatory 
insult to the gut can very well result in tumorigenesis when combined with processes of 
bacterial DNA damage and chromatin alterations (Zhu, et al., 2011). Studies on mouse 
models such as the IL-10-/- have demonstrated a protective role of the presence of gut 
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microbiome on inflammation, where the WT mice were rendered protected against 
inflammation in the gut while the germ-free (no microbiome) animals developed colitis (S. 
Wu, et al., 2009). It should be noted here that a germ-free animals may not represent the 
human gut as an individual can never be completely without microbiome in the gut. From 
the perspective of any given disease state that can be linked to microbiome, the basis of its 
linkage can only be an altered microbiome. It should also be noted that the process of 
inflammation is the one that alters the microbiome (Uronis & Jobin, 2009), although 
inflammation alone is not sufficient to promote colorectal cancer and altered microbiota 
works hand in hand with inflammatory insults that will eventually lead to cancer (Arthur 
& Jobin, 2013). The gut microbiome has been shown to complement AOM and DSS mouse 
models in causing tumorigenesis, but is yet to be elucidated if it is the increase or loss of 
certain bacterial populations that lead to development of polyps (Zackular, et al., 2013).  It 
is, however, not known what effect the microbial dysbiosis has at different stages of 
progression of tumorigenesis in the mouse, or if it leads to different consequences in normal 
versus tumorigenic conditions. 
 
What is unknown? 
Studies are needed to characterize the interplay between the gut microbiome, inflammation 
and cancer. Another aspect which will be helpful in correctly defining the microbiome and 
inflammation-to-cancer axis will be the progression of alterations in the microbiome with 
worsening disease pathology. Of all the diseases that are affected by a change or loss of 
gut microbiome, cancer of the small and large intestine is clearly the one which can be 
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physically and physiologically related to the presence of alterations in gut microbiome 
community.                                           
 
AIM 1: To examine the composition of gut microbiome during tumor initiation and 
development in the ApcMin/+ mouse. 
Rationale: An altered gut microbiome can cause inflammation ranging from acute bouts 
to chronically inflamed gut. An altered microbiome, which shifts from symbiotic to a more 
inflammation-inducing phenotype, leads to a vicious cycle of erosion of the gut epithelial 
lining that, in turn, leads to more and more inflammatory processes taking place inside the 
gut microenvironment (Saxena, et al., 2012; Wang & Zhang, 2015). Our previous study on 
chronic inflammation-induced colon cancer in the APNKO (Adiponectin-knockout) mice 
demonstrated microbiota profiles that were clearly altered during tumorigenesis (data not 
published). The alterations mainly pertained to the altered percentages of the Firmicutes 
and Bacteroidetes bacterial phyla during inflammation-induced tumorigenesis in the mice 
(Figure 1). As opposed to externally administered chemically-induced tumorigenesis in 
mice, the microbiota has not been studied with respect to a spontaneously induced 
tumorigenesis such as that in the ApcMin/+ mouse. It was recently concluded that an 
alteration of gut microbiome precedes polyposis in the ApcMin/+ mouse (Son, et al., 2015). 
Also, it has been seen that specific pathogen-free (SPF) ApcMin/+ exhibit a higher tumor 
load and anemia with a higher infiltration of inflammatory cells specifically at advanced 
stages as compared to germ-free animals, indicating that a mere modulation of gut 
microbiome profiles can abrogate the disease condition in the gut (Y. Li, et al., 2012). 
 130 
However, there are no studies that study the gut microbiome with respect to gut 
inflammation and tumorigenesis in an age/time- dependent manner. Therefore, the first aim 
of the present study will be directed towards characterization of alterations of microbiome 
profiles from early to later stages of tumorigenesis in an ApcMin/+ mouse model. 
Hypothesis: The gut microbiota in ApcMin/+ mice will exhibit a higher percentage of 
Firmicutes bacterial phyla and a reduction in the percentage of Bacteroidetes, along with 
reduction in overall bacterial diversity during onset of tumorigenesis when compared to 
the WT mice. Furthermore, the percentage of Firmicutes will increase, while overall 
diversity will decrease during the progression of tumorigenesis. 
AIM 1.1: To study the profile of the gut microbiome during intestinal tumor initiation. 
Hypothesis 1.1: The microbiome profile of ApcMin/+ mice will exhibit a higher percentage 
of Firmicutes bacteria and a lower percentage of Bacteroidetes as compared to WT mice 
at initiation of tumor development. The overall microbial diversity will be lower in ApcMin/+ 
mice as compared to their WT counterparts. 
AIM 1.2: To study the profile of the gut microbiome during the progression of intestinal 
tumor development. 
Hypothesis 1.2: The microbiome profile of ApcMin/+ mice will exhibit a higher percentage 
of Firmicutes bacteria and a lower percentage of Bacteroidetes as compared to their WT 
counterparts during tumor progression. Firmicutes population will be higher during later 
stages of tumorigenesis as compared to initial stages of tumorigenesis. Also, the microbial 
diversity values will be lower in ApcMin/+ mice during tumor progression as compared to 
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WT mice, and within ApcMin/+ mice at later stages of tumor development as compared to 
their initial stages of tumorigenesis. 
 
AIM 2: To determine if gut microbiome manipulation can regulate the ApcMin/+ mouse 
health and tumorigenesis. 
Rationale: The mucus layer tends to thickness with increased diversity of the microbiota 
(Jakobsson, et al., 2015). Our preliminary data from a study on chronic inflammation-
induced colon cancer using APNKO mice suggested that the gut microbiota changes in a 
way that favors an increased percentage of bacteria of certain phyla (here, Firmicutes) as 
compared to others (such as Bacteroidetes). It has not been studied yet as to whether there 
is a relation between the altered percentages of especially the Firmicutes and Bacteroidetes 
phyla populations, and tumor number, tumor size and goblet cell numbers. It is known that 
the mucus layer provides a source of nutritional carbon and therefore energy to some of 
the intestinal flora that are able to lyse the glycans present in the mucus, making the inter-
relationship between the gut bacteria and the mucus layer really important (H. Li et al., 
2015). Also, the metabolites produced by these microbes also influence the differentiation 
and function of the epithelial and immune cells in the intestinal mucosa (Kato, et al., 2014; 
Shan, et al., 2013). The regulation of the mucin gene expression as well as mucus 
production have been shown to be two levels at which the gut microbial community may 
modulate mucins (Comelli, et al., 2008). Our recent study (Kaur, et al., 2015) also 
suggested that a reduction in the secretory mucin profile is associated with an inflammatory 
phenotype of the gut (Figure 4). Therefore, the present aim will be directed at knowing the 
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mucus-producing phenotypes of the cells lining the gut of the experimental animals in 
relation to the changing profiles of the gut microbiota. 
Hypothesis: Manipulation of the gut microbiota will lead to a decrease in gut health and 
an increase in tumor number and size in the ApcMin/+ mouse. Furthermore, manipulation of 
the gut microbiota will decrease goblet cell number in the intestine and colon. 
AIM 2.1: To determine if manipulation of gut microbiome through antibiotic 
administration affects disease prognosis in the ApcMin/+ mouse. 
Hypothesis 2.1: The manipulation of gut microbiome by externally administered 
antibiotics will lead to a worsening of disease prognosis in the experimental mice. 
AIM 2.2: To determine if manipulation of gut microbiome through antibiotic 
administration affects tumor number and size in the ApcMin/+ mouse. 
Hypothesis 2.2: The manipulation of the gut microbiome by externally administered 
antibiotics will lead to an increase in tumor number and size in ApcMin/+ mice. 
AIM 2.3: To determine if gut microbiome manipulation effects goblet cell numbers in 
small intestine and colon of ApcMin/+ mice as compared to WT mice. 
Hypothesis 2.3: The manipulation of the gut microbiome by externally administered 
antibiotics will lead to a reduction in goblet cell numbers in the intestine and colon of 
ApcMin/+ mice. 
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AIM 3: To determine if the relative abundance of Bacteroidetes and Fimicutes 
bacterial populations is associated with intestinal and systemic inflammation in the 
ApcMin/+ mouse. 
Rationale: The induction of cancer in the gut by chronic inflammation has always 
indicated towards the importance of underlying altered inflammatory processes (Wang & 
Zhang, 2015). Different agents that have been documented to be effective against tumors 
and cancers are the agents that function by downregulating important inflammatory 
pathways and pro-inflammatory cytokines such as IL1-β, IL-6 and TNF-α, and reduction 
of macrophage infiltration (Y. Li, et al., 2012; Murphy, Davis, McClellan, & Carmichael, 
2011; Murphy, Davis, McClellan, Gordon, et al., 2011; Ritland, et al., 1999). It has also 
been shown that the intestinal commensal bacteria plays a role in the development of gut 
microenvironmental immune system comprising both the humoral and cellular components 
and maintains the protective steady state immune function throughout life (Cebra, 1999; 
Talham, et al., 1999). It may be more appropriate to say that any alteration in comparative 
numbers of certain bacteria often lead to upregulation or downregulation of certain 
inflammatory pathways. The systemic release of microbial products as a result of the 
manipulation of the gut epithelium invokes an IL-23 response and a further IL-17 response 
in order to neutralize further invasion by the microbes, and the process is brought about by 
the Firmicutes bacteria Clostridia sp. (Shih, et al., 2014). The bacteria especially promotes 
IL-17 cytokine in the small intestine which is the primary site of its attachment and survival 
(Omenetti & Pizarro, 2015). These Th17 cells may become autoreactive in case of 
intestinal epithelium insult. The bacteria Bacteroides fragilis from the Bacteroidetes 
phylum leads to an increase in the production of IL-10 cytokine (Omenetti & Pizarro, 
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2015), whereas its strains have been implicated in the production of the pro-inflammatory 
cytokine IL-17-dependent inflammation-related colon cancer (W. Wu, et al., 2015). 
Inflammation, which is an integral part of tumorigenesis should therefore, may strongly be 
correlated with a reduced bacterial diversity or numbers. 
Hypothesis: An increase in the population of Firmicutes bacteria and/or a reduction in the 
population of Bacteroidetes will lead to a higher inflammatory response in both the 
intestinal tissue and systemic circulation. 
AIM 3.1: To examine if the relative abundance of Bacteroidetes and Firmicutes 
populations regulate intestinal tissue inflammation in the ApcMin/+ mouse. 
Hypothesis 3.1: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial 
populations will increase the inflammatory cellular infiltration into the mucosa of the 
intestinal tissue of the experimental mice. 
AIM 3.2: To examine if the relative abundance of Bacteroidetes and Firmicutes 
populations regulate intestine-secreted IL-1β, IL-17 and TNF-α in ApcMin/+ mice. 
Hypothesis 3.2: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial 
populations will increase the intestine-secreted IL-1β, IL-17 and TNF-α levels in the 
experimental mice. 
AIM 3.3: To examine if the relative abundance of Bacteroidetes and Firmicutes 
populations regulate systemic levels of cytokines IL-1β, IL-17 and TNF-α in ApcMin/+ mice. 
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Hypothesis 3.3: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial 
populations will increase systemic levels of IL-1β, IL-17 and TNF-α cytokines in the 
experimental mice. 
Limitations and Pitfalls: 
1. The ApcMin/+ mouse model is different from the DSS-DMH chronic inflammation-
induced cancer model (preliminary data). Therefore, microbiome profile of the ApcMin/+ 
model may be different from that of the DSS-DMH model of chronic inflammation-
induced cancer model. 
2. The microbiome profiles to be studied will be obtained from the fecal samples and will 
be assumed to represent the bacterial repertoire of both small intestine and colon of the 
experimental animals. Microbiome of the small intestine may be different from that of the 
colon. 
3. The effects of antibiotic administration on goblet cell production and inflammatory index 
in the ApcMin/+ mouse model may be very different from those seen as a result of a single 
bout of inflammation in the DSS-induced colitis model (preliminary data). 
4. The ApcMin/+ mouse model is majorly an intestinal mouse model and most of the polyps 
are seen in the small intestine. Thus, changes in goblet cell expression and inflammatory 
index may be significant only in the small intestine of the experimental mice. 
5. Administration of antibiotics to the experimental animals may lead to an increase in 
intestine-secreted pro-inflammatory cytokines due erosion of the epithelial layer but may 
not necessarily change them systemically. 
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6. The study has a small sample size which may lead to lesser significant values of the 
results that will be obtained from the study. 
 
Working model 
  
 
 
The central idea of the present study is to study the role of gut microbiota (bacterial) in 
tumorigenesis, mucus producing phenotype and inflammation. In order to study this, we 
will be using the ApcMin/+ model of intestinal cancer. The ApcMin/+ mouse model is raised 
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from the C57BL/6 background where a point mutation on codon 850 of the Apc 
(Adenomatous Polyposis Coli) gene leads to spontaneous development of polyps 
(adenomas) in the intestinal mucosa (Zhang, et al., 2015). The mutation is responsible for 
the production of a truncated APC protein (2843 amino acids) that lacks its C-terminal 
domains. The protein functions to downregulate the Wnt signaling pathway by binding to 
and promoting the destruction of the β-catenin protein. It has been shown that altered 
interactions between the gut microbiota and colonic mucosa precede polyposis in the 
ApcMin/+ mouse (Son, et al., 2015). Using the basis of an altered gut microbiota preceding 
polyposis, we are trying to delve further into the processes that are hampered by alterations 
in the gut microbiota, which can be used to elucidate the ways in which the gut microbiota 
affects tumorigenesis. 
 The first aim of the study will be directed towards examining the composition of 
gut microbiome during tumor initiation and development in ApcMin/+ mouse. This aim will 
act as preliminary to aims 2 and 3 by characterizing and thereby defining the alterations 
occurring in the microbiome of ApcMin/+ mouse during initiation and progression of 
tumorigenesis. Previous studies have demonstrated an alteration in gut microbiota to be 
linked to a variety of conditions including diabetes, arthritis, colitis and cancer and even 
immune system. Conditions such as Crohn’s disease and obesity have implicated gut 
bacterial dysbiosis in pathogenesis (Chan, et al., 2015; Mai, et al., 2007). The 
characterization of the gut microbiome in the experimental ApcMin/+ mice will help define 
the abundance of different bacterial species in the gut and their relative diversity values 
during the initiation and progression of tumorigenesis. 
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 The second aim of the study will be directed towards elucidating the role of an 
altered microbiome on pathology of the experimental animals. Antibiotics will be 
administered to experimental mice in order to perturb the gut microbiota during the initial 
and progressive stages of tumorigenesis. The use of antibiotics not only help get rid of 
pathogenic bacteria but also deplete related micro-organisms, which fail to return to normal 
levels even long after the antibiotic usage subsides (Cresci & Bawden, 2015). This aim will 
thus help in elucidating the effect of alterations in microbiome in terms of their abundance 
and diversity on the disease condition of the animals. This aim will also be directed towards 
knowing if the tumor numbers and size are related to the microbiome and its alterations. 
The third part of this aim will elucidate the effects of altered gut microbiome on expression 
of goblet cells in the intestine and colon of mice. Our previous study (Saxena, et al., 2013) 
has demonstrated that a reduction in goblet cell numbers leads to worsened disease 
pathology and reduced protection against chronic inflammation-induced colon cancer. A 
reduction in the number of mucus-producing goblet cells may also be altered in the ApcMin/+ 
model and further worsen the disease state once they are administered antibiotics. 
 The third aim of the present study will demonstrate the effects of an altered 
microbiome on the inflammatory status of the experimental animals. Inflammation is an 
important route through which alterations in gut microbiota affect the overall milieu of 
inflammatory processes closely associated with the gut. The inflammatory response, along 
with being systemic, has also been demonstrated to occur at a more localized level such as 
the alterations in gut microbiota leading to increased levels of pro-inflammatory cytokines 
such as IL-1β and TNF-α (Singh, et al., 2015). In the first part of aim 3 we will study the 
effects of a changed microbiome on tissue-localized inflammation and infiltration 
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occurring at the level of intestinal mucosa. The second part of the aim will help study the 
effects of microbiome manipulation on intestine-secreted pro-inflammatory cytokines. 
Whether the inflammatory effect is systemic or not, will be elucidated through the third 
part of this aim where systemic levels of pro-inflammatory cytokines will be measured. 
 
CHAPTER 2 
Review of Literature 
The ApcMin/+ mouse model 
The ApcMin/+ mouse model is widely used by researchers to study gut inflammation and 
cancer. The ApcMin/+ mouse model is raised from the C57BL/6 background where a point 
mutation on codon 850 of the Apc (Adenomatous Polyposis Coli) gene leads to 
spontaneous development of polyps (adenomas) in the intestinal mucosa (Zhang, et al., 
2015). The mutation is responsible for the production of a truncated APC protein (2843 
amino acids) that lacks its C-terminal domains. The protein functions to downregulate the 
Wnt signaling pathway by binding to and promoting the destruction of the β-catenin 
protein. An altered APC protein thus leads to, apart from the development of intestinal 
polyps, dysregulation of processes like cell adhesion, cell migration, chromosome 
segregation and stability (McCart, et al., 2008). 
 The ApcMin/+ mouse model represents the human cancer syndrome called the 
Familial Adenomatous Polyposis (FAP) where the human intestine may contain several 
thousand adenomas by the age of 20-30 years, which corresponds to ~4-6 weeks in mouse. 
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The ApcMin/+ mouse exhibits more than 50 tumors along the entire length of the intestine 
and rarely live past the age of 21-22 weeks (Shoemaker, et al., 1997), which corresponds 
to ~60 years of age in humans. Since all intestinal tumors in B6 Min/+ mice are benign 
adenomas, the premature death of these animals is associated with secondary effects of 
tumor growth, including severe, chronic anemia and intestinal blockage (Shoemaker, et al., 
1995).  
 
The Gut Microbiome 
The gut microbiome is an integral and an important symbiotic system present in the gut, 
which comprises of bacteria, archaea, fungi and viruses residing in the gastrointestinal tract 
throughout its length. The gut bacteria itself comprises a major percentage of the total gut 
microbiome, where its numbers are in trillions. While the stomach and duodenum contain 
about 101 to 102 Colony Forming Units (CFU) per mL of bacterial forms, the jejunum and 
ileum comprise 104 to 108, and the colon has 1010 to 1012 CFU/mL of bacteria (Cresci & 
Bawden, 2015). The microbiome acts advantageous for the gut such that it regulates gut 
epithelial and endocrine cellular structure (Uribe, et al., 1994). The commensal bacterium 
B. thetaiotaomicron VPI-5482, for example, which is a member of the gut flora, has been 
linked to the functional processes of the gut such as nutrition absorption, mucosal barrier 
function, metabolism, angiogenesis and postnatal intestinal maturation (Hooper & Gordon, 
2001; Hooper, et al., 2001). 
Previously, many studies have demonstrated an alteration in gut microbiota to be 
linked to a variety of conditions including diabetes, arthritis, colitis and cancer and even 
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immune system. Conditions such as Crohn’s disease and obesity have implicated gut 
bacterial dysbiosis in pathogenesis (Chan, et al., 2015; Mai, et al., 2007). The highest 
bacterial load is found in the distal small intestinal tract and colon - areas commonly found 
to be associated with disease conditions (Hooper, et al., 2002; Kanauchi, et al., 2003). It 
was not clear if the bacterial dysbiosis is a cause or consequence of the disease until 
recently when it was shown that alterations in gut microbiome precede polyposis in the 
ApcMin/+ mouse (Son, et al., 2015). An altered gut microbiome can cause inflammation 
ranging from acute bouts to chronically inflamed gut. An altered microbiome, which shifts 
from symbiotic to a more inflammation-inducing phenotype, leads to a vicious cycle of 
erosion of the gut epithelial lining that, in turn, leads to more and more inflammatory 
processes taking place inside the gut microenvironment (Saxena, et al., 2012; Zhang, et al., 
2015). A need to address and characterize host-microbe relations has been emphasized in 
recent years in order to elucidate the processes and factors involved in the relationship 
between the gut microbiome and inflammation and related tumorigenesis. 
The intestinal epithelial lining has a strong relationship to the gut bacteria. The 
bacterial flora of the intestine helps in digesting the food (especially carbohydrates) that 
cannot be digested by the mammalian gut, and in turn, the intestinal epithelial cells 
metabolize the short-chain fatty acids that result from the bacterial fermentation of the 
undigested carbohydrates and use them as an energy source (Abreu, 2010). 
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Antibiotic usage, gut microbiome and inflammation 
Antibiotic treatments that are usually used against digestive tract infections not only target 
the pathogenic microbes but also the host-interactive useful microbes. It is already known 
that the use of antibiotics, especially broad spectrum, not only help get rid of pathogenic 
bacteria but also deplete related micro-organisms, which fail to return to normal levels even 
long after the antibiotic usage subsides (Cresci & Bawden, 2015). Microbial diversity also 
is seen to be reduced in the gut following antibiotic treatment which exerts detrimental 
effects (Lofmark, et al., 2006). 
 Antibiotic usage can severely and permanently affect 30% of the microbial 
population (Dethlefsen & Relman, 2011). Once the antibiotic treatment is stopped, and 
some resilient bacteria repopulate the gut, the final state is never a complete replacement 
of the initial state (Francino, 2015). Any early antibiotic treatment in humans reduces the 
overall diversity of the microbiota populations inside the gut which leads a disbalance of 
the inflammatory molecules in the body. The disbalance between the Th1 and Th2 
paradigm was at first thought to be the main culprit in bringing out the inflammatory effects 
of the microbiota dysbalance. An increased Th1 activation was linked to harmful 
inflammatory changes (Akdis & Akdis, 2009; Oboki, et al., 2008). However recently, 
alterations in the gut microbiota have been linked to a dysregulation of the regulatory T 
cell paradigm and their associated cytokines (Shen, et al., 2014), where the regulation of 
this immunological pathway depends on the relationship between the gut microbiota and 
the immune system. Different cocktails of antibiotics administered to mice have led to an 
upregulation of either the Th2 or a Th17 response (Atarashi & Honda, 2011; Dimmitt, et 
al., 2010), indicating that an alteration in the gut microbiota may favor one pathway and 
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downregulate another inflammatory pathway. How the microbiota changes in the first 
place and then a subsequent change occurs in the inflammatory pathways during 
spontaneous tumorigenesis is a question that the present study will be aiming to answer via 
studying different stages of tumorigenesis. 
 Inflammation is an important route through which alterations in gut microbiota 
affect the overall milieu of inflammatory processes closely associated with the gut. Gut 
microbiota manipulation through antibiotic treatment has been shown to cause a decrease 
in the expression of the Muc2 protein, a major component of the intestinal mucus layer 
(Dimmitt, et al., 2010). A thinning of the protective mucus layer leads to a direct contact 
between the gut lining and the gut bacteria residing in the lumen, thereby triggering innate 
immune responses and inflammation (Francino, 2015). The inflammatory response, along 
with being systemic, also occurs at a more localized level such as the alterations in gut 
microbiota leading to increased levels of pro-inflammatory cytokines such as IL-1β and 
TNF-α (Vijay-Kumar, et al., 2010). 
 For the completion of aims 2 and 3, antibiotics will administered to the treatment 
group of mice in three sets: 1). One cycle of antibiotic administration starting at 6 weeks 
of age for 10 days and sacrifice at 8 weeks; 2). Two cycles of antibiotic administration 
starting at 6 weeks and 10 weeks and sacrifice at 12 weeks; and 3). Three cycles of 
antibiotic administration starting at 6, 10 and 14 weeks of age and sacrifice at 16 weeks. 
Antibiotic administration at 6 weeks of age will signify the manipulation of gut microbiome 
at the onset of tumorigenesis. This stage of tumorigenesis is marked by a gradual increase 
in the number of polyps in the small intestine (Puppa, et al., 2011). Antibiotic 
administration at 6 and 10 weeks of age will help define effects of microbiome altered at 
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the beginning of tumorigenesis (6 weeks) and then at the middle of the life span of 
experimental mice which is marked by progression of tumor development resulting in more 
pronounced symptoms of anemia and intestinal blockage. While the polyp number reaches 
a plateau, they only increase in size during this stage and the animals continue to lose body 
weight (Puppa, et al., 2011). Antibiotic treatment at 6, 10 and 14 weeks will represent the 
alterations in microbiome throughout the processes initiation of tumorigenesis. This stage 
is marked by severe inflammation, continuation of tumor size and maximum weight loss 
(Puppa, et al., 2011). 
 
Impact of antibiotics 
Although antibiotics are used against pathogenic microbes, their usage affects other 
microbial members of the community as well. The effects that are established as a result of 
an altered microbiome can be long-lasting even after the antibiotic treatment has subsided 
(Jakobsson, et al., 2015; Jernberg, et al., 2007). While the more resilient bacteria are 
successful at returning to their pre-treatment levels, others are lost indefinitely (Willing, et 
al., 2011). Moreover, the occurrence of co-dependence between members of the 
community based on differential metabolite production and utilization pathways leads to 
perturbation of members that are not necessarily directly targeted by the antibiotic. 
The direct and indirect effects of the antibiotics are brought about at different levels 
and ways. The indirect effects are brought about by the changed gut microbiota. A change 
in the bacterial population is known to cause a change in the downstream signaling by the 
Pattern Recognition Receptors (PPRs) which help maintain epithelial integrity and repair 
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process, while change in some bacterial populations that bind to Toll-like receptors, such 
as TLR4, are linked to an altered innate immune defenses (Willing, et al., 2011). A reduced 
production of short-chain fatty acids (SCFAs) is also a common feature of human 
metabolic profiles after antibiotic treatment (Romick-Rosendale, et al., 2009; Yap, et al., 
2008). Changes in bacterial populations also affects differentiation of certain immune 
system molecules such as IL-17 and often lead to a dysregulation of the immune system 
(Ivanov, et al., 2009). 
More direct effects include undesirable inflammation of the gut such as 
gastroenteritis (Barthel, et al., 2003) and even dermatitis (J. Watanabe, et al., 2010). 
Intestinal mucus layer 
The gut lining is folded into tubular invaginations called the villi in the intestine and crypts 
(of Leiberkuhn) in the colon. The gut lining is protected from the lumen microenvironment 
by a single-cell layer comprising of absorptive enterocytes (which make most of the 
epithelial cells), mucus-producing goblet cells, hormone-producing enteroendocrine cells 
and Paneth cells that produce anti-microbial products in the gut (Abreu, 2010). The four 
types of the cells line the single-celled layer of the gut that faces the lumen. All the four 
types of cell arise from the pluripotent stem cells that lie at the base of the crypts. The 
differentiated cells that arise from the stem cells of the crypts slowly and continuously rise 
towards the crypt apex from where the single-celled layer is regularly shed and renewed to 
maintain a healthy gut, also providing the crypt with a feature of polarity. 
The mucus in the small and large intestine is secreted by the goblet cells. It forms 
the first line of defense between the gut lumen microenvironment and the underlying 
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epithelial layer and the submucosa. The mucin proteins in the gut mainly comprise of the 
MUC2 and MUC5AC proteins. They have properties of forming gel like coating onto the 
gut lumen once getting hydrated and form highly glycosylated proteins that are resistant to 
the digestive environment of the gut (Koboziev, et al., 2014). Changes in goblet cell 
function, secretion of mucins into the lumen and composition of this mucus layer are shown 
to be altered by an altered microbiome (Deplancke & Gaskins, 2001). The mucus layer 
provides a balanced ecosystem for the resident and as well as pathogenic bacteria in the 
intestinal lumen by acting as a source of nutrition, thus indicating a homeostatic balance 
between the host gut microenvironment and the microbiome associated with it (Aristoteli 
& Willcox, 2003). An alteration in one of them may render the other dysfunctional. It is 
also said that the resident bacteria may inhibit the adherence of pathogenic bacteria to the 
intestinal epithelial cells by increasing the production of intestinal mucus (Mack, et al., 
2003; Mack, et al., 1999; Smirnova, et al., 2003). 
 
Mucus and gut microbiome 
It has been shown that the mucus layer tends to thickness with increased diversity of the 
microbiota (Jakobsson, et al., 2015). The mucus layer provides a source of nutritional 
carbon and therefore energy to some of the intestinal flora that are able to lyse the glycans 
present in the mucus, making the inter-relationship between the gut bacteria and the mucus 
layer really important (H. Li, et al., 2015). Also, the metabolites produced by these 
microbes also influence the differentiation and function of the epithelial and immune cells 
in the intestinal mucosa (Kato, et al., 2014; Shan, et al., 2013). Our recent study (Kaur, et 
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al., 2015) also suggested that a reduction in the secretory mucin profile is associated with 
an inflammatory phenotype of the gut. Inflammation, which is an integral part of 
tumorigenesis should therefore, may strongly be correlated with a reduced bacterial 
diversity or numbers. Moreover, both Gram-positive and Gram-negative bacteria are 
known to enhance the intestinal mucin expression (Dohrman, et al., 1998). The regulation 
of the mucin gene expression as well as mucus production have been shown to be two 
levels at which the gut microbial community may modulate mucins (Comelli, et al., 2008). 
Gut microbiota manipulation through antibiotic treatment has been shown to cause a 
decrease in the expression of the Muc2 protein, a major component of the intestinal mucus 
layer (Wlodarska, et al., 2011). A thinning of the protective mucus layer leads to a direct 
contact between the gut lining and the gut bacteria residing in the lumen, thereby triggering 
innate immune responses and inflammation (Francino, 2015). 
 
Gut microbiome and Apc-min 
Studies that work at elucidating the role of gut microbes in disease models, have been 
limited, especially due to the fact that most of the important gut bacteria are difficult to 
grow in a laboratory setting making them unavailable for studying unless mammalian 
models are used. However, there are evidences that the manipulation of the gut microbiome 
through diet modulations, can alter the disease conditions such as those in Crohn’s disease 
and Inflammatory Bowel Disease (Mai, et al., 2007). Studies that use the ApcMin/+ mouse 
model for studying gut diseases and their association with microbiota often report 
significant changes in microbiome profiles of the large intestine, but also report that 
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differences in the polyps is only significant in the small intestine (Mai, et al., 2007) The 
detrimental effects are also brought about via loss of certain colonizing bacterial species 
that are dependent on other colonizers for processes such as nutritional interactions and 
removal of secondary metabolites and toxic waste products (Belenguer, et al., 2006), or 
through loss of useful co-evolved processes brought about by the host-microbial co-
dependence (Atarashi & Honda, 2011; Ferreira, et al., 2011). There are no studies that 
study the gut microbiome with respect to gut inflammation and tumorigenesis in an 
age/time- dependent manner. It has been seen that specific pathogen-free (SPF) ApcMin/+ 
exhibit a higher tumor load and anemia with a higher infiltration of inflammatory cells 
specifically at advanced stages as compared to germ-free animals, indicating that a mere 
modulation of gut microbiome profiles can abrogate the disease condition in the gut (Y. 
Li, et al., 2012). 
 
Gut microbiome, inflammatory cytokines and tumorigenesis 
It is a fact that till date, one of the most effective class of chemopreventive agents is the 
non-steroidal anti-inflammatory drugs (NSAIDs). The induction of cancer in the gut by 
chronic inflammation has always indicated towards the importance of underlying altered 
inflammatory processes (Zhang, et al., 2015). Different agents that have been documented 
to be effective against tumors and cancers are the agents that function by downregulating 
important inflammatory pathways and pro-inflammatory cytokines. Apart from the usual 
NSAIDs that function by downregulating the metabolism of the arachidonic acid through 
the Cyclooxygenase (COX) pathways agents such as curcumin and quercetin exert their 
 149 
chemopreventive effects through the downregulation of mRNA expression levels of pro-
inflammatory cytokines such as IL1-β, IL-6 and TNF-α, and reduction of macrophage 
infiltration (Y. Li, et al., 2012; Murphy, Davis, McClellan, & Carmichael, 2011; Murphy, 
Davis, McClellan, Gordon, et al., 2011; Ritland, et al., 1999).  
 It has also been shown that the intestinal commensal bacteria plays a role in the 
development of gut microenvironmental immune system comprising both the humoral and 
cellular components and maintains the protective steady state immune function throughout 
life (Cebra, 1999; Talham, et al., 1999). It may be more appropriate to say that any 
alteration in the composition of the gut microbiome will lead to a dysfunctional immune 
system. 
 Certain bacterial species such as B. thetaiotaomicron bacterium have been 
associated with the attenuation of pro-inflammatory responses by reducing the levels of the 
pro-inflammatory cytokine IL-8 (Zhao, et al., 2001). 
 Comparative numbers of certain bacteria often lead to upregulation or 
downregulation of certain inflammatory pathways. The systemic release of microbial 
products as a result of the manipulation of the gut epithelium invokes an IL-23 response 
and a further IL-17 response in order to neutralize further invasion by the microbes, and 
the process is brought about by the Firmicutes bacteria Clostridia sp. (Shih, et al., 2014). 
The bacteria especially promotes IL-17 cytokine in the small intestine which is the primary 
site of its attachment and survival (Omenetti & Pizarro, 2015). These Th17 cells may 
become autoreactive in case of intestinal epithelium insult. The bacteria Bacteroides 
fragilis from the Bacteroidetes phylum leads to an increase in the production of IL-10 
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cytokine (Omenetti & Pizarro, 2015), whereas its strains have been implicated in the 
production of the pro-inflammatory cytokine IL-17-dependent inflammation-related colon 
cancer (W. Wu, et al., 2015). 
 It is widely accepted that inflammation contributes to the development of cancer 
and inflammatory cells have been noted in and around tumors (Hanahan & Weinberg, 
2011). A relationship between inflammation and intestinal neoplasia is supported by the 
facts that inflammatory bowel disease predisposes patients to intestinal carcinomas and 
that the anti-inflammatory drugs aspirin (Baron, et al., 2003), celecoxib (Bertagnolli, et al., 
2006), and rofecoxib (Bertagnolli, et al., 2006), all have proven efficacy in preventing 
human colorectal adenoma development. 
Adenoma formation has been shown to increase following adoptive transfer of pro-
inflammatory lymphocytes (Rao, et al., 2006) and decreased after the adoptive transfer of 
anti-inflammatory regulatory T-cells (Treg cells) (Erdman, et al., 2005). Apart from direct 
effects of inflammatory cells, adenomas are also known to be impaired by the absence of 
the molecule MyD88 which mediates the downstream inflammatory signaling as a 
response to bacterial and viral products (Rakoff-Nahoum & Medzhitov, 2007). Pro-
inflammatory pathways such as those involved with IL-17 secretion are associated with 
many chronic inflammatory conditions such as asthma (Schnyder-Candrian, et al., 2006) 
and inflammatory bowel disease (Yen, et al., 2006), along with colon carcinogenesis 
(Langowski, et al., 2006). IL-17, especially, has been denoted as a marker and mediator of 
tumor angiogenesis (Langowski, et al., 2006). Over-expression of pro-inflammatory 
factors such as IL-6, MCP-1, NF-ᴋB and IL-8 can aggravate tumors (Wang & Zhang, 
2015). 
 151 
In the context of the ApcMin/+ mouse model, the mutual interaction of macrophages 
with cancer cells enhances production of inflammatory cytokines such as IL-1, IL-6 and 
TNF-α that transform the tumor microenvironment so that it favors the survival, growth 
and motility of cancer cells. Reduction in pro-inflammatory molecules such as MCP-1 
leads to a decrease in the total polyp number and size in the ApcMin/+ mouse along with 
downregulating inflammatory processes in tumor tissues and surrounding tumor 
microenvironment (McClellan, Davis, Steiner, Day, et al., 2012). An elevation in the 
intestinal inflammatory cytokine (MCP-1, IL-1β, IL-6 and TNF-α) response occurs at 12 
weeks of age as a result of the rapid increase in polyp number, which are further elevated 
with increase in polyp size. A similar study by McClellan et al (2012) (McClellan, Davis, 
Steiner, Enos, et al., 2012) shows an increased mRNA expression of MCP-1, IL-1b, IL-6 
and TNF-α that is evident at 12 weeks of age and is consistent with the increase in polyp 
number that occurs at this time. After the age of 12 weeks which is associated with the 
largest number of small polyps, the inflammatory response continues to increase while the 
number of polyps remain constant which indicates that the inflammatory response after 12 
weeks could largely be driven by polyp size. However, it is still unclear whether the 
changes in polyp number and size that occurs in this model is a result of the elevated 
inflammatory response or vice versa (McClellan, Davis, Steiner, Enos, et al., 2012). 
 
16S rRNA gene profiling and sequencing 
The 16S rRNA gene method is one of the earliest and most widely used methods used for 
phylogenetic, taxonomic and bioinformatics analyses. It targets the 16S rRNA bacterial 
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genes to know diversity or similarities in biological samples. The 16S rRNA gene provides 
many advantages in microbiome analyses including its universal distribution in bacterial 
species, relative stability in evolution and ideal size (1500 bp). Consisting of both constant 
and variable regions, the 16S gene is easy to amplify used broad-range primers used against 
regions flanking its variable regions (Sankar, et al., 2015). 
 
Statistical Power of the study 
The microbiome analysis in our study will be done using the fecal samples from 
experimental mice. A 16S rRNA gene sequencing technique will be used to study the gut 
microbial populations in the animals. The sample size for the study is 4. Some of the 
previous studies that have been directed towards similar microbial analyses have used 
similar samples sizes. Russell et al (2012) (Russell, et al., 2012) used n = 3-5 to study 
changes in the gut microbial communities in C57BL/6 mice following antibiotic treatment 
at neonatal and adult stages of life. The results showed significant reductions in the overall 
bacterial diversity and phyla abundance in antibiotic-treated mice as compared to control 
mice (p value<0.05). Oh et al (2016) (Oh, et al., 2016) used a sample size of 5 mice per 
group in order to show significant differences in bacterial load and diminished rDNA in 
antibiotic-treated mouse fecal samples as compared to their control counterparts. Similar 
studies have used n = 4-6 mice per group in order to show Significant (p value<0.01) 
changes in gut microbial constituents as a result of administration of the antibiotic 
enrofloxacin with an increase in type-2 cytokines has been shown in a study that used 4 to 
6 (n) mice per group (Strzepa, et al., 2016). 
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PRELIMINARY DATA 
Preliminary data for Aim 1: 
Chronic inflammation and colon cancer was induced in Dextran Sodium Sulphate (DSS) + 
DMH treatment group in both APNKO (n=5) and WT (n=5) mice by administering DSS 
dissolved in their drinking water for five days followed by five days of regular drinking 
water along with administering a single injection of DMH intraperitoneally once a week 
for 12 weeks at a concentration of 20mg/kg body weight of mice at the beginning of DSS 
treatment. Fecal samples were collected at the time of sacrifice and were analyzed by 
sequencing the V3 variable region of bacterial 16S rRNA gene to profile the composition 
of the microbiome (Figure 1). 
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Figure 1. Bacterial phylum profiles are altered during cancer development. The figure 
illustrates distribution of different bacterial phyla (percentages) in colons tissues of WT 
(C57BL/6) and APNKO mice belonging to control and DSS+DMH treatment groups. 
 
Preliminary data for Aim 2: 
Clinical score which is a summation of weight loss, diarrhea and fecal hemoccult was 
determined during the length of the study thrice a week till the date of sacrifice (day 153). 
We found a significant increase in the clinical score of the APNKO mice on day 30 and 
then at day 67 which remained significantly high till the end of the study as compared to 
WT mice given the same treatment (Figure 2). 
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Figure 2. Clinical score of increases during tumor development. Clinical score for 
DSS+DMH treatment was plotted against different time points of the study. The score was 
calculated out of a total of twelve points; four points each for the observations of weight 
loss, diarrhea and hemoccult. Two-way repeated measure analysis of variance (ANOVA) 
was applied to calculate the significant difference between the clinical score for APNKO 
and WT mice throughout the length of the study. **pb0.05, #pb0.001, *pb0.03. 
The data shown in figures 1 and 2 demonstrate that there may be a correlation between the 
abundance of Firmicutes bacterial phylum and clinical score such that an increased 
abundance of Firmicutes may be associated with disease severity in colon cancer. 
Mice were sacrificed on day 153 and the colon was excised and flushed with PBS. Colon 
was cut open longitudinally and stained with 2% methylene blue to count the tumor number 
and tumor area. Significant increase in the tumor number and area was found in the 
APNKO mice as compared to the WT mice (Figure 3). 
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Figure 3. Tumor development in APNKO and WT mice treated with DSS+DMH. (A) 
Average number of tumors counted per mice per group. (B) Average tumor area in mm2 
counted for each mouse per group plotted in the order of their severity. One-way ANOVA 
was used to calculate significant difference between APNKO and WT mice. *p<0.05. 
The data shown in figures 1 and 3 demonstrate that there may also be a correlation between 
the abundance of Firmicutes bacterial phylum and tumor number and size such that an 
increased abundance of Firmicutes may be associated with a higher tumor load in colon 
cancer. 
Mice colon were harvested in 2 mm2 sections and were embedded in embedded in paraffin. 
5 µm sections were cut using a microtome. Standard deparaffinization procedure was 
followed using xylene and gradation of ethanol. Alcian blue solution (1 %) of pH 2.5 in 3 
% acetic acid and nuclear fast red in aluminum sulfate was prepared. Tissues were stained 
with Alcian blue and counterstained with nuclear fast red solution. Goblet to epithelial cell 
ratio was counted per crypt with ten crypts per section and five sections per group (Figure 
4). The staining revealed a reduction in the number of mucus-producing goblet cells in the 
DSS+DMH group both in APNKO and WT groups. 
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Figure 4. Goblet to epithelial cell ratio is decreased in colon cancer. Descending colon, 2 
mm2 sections of the mice stained with Alcian blue dye representing goblet cells (blue) in 
APNKO and WT groups belonging to Control and DSS+DMH groups. 
The data shown in figures 1 and 4 may indicate a correlation between the abundance of 
Firmicutes bacterial phylum and a decreased expression of mucus-producing phenotype of 
the cells lining the gut epithelium which renders a reduced protection from epithelial insult 
and inflammation during cancer. 
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Preliminary data for Aim 3: 
Mice colon paraffinized sections were cut using a microtome into 5 µm thickness. Standard 
deparaffinization procedure was followed using xylene and gradation of ethanol. 
Hematoxylin and Eosin staining was performed to highlight the general tissue structure 
(Figure 5). The DSS+DMH group revealed increased cellular infiltration into the colonic 
mucosal layers indicative of an increased inflammatory index. 
 
Figure 5. Inflammation and infiltration of colon epithelium. H&E stained sections of the 
descending colon of APNKO and WT mice in DSS+DMH group with 20X magnification 
(scale bar=120 μm). 
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RESEARCH DESIGN AND METHODS 
Overall Research Design: The overall purpose of the present study is to elucidate the role 
of alteration in the gut microbiome on disease severity in an intestinal cancer model of 
mouse. The study will firstly comprise of a preliminary data on characterizing the 
alterations in the gut microbiome of the ApcMin/+ mouse. An external manipulation of the 
microbiome with the help of an antibiotic cocktail will then be used in order to control the 
microbiome manipulation cycles and accurately understanding the role of the microbial 
alteration on health, tumorigenesis, mucus production and inflammation. So far, no study 
has demonstrated these effects brought about by an altered gut microbiome throughout the 
development of tumor. 
The first aim of the study will be directed towards examining the composition of 
gut microbiome during tumor initiation and development in ApcMin/+ mouse. This aim will 
act as preliminary to aims 2 and 3 by characterizing and thereby defining the alterations 
occurring in the microbiome of ApcMin/+ mouse during initiation and progression of 
tumorigenesis. The characterization of the gut microbiome in the experimental ApcMin/+ 
mice will help define the abundance of different bacterial species in the gut and their 
relative diversity values during the initiation and progression of tumorigenesis. 
 The second aim of the study will be directed towards elucidating the role of a 
manipulated microbiome on pathology of the experimental animals. Antibiotics will be 
administered to experimental mice in order to perturb the gut microbiota during the initial 
and progressive stages of tumorigenesis. This aim will thus help in elucidating the effect 
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of alterations in microbiome in terms of their abundance and diversity on the disease 
condition, tumorigenesis and goblet cell expression levels in the animals. 
The third aim of the present study will demonstrate the effects of microbial 
manipulation on the inflammatory status of the experimental animals. In the first part of 
aim 3 we will study the effects of an altered microbiome on tissue-localized inflammation 
and infiltration occurring at the level of intestinal mucosa. The second part of the aim will 
help study the effects of microbiome alteration on intestine-secreted pro-inflammatory 
cytokines. Whether the inflammatory effect is systemic or not, will be elucidated through 
the third part of this aim where systemic levels of pro-inflammatory cytokines will be 
measured. 
 
A timeline for the present study is provided below: 
 
Figure 6. Study timeline and time points. 
 
AIM 1: To examine the composition of gut microbiome during tumor initiation and 
development in ApcMin/+ mouse. 
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Rationale: An altered gut microbiome can cause inflammation ranging from acute bouts 
to chronically inflamed gut. An altered microbiome, which shifts from symbiotic to a more 
inflammation-inducing phenotype, leads to a vicious cycle of erosion of the gut epithelial 
lining that, in turn, leads to more and more inflammatory processes taking place inside the 
gut microenvironment (Saxena, et al., 2012; Zhang, et al., 2015). Our previous study on 
chronic inflammation-induced colon cancer in the APNKO (Adiponectin-knockout) mice 
demonstrated microbiota profiles that were clearly altered during tumorigenesis. The 
alterations mainly pertained to the altered percentages of the Firmicutes and Bacteroidetes 
bacterial phyla during inflammation-induced tumorigenesis in the mice (Figure 1). As 
opposed to externally administered chemically-induced tumorigenesis in mice, the 
microbiota has not been studied with respect to a spontaneously induced tumorigenesis 
such as that in the ApcMin/+ mouse. It was recently concluded that an alteration of gut 
microbiome precedes polyposis in the ApcMin/+ mouse (Son, et al., 2015). Also, it has been 
seen that specific pathogen-free (SPF) ApcMin/+ exhibit a higher tumor load and anemia with 
a higher infiltration of inflammatory cells specifically at advanced stages as compared to 
germ-free animals, indicating that a mere modulation of gut microbiome profiles can 
abrogate the disease condition in the gut (Y. Li, et al., 2012). However, there are no studies 
that study the gut microbiome with respect to gut inflammation and tumorigenesis in an 
age/time- dependent manner. Therefore, the first aim of the present study will be directed 
towards characterization of alterations of microbiome profiles from early to later stages of 
tumorigenesis in an ApcMin/+ mouse model. 
AIM 1.1: To study the gut microbiome profiles of ApcMin/+ mice during intestinal 
tumor initiation. 
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AIM 1.2: To study the gut microbiome profiles for ApcMin/+ mice during intestinal 
tumor progression. 
AIM 1.3: To study the gut microbiome profiles of ApcMin/+ mice during peak of 
intestinal tumorigenesis. 
Experimental Design Specific Aim 1: Aim 1 will study the composition of the gut 
microbiome during initiation and development of tumorigenesis in ApcMin/+ mouse model. 
Four weeks old male ApcMin/+ and C57BL/6 (WT) mice will be housed at the Animal 
Resource Facility, USC. Food (Purina chow) and drinking water will be available to the 
mice ad libidum under a 12:12 hour light-dark cycle and a low-stress environment (22oC, 
50% humidity and low noise). Cumulative clinical scores will be obtained for each mouse 
twice a week with a maximum clinical score of 12. The clinical score for each mouse will 
be based on weight loss measurement, diarrhea and fecal hemoccult. The experimental 
animals will be sacrificed at 8, 12 and 16 weeks as per figure 6, without any antibiotic 
treatment, and microbiome profiles will be studied using fecal samples at each of the three 
time points. 
Animal Model and Handling: Four weeks old ApcMin/+ mice will be obtained from the 
Jackson Laboratories and bred at the Animal Resource Facility at University of South 
Carolina. Food (Purina chow) and drinking water will be available to the mice ad libidum 
under a 12:12 hour light-dark cycle and a low-stress environment (22oC, 50% humidity 
and low noise). All animal care followed institutional guidelines under a protocol approved 
by the Institutional Animal Care and Use Committee at the University of South Carolina. 
Cumulative clinical scores will be obtained for each mouse twice a week with a maximum 
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clinical score of 12. The clinical score for each mouse will be based on weight loss 
measurement, diarrhea and fecal hemoccult with a maximum score of 4 within each of the 
three quantitative parameters. ApcMin/+ and WT mice will be randomLy assigned to three 
groups (n=4): 1) 8 weeks; 2) 12 weeks; 3) 16 weeks. 
                         
Mice will be monitored throughout the course of study for weight loss, diarrhea and fecal 
hemoccult. Mice will sacrificed at the three different time points by cervical dislocation. 
Blood will be collected before sacrifice through retro-orbital puncture, centrifuged at 
10,000 rpm for 15 minutes and serum will be isolated and stored at -20°C. Small intestine 
and colon will be excised and flushed clean with PBS. 2 mm2 colon tissue sections will be 
fixed in 10% formalin and after 24 hours will be replaced with 70% ethanol followed by 
paraffin embedding and sectioning to obtain 5 µm thin sections on glass slides. 2 mm2 
intestine and colon tissue sections will be incubated in RPMI medium at 37°C for 24 hours 
followed by centrifugation at 2500 rpm for 15 minutes. Supernatant will be obtained and 
stored at -20°C for tissue-secreted cytokine expression analyses. The rest of tissues will be 
stored at -80oC for further usage. Fecal samples will be snap frozen at the time of sacrifice 
for microbiome analysis. 
 
Material and methods: 
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Clinical score 
Clinical score will be measured for each mouse twice during each week of the study. Mice 
will be sacrificed after the last clinical score measurement. Cumulative clinical scores will 
be obtained for each mouse twice a week with a maximum clinical score of 12. The clinical 
score for each mouse will be based on weight loss measurement, diarrhea and fecal 
hemoccult (kit, BECKMAN COULTER) with a maximum score of 4 within each of the 
three quantitative parameters. The clinical score will be calculated by the following 
method: 
 
Table 1. Clinical score measurement criteria 
Tissue and serum collection 
Mice will sacrificed at the three different time points by cervical dislocation. Blood will be 
collected before sacrifice through retro-orbital puncture, centrifuged at 10,000 rpm for 15 
minutes and serum will be isolated and stored at -20°C. Small intestine and colon will be 
excised and flushed clean with PBS. 2 mm2 small intestine and colon tissue sections will 
be fixed in 10% formalin and after 24 hours will be replaced with 70% ethanol followed 
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by paraffin embedding and sectioning to obtain 5 µm thin sections on glass slides. 2 mm2 
intestine and colon tissue sections will be incubated in RPMI medium at 37°C for 24 hours 
followed by centrifugation at 2500 rpm for 15 minutes. Supernatant will be obtained and 
stored at -20°C for tissue-secreted cytokine expression analyses. The rest of tissues will be 
stored at -80oC for further usage. Fecal samples will be snap frozen at the time of sacrifice 
for microbiome analysis. 
 
16S rRNA-based Metagenomics 
At sacrifice, fecal samples will be obtained from the experimental mice to perform bacterial 
(luminal) microbiome analysis. Bacterial n16S rRNA gene amplification and sequencing 
will be performed at the Alkek Center for Metagenomics and Microbiome Research, 
Department of Molecular Virology and Microbiology, Baylor College of Medicine 
(Houston, TX). Polymerase Chain Reaction (PCR) amplification of the V4 region of the 
bacterial 16 S rRNA gene will be performed using the Illumnia Miseq sequencer. The 
consensus sequences obtained from the analysis will be mapped into Operational 
Taxonomic Units (OTUs). Alpha- and beta-diversity values will be obtained based on the 
OTUs’ relative abundance table. Chao1 (estimator of richness) and Shannon Diversity 
Index (richness and evenness) will be used to obtain the alpha diversity values. Weighted 
Unifrac (dissimilarity based on phylogenetic differences and taxonomic abundance) and 
Unweighted Unifrac (dissimilarity based on phylogenetic differences but not abundance) 
will be performed to obtain the beta-diversity values for the experimental samples (He, et 
al., 2016). Kruskal Wallis and Mann Whitney statistical analyses will be performed to 
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calculate significance in diversity and relative abundance respectively, by comparing 
different treatments and disease stages. A p value of less than 0.05 will be considered 
significant. 
 
Primary Outcomes: 
Alpha diversity 
The metagenomics Chao1 and Shannon indices will be used to measure the alpha diversity 
values for different groups of experimental animals. Alpha diversity values will be used to 
measure total species richness within the individual fecal samples (Weir et al., 2013). 
Beta diversity 
The metagenomics Unifract index will be used to measure the beta diversity values among 
the different experimental groups. The beta diversity values will be used to measure the 
degree of diversity among the different experimental groups and thus will give a measure 
of difference in diversity between different groups (Weir, et al., 2013). 
Relative abundance of different bacterial phyla 
The relative abundance of different phyla will be plotted for each of the experimental 
groups in order to characterize the dominance of one or more phyla during initiation and 
development of tumorigenesis and under normal conditions. 
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AIM 2: To determine if gut microbiome manipulation can regulate ApcMin/+ mouse 
health and tumorigenesis. 
Rationale: The mucus layer tends to thickness with increased diversity of the microbiota 
(Jakobsson, et al., 2015). Our preliminary data from a study on chronic inflammation-
induced colon cancer using APNKO mice suggested that the gut microbiota changes in a 
way that favors an increased percentage of bacteria of certain phyla (here, Firmicutes) as 
compared to others (such as Bacteroidetes). It is not been studied yet as to whether there is 
a relation between the altered percentages of especially the Firmicutes and Bacteroidetes 
phyla populations, and tumor number, tumor size and goblet cell numbers. It is known that 
the mucus layer provides a source of nutritional carbon and therefore energy to some of 
the intestinal flora that are able to lyse the glycans present in the mucus, making the inter-
relationship between the gut bacteria and the mucus layer really important (H. Li, et al., 
2015). Also, the metabolites produced by these microbes also influence the differentiation 
and function of the epithelial and immune cells in the intestinal mucosa (Kato, et al., 2014). 
The regulation of the mucin gene expression as well as mucus production have been shown 
to be two levels at which the gut microbial community may modulate mucins (Comelli, et 
al., 2008). Our previous study (Saxena, et al., 2013) also suggested that a reduction in the 
secretory mucin profile is associated with an inflammatory phenotype of the gut (Figure 
4). Therefore, the present aim will be directed at knowing the mucus-producing phenotypes 
of the cells lining the gut of the experimental animals in relation to the changing profiles 
of the gut microbiota. 
AIM 2.1: To determine if gut microbiome manipulation effects intestinal tumor number 
and size in small intestine and colon of ApcMin/+ mice. 
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AIM 2.2: To determine if gut microbiome manipulation effects goblet cell numbers in 
small intestine and colon of ApcMin/+ mice as compared to C57BL/6 mice. 
AIM 2.3: To determine if gut microbiome manipulation leads to a differential 
recolonization of Bacteroidetes and Firmicutes populations of bacteria ApcMin/+ mice as 
compared to C57BL/6 mice. 
Experimental Design Specific Aim 2: Aim 2 will study the effects of manipulation of the 
gut microbiome primarily on health in terms of disease severity and tumorigenesis in terms 
if tumor number and size. Secondarily, aim 2 will also be directed towards quantifying the 
number of goblet cells in the small intestine and colon of the experimental animals. 
 The first part of aim 2 will be to study the role of manipulation of microbiota on 
the health of the experimental animals. The gut health of the animals will be monitored by 
clinical score which will be calculated in the same way as that in aim 1. 
The second part of aim 2 will decipher the role of an altered microbiome via 
administration of antibiotics to the animals, on tumor number and size throughout the 
process of tumorigenesis. 
The third part of aim 2 will be directed towards determining the role of microbiome 
manipulation on the expression of mucus-producing goblet cells in the epithelium of small 
intestine and colon of the experimental animals. 
Aim 2 will provide a mechanistic way of deciphering the role of an altered 
microbiome on three of the processes which define a disease state pertaining to the gut. 
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Animal Model and Handling: 4 weeks old ApcMin/+ and C57BL/6 (WT) mice will be 
obtained from Jackson Laboratories and bred in-house at the Animal Resource Facility, 
University of South Carolina. Food (Purina chow) and drinking water will be available to 
the mice ad libidum under a 12:12 hour light-dark cycle and a low-stress environment 
(22oC, 50% humidity and low noise). The ApcMin/+ and C56BL/6 mice will be assigned to 
the following groups:  WT-Control (no antibiotic)-8 weeks, WT-Antibiotic (ABT)-8 
weeks, WT-Control-12 weeks, WT-ABT-12 weeks, WT-Control-16 weeks, WT-ABT-16 
weeks, ApcMin/+-Control-8 weeks, ApcMin/+-ABT-8 weeks, ApcMin/+-Control-12 weeks, 
ApcMin/+-ABT-12 weeks, ApcMin/+-Control-16 weeks and ApcMin/+-ABT-16 weeks. All 
animal care will follow institutional guidelines under a protocol approved by the 
Institutional Animal Care and Use Committee at the University of South Carolina. 
Cumulative clinical scores will be obtained for each mouse twice a week with a maximum 
clinical score of 12. The clinical score for each mouse will be based on weight loss 
measurement, diarrhea and fecal hemoccult with a maximum score of 4 within each of the 
three quantitative parameters. The ApcMin/+ -Control animals to be used in aim 2 will be the 
same as those used in aim 1. 
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Mice will be monitored throughout the course of study for weight loss, diarrhea and fecal 
hemoccult. Mice will sacrificed at the three different time points by cervical dislocation. 
Blood will be collected before sacrifice through retro-orbital puncture, centrifuged at 
10,000 rpm for 15 minutes and serum will be isolated and stored at -20°C. Small intestine 
and colon will be excised and flushed clean with PBS. 2 mm2 colon tissue sections will be 
fixed in 10% formalin and after 24 hours will be replaced with 70% ethanol followed by 
paraffin embedding and sectioning to obtain 5 µm thin sections on glass slides. 2 mm2 
intestine and colon tissue sections will be incubated in RPMI medium at 37°C for 24 hours 
followed by centrifugation at 2500 rpm for 15 minutes. Supernatant will be obtained and 
stored at -20°C for tissue-secreted cytokine expression analyses. The rest of tissues will be 
stored at -80oC for further usage. Fecal samples will be snap frozen at the time of sacrifice 
for microbiome analysis. 
 
 
 
 
Material and methods: 
Antibiotic administration: An antibiotic mixture containing Vancomycin, Neomycin and 
Streptomycin (each 1 mg/mL) will be administered to experimental mice under the 
antibiotic treatment groups. While neomycin and streptomycin act against Gram-negative 
bacteria, vancomycin is used against Gram-positive bacteria. The antibiotics mixture will 
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be administered to the mice through drinking water starting at the 5th, 10th and 14th weeks 
for 10 days followed by normal drinking water. 
 
Clinical score: Clinical score will be measured for each mouse twice during each week of 
the study. Mice will be sacrificed after the last clinical score measurement. Cumulative 
clinical scores will be obtained for each mouse twice a week with a maximum clinical score 
of 12. The clinical score for each mouse will be based on weight loss measurement, 
diarrhea and fecal hemoccult (kit, BECKMAN COULTER) with a maximum score of 4 
within each of the three quantitative parameters. Score for the weight loss is based on the 
following published scale where 0 = 0–5% weight loss; 1 = 6–10% weight loss; 2 = 11–
15% weight loss; 3 = 16–20% weight loss; and 4 = >20% weight loss. Scoring of diarrhea 
is as follows: 0 = well-formed pellets, 2 = pasty and semi-formed stools that do not adhere 
to the anus, 4 = liquid stools that adhere to the anus. Detection of blood in the stools will 
be determined using hemoccult kit (BECKMAN COULTER). The higher intensity of blue 
color indicates greater bleeding. The followings are the score rates for the fecal hemoccult: 
0 = no blood, 2 = positive hemoccult, 4 = gross bleeding. The total clinical score will be 
the summation of the individual score of weight loss, diarrhea and fecal hemoccult. The 
maximum score a mouse could get is 12. 
 
Tissue and serum collection: Mice will sacrificed at the three different time points by 
cervical dislocation. Blood will be collected before sacrifice through retro-orbital puncture, 
centrifuged at 10,000 rpm for 15 minutes and serum will be isolated and stored at -20°C. 
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Small intestine and colon will be excised and flushed clean with PBS. 2 mm2 small intestine 
and colon tissue sections will be fixed in 10% formalin and after 24 hours will be replaced 
with 70% ethanol followed by paraffin embedding and sectioning to obtain 5 µm thin 
sections on glass slides. 2 mm2 intestine and colon tissue sections will be incubated in 
RPMI medium at 37°C for 24 hours followed by centrifugation at 2500 rpm for 15 minutes. 
Supernatant will be obtained and stored at -20°C for tissue-secreted cytokine expression 
analyses. The rest of tissues will be stored at -80oC for further usage. Fecal samples will 
be snap frozen at the time of sacrifice for microbiome analysis. 
 
Tumor Number and Area: Small intestine and colon from the experimental animals will 
be excised and flushed with PBS. Tumor number and area will be counted using 1% Methyl 
Blue stain under the light microscope for all mice in different groups and significant 
difference will be calculated.  
 
Alcian Blue staining: Standard deparaffinization procedure will be followed using xylene 
and gradations of ethanol. Alcian Blue dye solution for staining mucus-containing goblet 
cells will be prepared by dissolving the dye powder (8GX) at 1% concentration in 3% 
acetic acid solution and setting the pH at 2.5. Nuclear Fast Red solution for staining the 
epithelial cells of the mucosa will be prepared at a final concentration of 0.1% dissolved in 
5% aluminium sulfate solution. Tissues will firstly be stained with Alcian Blue and then 
counterstained with Nuclear Fast Red solution. Goblet to epithelial cell ratio will be 
counted per crypt with ten crypts per section and five sections per group. 
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Statistical analysis: Two-way analysis of variance (ANOVA), Two-way repeated measure 
ANOVA and One-way ANOVA will be used to analyze the data with Tukey post hoc-
analyses. A p<0.05 will be considered statistically significant. All the statistical analyses 
will be done using SigmaStat 3.5 (SPSS, Chicago, IL). 
 
PRIMARY OUTCOMES: 
Clinical score 
Clinical score will be measured for each mouse twice during each week of the study. Mice 
will be sacrificed after the last clinical score measurement. Cumulative clinical scores will 
be obtained for each mouse twice a week with a maximum clinical score of 12. The clinical 
score for each mouse will be based on weight loss measurement, diarrhea and fecal 
hemoccult (kit, BECKMAN COULTER) with a maximum score of 4 within each of the 
three quantitative parameters. Score for the weight loss is based on the following published 
scale where 0 = 0–5% weight loss; 1 = 6–10% weight loss; 2 = 11–15% weight loss; 3 = 
16–20% weight loss; and 4 = >20% weight loss. Scoring of diarrhea is as follows: 0 = well-
formed pellets, 2 = pasty and semi-formed stools that do not adhere to the anus, 4 = liquid 
stools that adhere to the anus. Detection of blood in the stools will be determined using 
hemoccult kit (BECKMAN COULTER). The higher intensity of blue color indicates 
greater bleeding. The followings are the score rates for the fecal hemoccult: 0 = no blood, 
2 = positive hemoccult, 4 = gross bleeding. The total clinical score will be the summation 
of the individual score of weight loss, diarrhea and fecal hemoccult. The maximum score 
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a mouse could get is 12. The clinical score will be studied as an effect due to the 
perturbation of microbiome. 
Tumor number and area 
Small intestine and colon from the experimental animals will be excised and flushed with 
PBS. Tumor number and area will be counted using 1% Methyl Blue stain under the light 
microscope for all mice in different groups and significant difference will be calculated. 
Tumor number and/or area will also be correlated with the manipulation of the microbiome. 
 
Secondary outcomes: 
Goblet cells 
Goblet cells counted through Alcian Blue staining will form a secondary outcome of aim 
2 in the present study. Since goblet cells form a mucus-producing phenotype of the gut 
lining, their presence is associated with better prognosis of disease. A manipulation of 
microbiome may work to reduce the numbers of goblet cells in small intestine and colon. 
 
AIM 3: To determine if a change in relative abundance Bacteroidetes and Fimicutes 
population regulate(s) systemic inflammation in ApcMin/+ mice. 
Rationale: The induction of cancer in the gut by chronic inflammation has always 
indicated towards the importance of underlying altered inflammatory processes (Zhang, et 
al., 2015). Different agents that have been documented to be effective against tumors and 
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cancers are the agents that function by downregulating important inflammatory pathways 
and pro-inflammatory cytokines such as IL1-β, IL-6 and TNF-α, and reduction of 
macrophage infiltration (Y. Li, et al., 2012). It has also been shown that the intestinal 
commensal bacteria plays a role in the development of immune system of the gut 
microenvironment comprising both the humoral and cellular components and maintains 
the protective steady state immune function throughout life (Cebra, 1999). It may be more 
appropriate to say that any alteration numbers of certain bacteria often lead to upregulation 
or downregulation of certain inflammatory pathways. The systemic release of microbial 
products as a result of the perturbation of the gut epithelium invokes an IL-23 response and 
a further IL-17 response in order to neutralize further invasion by the microbes, and the 
process is brought about by the Firmicutes bacteria Clostridia sp. (Shih, et al., 2014). The 
bacteria especially promotes IL-17 cytokine in the small intestine which is the primary site 
of its attachment and survival (Omenetti & Pizarro, 2015). These Th17 cells may become 
autoreactive in case of intestinal epithelium insult. The bacteria Bacteroides fragilis from 
the Bacteroidetes phylum leads to an increase in the production of IL-10 cytokine, whereas 
its strains have been implicated in the production of the pro-inflammatory cytokine IL-17-
dependent inflammation-related colon cancer (W. Wu, et al., 2015). Inflammation, which 
is an integral part of tumorigenesis should therefore, may strongly be correlated with a 
reduced bacterial diversity or numbers. 
AIM 3.1: To examine if a change in Bacteroidetes and Firmicutes populations regulate 
intestinal goblet cell numbers in ApcMin/+ mice. 
AIM 3.2: To examine if a change in Bacteroidetes and Firmicutes populations regulate 
systemic levels of cytokines IL-6 and TNF-α in ApcMin/+ mice. 
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Experimental Design Specific Aim 3: The experimental design for aim 3 will be the same 
as that for aim 2. The experimental animals and groups will be the same as those used for 
aim 2. 
The first part of aim 3 will be directed towards elucidating the effect of an altered 
microbiome on the process of inflammation localized at the level of epithelial lining in the 
form of intestinal insult and undesirable infiltration of immune cells at the gut lining. 
The second part of aim 3 will elucidate an inflammatory effect of microbiome 
dysbiosis which can be studied through the measuring tissue-secreted cytokines as a result 
of the aforesaid localized inflammation. 
The third part of aim 3 is aimed at studying an inflammatory response of the body 
to microbiome dysbiosis at a systemic level. 
Material and methods: 
Tissue and serum collection: The experimental tissue and serum collected in aim 1 and 2 
will also be used in aim 3. 
 
16S rRNA-based Metagenomics 
At sacrifice, fecal samples will be obtained from the experimental mice to perform bacterial 
(luminal) microbiome analysis. Bacterial n16S rRNA gene amplification and sequencing 
will be performed at the Alkek Center for Metagenomics and Microbiome Research, 
Department of Molecular Virology and Microbiology, Baylor College of Medicine 
(Houston, TX). Polymerase Chain Reaction (PCR) amplification of the V4 region of the 
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bacterial 16 S rRNA gene will be performed using the Illumnia Miseq sequencer. The 
consensus sequences obtained from the analysis will be mapped into Operational 
Taxonomic Units (OTUs). Alpha- and beta-diversity values will be obtained based on the 
OTUs’ relative abundance table. Chao1 (estimator of richness) and Shannon Diversity 
Index (richness and evenness) will be used to obtain the alpha diversity values. Weighted 
Unifrac (dissimilarity based on phylogenetic differences and taxonomic abundance) and 
Unweighted Unifrac (dissimilarity based on phylogenetic differences but not abundance) 
will be performed to obtain the beta-diversity values for the experimental samples (He, et 
al., 2016). Kruskal Wallis and Mann Whitney statistical analyses will be performed to 
calculate significance in diversity and relative abundance respectively, by comparing 
different treatments and disease stages. A p value of less than 0.05 will be considered 
significant. 
 
Hematoxylin and Eosin staining: Paraffin embedded 5 µm sections from aim 2 will be 
used for performing Hematoxylin and Eosin staining in order to determine the morphology 
of small intestine and colon epithelial layer. Histopathology will be quantified visually in 
a double-blind condition using light microscopy. Localized inflammatory status will be 
indicated by inflammatory cells present in the mucosal layers of intestine and colon. 
Aberrant villi and crypts will also be used as indicators of intestinal and colonic insults due 
to inflammatory response. 
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Enzyme-linked Immunosorbent Assay (ELISA): Supernatents obtained from 2 mm2 
small intestinal tissues kept in RPMI for 24 hours at 37oC will be used to perform ELISA 
to quantify small-intestinal secreted pro-inflammatory cytokines IL-1β, IL-17 and TNF-α. 
Serum samples obtained from the experimental animals at the time of sacrifice will be used 
to quantify systemic levels inflammatory response by measurement of systemic levels of 
pro-inflammatory cytokines IL-1β, IL-17 and TNF-α. 
 
Statistical Analysis: Two-way analysis of variance (ANOVA), Two-way repeated 
measure ANOVA and One-way ANOVA will be used to analyze the data with Tukey post 
hoc-analyses. A p<0.05 will be considered statistically significant. All the statistical 
analyses will be done using SigmaStat 3.5 (SPSS, Chicago, IL). 
 
Primary Outcomes: 
Relative abundance of Firmicutes and Bacteroidetes 
The inflammatory status is often associated with the abundance of Firmicutes population 
that tends to further increase the levels of inflammation. Thus, quantifiucation of 
Firmicutes will be an important primary outcome of aim 3. 
Visually quantifiable levels of mucosal inflammation 
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Abnormal infiltration by immune cells at the mucosal layer can be used as a measure to 
determine the effect of an altered microbiome on an inflammatory response at the mucosal 
level. 
Tissue-localized inflammatory response 
Certain measurable quantities of pro-inflammatory cytokines can be secreted locally by the 
intestinal tissue as a response to either the localized mucosal layer infiltration by immune 
cells or due to increased levels of systemic inflammation. 1 cm long sections of small 
intestine will be excised from the experimental mice at the time of sacrifice and incubated 
in 1 mLl of RPMI buffer in 12-well plates at 37oC overnight. The tissue supernatant will 
be centrifuged at 4000 rpm for 10 minutes at 15oC and will be stored at -20oC till analysis. 
Systemic inflammatory response 
Systemic levels of pro-inflammatory cytokine proteins IL-1β, IL-17 and TNF-α will be 
measured to quantify inflammation as a result of perturbed microbiome at systemic levels. 
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